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Scientific Opinion on the safety of caffeine
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EFSA Panel on Dietetic Products, Nutrition and Allergies (NDA)
2,3
 
European Food Safety Authority (EFSA), Parma, Italy 
ABSTRACT 
Following a request from the European Commission, the EFSA Panel on Dietetic Products, Nutrition and 
Allergies was asked to deliver a scientific opinion on the safety of caffeine, providing advice on caffeine intakes, 
from all dietary sources that do not give rise to concerns about adverse health effects for the general healthy 
population and subgroups thereof. Possible interactions between caffeine and other constituents of so-called 
“energy drinks”, alcohol, p-synephrine and physical exercise should also be addressed. Single doses of caffeine 
up to 200 mg (about 3 mg/kg bw for a 70-kg adult) do not give rise to safety concerns. The same amount does 
not give rise to safety concerns when consumed < 2 hours prior to intense physical exercise under normal 
environmental conditions. Other constituents of “energy drinks” at typical concentrations in such beverages 
(about 300–320, 4 000 and 2 400 mg/L of caffeine, taurine and D-glucurono-γ-lactone, respectively), as well as 
alcohol at doses up to about 0.65 g/kg bw, would not affect the safety of single doses of caffeine up to 200 mg. 
Habitual caffeine consumption up to 400 mg per day does not give rise to safety concerns for non-pregnant 
adults. Habitual caffeine consumption up to 200 mg per day by pregnant women does not give rise to safety 
concerns for the fetus. Single doses of caffeine and habitual caffeine intakes up to 200 mg consumed by lactating 
women do not give rise to safety concerns for breastfed infants. For children and adolescents, the information 
available is insufficient to derive a safe caffeine intake. The Panel considers that caffeine intakes of no concern 
derived for acute caffeine consumption by adults (3 mg/kg bw per day) may serve as a basis to derive single 
doses of caffeine and daily caffeine intakes of no concern for these population subgroups. 
© European Food Safety Authority, 2015 
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SUMMARY 
Following a request from the European Commission, the European Food Safety Authority (EFSA) 
Panel on Dietetic Products, Nutrition and Allergies (NDA) was asked to deliver a scientific opinion on 
the safety of caffeine. Possible interactions between caffeine and other common constituents of so-
called “energy drinks”, alcohol, synephrine and physical exercise should also be addressed. 
Caffeine is an alkaloid found in various plant constituents, such as coffee and cocoa beans, tea leaves, 
guarana berries and the kola nut, and has a long history of human consumption. It is an ingredient 
added to a variety of foods, e.g. baked goods, ice creams, soft candy, cola-type beverages. Caffeine is 
also an ingredient of so-called “energy drinks” and it is present in combination with synephrine in a 
number of food supplements marketed for weight loss and sports performance, among others. Some 
medicines and cosmetics also contain caffeine. “Energy drinks” most often contain combinations of 
caffeine, taurine and D-glucurono-γ-lactone, among other ingredients. Synephrine is a biogenic amine 
of the chemical group of phenylethanolamines/phenylpropanolamines. The protoalkaloid (–)-p-
synephrine is naturally found in bitter orange fruit (Citrus aurantium L.) and other citrus fruits. The 
presence of (+)-p-synephrine or m-synephrine in food supplements containing C. aurantium extracts is 
indicative of adulteration. Only (–)-p-synephrine, the natural compound from C. aurantium extracts 
found in food supplements, is considered in this opinion (referred to as p-synephrine hereafter). 
This opinion addresses possible adverse health effects of caffeine consumption from all dietary 
sources, including food supplements, in the general healthy population and in relevant specific 
subgroups of the general population (e.g. children, adolescents, adults, the elderly, pregnant and 
lactating women, subjects performing physical exercise). Whether other substances present in “energy 
drinks” (D-glucurono-γ-lactone and taurine), alcohol or p-synephrine may modify the possible adverse 
health effects of caffeine and/or the doses at which such adverse effects may occur is also addressed. It 
is outside the scope of the present opinion to address possible adverse health effects of caffeine given 
as medicine or administered via routes other than the oral route; in subgroups of the population 
selected on the basis of a disease condition or in sub-populations with extreme and distinct 
vulnerabilities due to genetic predisposition or other conditions which may require individual advice; 
or in combination with medicines and/or drugs of abuse, or in combination with alcohol doses which, 
by themselves, pose a risk to health (e.g. during pregnancy, binge drinking). It is also outside the scope 
of this opinion to assess possible beneficial health effects of caffeine or of particular dietary sources of 
caffeine. 
The Panel interprets the request from the European Commission as follows: (i) to provide advice on a 
daily intake of caffeine from all sources which, if consumed ad libitum and throughout the day for 
long periods of time, does not give rise to concerns about harmful effects to health for the healthy 
population, divided into various life-stage groups as appropriate; (ii) for the specific group of 
individuals performing physical activity, to advise on caffeine consumption (dose and timing) prior to 
physical activity which does not give rise to concerns about harmful effects to health for this 
population subgroup; and (iii) to advise on whether or not, and if so to what extent, the consumption of 
caffeine together with other food constituents (such as alcohol, substances found in energy drinks or p-
synephrine) presents a health risk and if additional or different recommendations for caffeine intakes 
need to be provided, regarding either the dose of caffeine or the time interval between the 
consumption of caffeine and the aforementioned food constituents. 
The EFSA Comprehensive European Food Consumption Database was used to calculate caffeine 
intake from food and beverages. It contains data from 39 surveys in 22 different European countries 
for a total of 66 531 participants. These surveys do not provide information about the consumption of 
caffeine-containing food supplements. The EFSA report on energy drinks was used to calculate 
caffeine intakes from “energy drinks” in a “single session” in adults, either alone or in combination 
with physical exercise. 
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Owing to the abundance of scientific literature available, previous risk assessments on the safety of 
caffeine consumption in humans conducted by authoritative bodies will be reviewed first to identify 
the major health concerns raised in relation to the consumption of caffeine, either alone or in 
combination with other components of “energy drinks”, alcohol or p-synephrine, and the specific 
population subgroups which are relevant for the assessment. 
The Panel reviewed the literature reporting on the effects of single and repeated doses of caffeine 
consumed within a day, either alone or in combination with other constituents of “energy drinks” and 
with p-synephrine, on cardiovascular outcomes, hydration and body temperature in adults, both at rest 
and in relation to physical exercise. The effects of single and repeated doses of caffeine consumed 
within a day on the central nervous system were assessed in adults (sleep, anxiety, perceived exertion 
during exercise and subjective perception of alcohol intoxication) and children (sleep, anxiety and 
behavioural changes). Adverse effects of longer-term and habitual caffeine consumption were 
evaluated in children in relation to behavioural changes and in pregnant women in relation to adverse 
birth weight-related outcomes (e.g. fetal growth retardation, small for gestational age) in the offspring. 
In adults, the adverse effects of habitual caffeine consumption, either alone or in combination with 
other constituents of “energy drinks” and with p-synephrine, were evaluated in relation to 
cardiovascular outcomes. The scientific publications identified almost exclusively reported no 
relationship or an inverse relationship between habitual caffeine intake and other adverse health 
effects. 
The scientific assessment is based on human intervention and observational studies with adequate 
control for confounding variables, which have been conducted in healthy subjects at recruitment. 
Whenever available, human intervention studies and prospective cohort studies have been preferred 
over case–control and cross-sectional studies because of the lower risk of reverse causality and recall 
bias. Case reports of adverse events have not been considered for the scientific assessment. Systematic 
reviews and meta-analysis have been used to summarise the scientific evidence whenever available. 
On the basis of the data available, the NDA Panel reached the following conclusions on caffeine 
intakes which do not give rise to safety concerns for specific groups of the general population. 
Adults 
Single doses of caffeine 
Single doses of caffeine up to 200 mg (about 3 mg/kg bw for a 70-kg adult) from all sources do not 
give rise to safety concerns for the general healthy adult population. The same amount of caffeine does 
not give rise to safety concerns when consumed less than two hours prior to intense physical exercise 
under normal environmental conditions. No studies are available in pregnant women or middle-
aged/elderly subjects undertaking intense physical exercise. Single doses of 100 mg (about 
1.4 mg/kg bw for a 70-kg adult) of caffeine may increase sleep latency and reduce sleep duration in 
some adult individuals, particularly when consumed close to bedtime. 
Other common constituents of “energy drinks” at concentrations commonly present in such beverages 
(typically about 300–320, 4 000 and 2 400 mg/L of caffeine, taurine and D-glucurono-γ-lactone, 
respectively) would not affect the safety of single doses of caffeine up to 200 mg. Up to these levels of 
intake, other common constituents of “energy drinks” are not expected to adversely interact with 
caffeine on its effects on the cardiovascular system, the central nervous system or hydration status. 
Alcohol consumption at doses up to about 0.65 g/kg bw, leading to a blood alcohol concentration of 
about 0.08 %, would not affect the safety of single doses of caffeine up to 200 mg from any dietary 
source, including “energy drinks”. Up to these levels of intake, caffeine is unlikely to mask the 
subjective perception of alcohol intoxication. 
The human intervention studies on which these conclusions are based were primarily conducted with 
caffeine supplements for most of the outcomes assessed (i.e. changes in myocardial blood flow, 
hydration status, body temperature, perceived exertion/effort during exercise, sleep). Changes in blood 
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pressure were assessed using caffeine supplements, coffee, tea and “energy drinks” as sources of 
caffeine, whereas the subjective perception of alcohol intoxication was tested using caffeine either 
from supplements or from “energy drinks”. 
The question of whether or not p-synephrine modifies the acute cardiovascular effects of single doses 
of caffeine has not been adequately investigated in humans, particularly if consumed shortly before 
intense physical exercise, and therefore no conclusions could be drawn. 
About 6 % of the adult population may exceed 200 mg of caffeine in a single session of “energy 
drink” consumption, and about 4 % do so in connection with physical exercise. This information is not 
available for other sources of caffeine. 
Habitual caffeine consumption 
Caffeine intakes from all sources up to 400 mg per day (about 5.7 mg/kg bw per day for a 70-kg adult) 
consumed throughout the day do not give rise to safety concerns for healthy adults in the general 
population, except pregnant women (see below). No health concerns in relation to acute toxicity, bone 
status, cardiovascular health, cancer risk or male fertility have been raised by other bodies in previous 
assessments for this level of habitual caffeine consumption and no new data have become available on 
these or other clinical outcomes which could justify modifying these conclusions. 
Other common constituents of “energy drinks” at the doses commonly present in such beverages 
and/or moderate habitual alcohol consumption would not affect the safety of habitual caffeine 
consumption up to 400 mg per day. 
The question of whether or not p-synephrine modifies the acute cardiovascular effects of single doses 
of caffeine or the long-term effects of caffeine on the cardiovascular system has not been adequately 
investigated in humans and therefore no conclusions could be drawn. 
In 7 out of 13 countries, the 95
th
 percentile of daily caffeine intake from foods and beverages exceeded 
400 mg. In these countries, the estimated proportion of the adult population exceeding daily intakes of 
400 mg ranged from about 6 % to almost one-third (33 %), and coffee was the main source of 
caffeine. More accurate estimates of caffeine intakes within a given country could be obtained by 
using national caffeine occurrence data, if available. 
Pregnant women 
Single doses of caffeine 
There are no studies on the health effects of single doses of caffeine consumed by pregnant women 
prior to intense physical exercise. With regard to the different kinetics of caffeine in this population 
subgroup, single doses of caffeine which are of no safety concern for non-pregnant adults do not apply 
to pregnant women performing physical exercise. 
Habitual caffeine consumption 
Caffeine intakes from all sources up to 200 mg per day consumed throughout the day by pregnant 
women in the general population do not give rise to safety concerns for the fetus. This conclusion is 
based on prospective cohort studies showing a dose-dependent positive association between caffeine 
intakes during pregnancy and the risk of adverse birth weight-related outcomes (i.e. fetal growth 
retardation, small for gestational age) in the offspring. In these studies, the contribution of “energy 
drinks” to total caffeine intake was low (about 2 %). 
Data to characterise the risk of habitual caffeine consumption in this population subgroup are scarce. 
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Lactating women 
Single doses of caffeine and habitual caffeine consumption 
Single doses of caffeine up to 200 mg and habitual caffeine consumption at doses of 200 mg per day 
consumed by lactating women in the general population do not give rise to safety concerns for the 
breastfed infant. At these doses of caffeine, daily caffeine intakes by the breastfed infant would not 
exceed 0.3 mg/kg bw, which is 10-fold below the lowest dose of 3 mg/kg bw tested in a dose finding 
study and at which no adverse effects were observed in the majority of infants. 
There are no data to characterise the risk of single doses of caffeine consumed by lactating women, 
and data on habitual caffeine consumption in this population subgroup are scarce. 
Children and adolescents 
The information available for this population subgroup on the relationship between caffeine intakes 
and health outcomes is insufficient to derive a safe level of caffeine intake. 
Single doses of caffeine 
Single doses of caffeine of no concern derived for adults (3 mg/kg bw per day) may also apply to 
children, considering that caffeine clearance in children and adolescents is at least that of adults, and 
that the limited studies available on the acute effects of caffeine on anxiety and behaviour in children 
and adolescents support this level of no concern. Like for adults, caffeine doses of about 1.4 mg/kg bw 
may increase sleep latency and reduce sleep duration in some children and adolescents, particularly 
when consumed close to bedtime. 
There are no data available to characterise the risk of single doses of caffeine from all sources 
consumed by children and adolescents. Estimates of the proportion of single days in which caffeine 
intake exceeds 3 mg/kg bw among all survey days using the EFSA Comprehensive Database were 
used as a conservative approximation. 
The estimated 95
th
 percentile of caffeine intake from foods and beverages on a single day exceeded 
3 mg/kg bw in 6 out of 16 countries for adolescents (10 to < 18 years), in 9 out of 16 countries for 
children (3 to < 10 years) and in 3 out of 10 countries for toddlers (12 to < 36 months). The proportion 
of survey days in which the level was exceeded ranged from about 7 to 12 % in adolescents, from 6 to 
15 % in children and from 7 to 37 % in toddlers in the aforementioned countries. Chocolate beverages 
were important contributors to total caffeine intakes in children and toddlers in most countries, and the 
use of a conservative caffeine value for this food category may have led to an overestimation of 
caffeine intakes in these age groups. 
Habitual caffeine consumption 
As caffeine clearance in children and adolescents is at least that of adults, the same levels of no safety 
concern derived for adults (i.e. 5.7 mg/kg bw) may also apply to children, unless there are data 
showing a higher sensitivity to the effects of caffeine in this age group (i.e. difference in 
pharmacodynamics). As only limited studies are available on the longer-term effects of caffeine on 
anxiety and behaviour in children and adolescents, there is substantial uncertainty regarding longer-
term effects of habitual caffeine consumption in this age group. A level of no safety concern of 
3 mg/kg bw per day (i.e. the level of no concern derived for single doses of caffeine for adults) is 
proposed for habitual caffeine consumption by children and adolescents. This approach is rather 
conservative in relation to the effects of caffeine on the cardiovascular system, but the limited studies 
available regarding the longer-term effects of caffeine on anxiety and behaviour in children and 
adolescents support the proposed caffeine intake level of no safety concern. 
The estimated 95
th
 percentile of daily caffeine intake from foods and beverages exceeded 3 mg/kg bw 
in 5 out of 13 countries for adolescents, in 6 out of 14 countries for children (3 to < 10 years) and in 
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1 out of 9 countries for toddlers (12 to < 36 months). The proportion of subjects exceeding that level 
of intake in the above-mentioned countries was about 5 to 10 % for adolescents, 6 to 13 % for children 
and about 6 % for toddlers. Chocolate beverages were important contributors to total caffeine intakes 
in children and toddlers in most countries, and the use of a conservative caffeine value for this food 
category may have led to an overestimation of caffeine intakes in these age groups. 
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BACKGROUND AS PROVIDED BY THE EUROPEAN COMMISSION 
Member States raised concerns in relation to the risk of adverse health effects as a result of the intake 
of caffeine from all sources, in relation to the safety of caffeine consumption in the general population 
and in specific target groups (e.g. adults performing physical activity of various intensities, individuals 
(including adolescents) consuming foodstuffs containing caffeine together with other food constituents 
such as alcohol or substances found in energy drinks, and in relation to the validity and 
appropriateness of the total daily intake for the general population proposed in the conditions of use 
for the claims by the Commission, i.e. 300 mg per day, which is based on the conclusions for pregnant 
women in the report of the Scientific Committee on Food of 1999 (SCF, 1999). 
In its reports, the Scientific Committee on Food (1999, 2003) concluded inter alia, that “the 
contribution of energy drinks to overall caffeine intake, even when combined with other caffeine 
containing beverages, was not a matter of concern for non-pregnant adults. For pregnant adults, the 
Committee concluded that while intakes of caffeine up to 300 mg per day appeared to be safe, the 
question of possible effects on pregnancy and the offspring at regular intakes above 300 mg per day 
remained open and therefore moderation of caffeine intake, from whatever source, was advisable 
during pregnancy.” 
Belgium’s Superior Health Council (SHC, 2012) recently assessed the use of caffeine in foodstuffs4 in 
January 2012 and concluded that “in healthy adults a maximal daily intake of 400 mg per day does not 
raise concerns for adverse health effects. For women of childbearing age a maximal daily intake of 
300 mg, or even 200 mg, is recommended. For children prior to adolescence an acceptable maximal 
daily intake of 2.5 mg per kg body weight is advisable.” Another assessment conducted in December 
2009 by the same risk assessment body on energy drinks
5
 leads to the recommendation that “regular 
or excessive consumption of energy drinks should be avoided while ensuring that the total daily intake 
of caffeine remains below 400 mg, or even 300 mg.” It was also advised “to avoid consumption of 
energy drinks when consuming alcoholic beverages or during intense physical activity”. Finally it was 
suggested that “the consumption of energy drinks should be avoided during pregnancy, during 
breastfeeding, by children up to 16 years old and by people who are susceptible to caffeine.” It is 
noted that Belgium’s recommendation on the upper intake limit of caffeine for the general population 
is also in line with Health Canada and the US Food and Drug Administration (FDA)
6
 which confirmed 
that “the general population of healthy adults is not at risk for potential adverse effects from caffeine 
if they limit their caffeine intake to 400 mg per day”. 
Similarly, the French Agency for Food Safety
7
 concluded that “it is not possible to rule out a possible 
risk related to consumption of foodstuffs containing caffeine on cardiovascular health in people 
performing intense physical activity: however, further evaluation on this is needed”. According to the 
French Agency
8
, “current knowledge on the risks related to the consumption of energy drinks should, 
however, help to better understand the role of caffeine in the observed effects”. Further cases of 
deleterious effects of caffeine consumption have been reported through the nutri-vigilance system for 
products containing caffeine. 
Overall, at EU level to date, caffeine has only been assessed in the context of energy drinks but the 
safety of overall caffeine intake, from all sources, and acceptable use levels has not yet been assessed. 
In order to inform on-going discussions with Member States, the European Commission asks the 
                                                     
4 Avis du conseil supérieur de la santé No 8689, “Utilisation de la caféine dans les denrées alimentaires”, 11 January 2012. 
Available online: http://www.health.belgium.be/internet2Prd/groups/public/@public/@shc/documents/ie2divers/19076526_fr.pdf 
5 Avis du conseil supérieur de la santé No 8622, “Boissons énergisantes”, 2 December 2009. Available online: 
http://www.health.belgium.be/internet2Prd/groups/public/@public/@shc/documents/ie2divers/17982877_fr.pdf 
6 Health Canada, 2010. Available online: http://www.hc-sc.gc.ca/hl-vs./alt_formats/pdf/iyh-vs.v/food-aliment/caffeine-
eng.pdf, US FDA letter to Senator Richard J. Durbin, 10 August 2012. 
7 Agence Française de Sécurité Sanitaire des Aliments. 
8 Afssa—Saisine No 2002-SA-0260, 5 May 2003; Afssa—Saisine No 2005-SA-0111, 30 January 2006; Afssa Saisine No 
2006-SA-0236, 9 November 2006. 
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Authority to review the existing scientific data on the possible link between the intake of caffeine, 
from all sources, and adverse health effects. 
TERMS OF REFERENCE AS PROVIDED BY THE EUROPEAN COMMISSION 
In accordance with Article 29 (1) (a) of Regulation (EC) No 178/2002 the European Commission
9
 asks 
EFSA to: 
 Review the existing scientific data on the potential link between caffeine intakes, from all 
sources, and possible adverse health effects in the general population and as appropriate, in 
specific subgroups of the population, including but not limited to, individuals performing 
physical activity of various intensities, women of childbearing age, pregnant women, 
breastfeeding women, children and adolescents; 
 Provide advice on a tolerable upper intake level (UL) for caffeine, from all sources, for the 
general population and as appropriate, for specific subgroups of the population, including but 
not limited to, individuals performing physical activity of various intensities, women of 
childbearing age, pregnant women, breastfeeding women, children and adolescents. For the 
specific group of individuals performing physical activity, advice should be provided on a 
safe/recommended timing of caffeine consumption prior to the physical activity. 
 In the absence of tolerable upper intake level (UL), to provide advice on a daily intake of 
caffeine, from all sources, that does not give rise to concerns about harmful effects to health 
for the general population and as appropriate, for specific subgroups of the population. 
 Advise whether, and the extent to which, the consumption of caffeine together with other food 
constituents, such as alcohol or substances found in energy drinks, could present a risk to 
health and for which additional or different recommendations should be provided. Advice 
should focus inter alia on: 1) a daily intake of caffeine when combined with other food 
constituents and 2) a recommended interval between caffeine and other food constituents’ 
consumption to prevent possible interactions. 
In a follow-up communication, the European Commission informed EFSA that a number of Member 
States have issued risk assessments or warnings in relation to “fat-burning” food supplements 
containing synephrine in combination with caffeine. In addition the European Commission referred to 
a number of Rapid Alert System for Food and Feed (RASFF) notifications on food supplements 
containing synephrine which often contain also caffeine. The European Commission and EFSA agreed 
that this mandate will also cover possible interactions between caffeine and synephrine and the safety 
of food products containing these two substances. 
                                                     
9  Regulation (EC) No 178/2002 of the European Parliament and of the Council of 28 January 2002 laying down the general 
principles and requirements of food law, establishing the European Food Safety Authority and laying down procedures in 
matters of food safety. OJ. L 31, 1.2.2002. p. 1.  
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ASSESSMENT 
1. Introduction and interpretation of the terms of reference 
Chemically, caffeine (1,3,7-trimethylxanthine) is a stable, unionised alkaloid and one of several 
related methylxanthines. It is found in various plant constituents, such as coffee and cocoa beans, tea 
leaves, guarana berries and the kola nut, and has a long history of human consumption. It is an 
ingredient added to a variety of foods, e.g. baked goods, ice creams, soft candy, cola-type beverages. 
Caffeine is also an ingredient of so-called “energy drinks” and it is present in combination with 
synephrine in a number of food supplements marketed for weight loss and sports performance, among 
others. Some medicines and cosmetics also contain caffeine. 
“Energy drinks” most often contain combinations of caffeine, taurine and D-glucurono-γ-lactone, 
among other ingredients. 
Synephrine is a biogenic amine of the chemical group of phenylethanolamines/phenylpropanolamines. 
Amphetamine, ephedrine, octopamine, adrenaline, noradrenaline and dopamine belong to this group. 
Different isomers of synephrine have been identified in food supplements. The protoalkaloid  
(–)-p-synephrine is naturally found in bitter orange fruit (Citrus aurantium L.) and other citrus fruits. 
One litre of orange juice contains about 15–27 mg of (–)-p-synephrine (EFSA, 2009b). C. aurantium 
extract, most often standardised for (–)-p-synephrine at concentrations of 6–10 %, is the predominant 
ingredient used in synephrine-containing food supplements. The synthetic racemate of the optical 
isomers (–)-p-synephrine and (+)-p-synephrine and the synthetic m-isomer (m-synephrine or 
phenylephrine) are drugs which induce vasoconstriction of the arterial bed (O’Neil, 2008; Martindale 
et al., 2011; BfR, 2012; SLE, 2012). The presence of small amounts of (+)-p-synephrine or  
m-synephrine in food supplements containing C. aurantium extracts is indicative of adulteration. Only  
(–)-p-synephrine, the natural compound from C. aurantium extracts found in food supplements, will 
be considered in this opinion (for convenience, referred to as p-synephrine hereafter). 
This opinion addresses possible adverse health effects of caffeine consumption: 
 from all dietary sources, including food supplements, in the general healthy population and in 
relevant specific subgroups thereof (e.g. children, adolescents, adults, the elderly, pregnant 
and lactating women, subjects performing physical exercise); 
 in combination with other substances present in “energy drinks” (D-glucurono-γ-lactone and 
taurine), alcohol or p-synephrine, i.e. whether or not these substances modify the possible 
adverse health effects of caffeine and/or the doses at which such adverse effects may occur. 
It is outside the scope of the present opinion to address: 
 possible adverse health effects of caffeine: 
– given as a medicine, or administered via routes other than the oral route (e.g. through the 
skin); 
– in subgroups of the population selected on the basis of a disease condition; 
– in combination with medicines and/or drugs of abuse; 
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– in combination with alcohol at doses which, by themselves, pose a risk to health (e.g. 
during pregnancy, binge drinking
10
). 
 possible adverse health effects of alcohol, p-synephrine or substances present in “energy 
drinks” other than caffeine (D-glucurono-γ-lactone and taurine), and/or the doses at which 
adverse effects may occur, when consumed on their own, rather than in combination with 
caffeine; 
 possible adverse effects of the synthetic racemate of the optical isomers (–)-p-synephrine and 
(+)-p-synephrine or of the synthetic m-isomer (m-synephrine or phenylephrine); 
 possible beneficial health effects of caffeine or of particular dietary sources of caffeine; 
 possible beneficial or adverse health effects of components other than caffeine in foods and 
beverages which are common dietary sources of caffeine (e.g. coffee, tea, soft drinks other 
than “energy drinks”, chocolate). 
The Panel notes that the concept of a tolerable upper intake level (UL) was developed for essential 
nutrients and refers to the maximum level of total chronic daily intake of a nutrient (from all sources) 
judged to be unlikely to pose a risk of adverse health effects to humans. Decisions on whether or not 
any effect is adverse require expert judgement. Nutritional requirements need to be taken into 
consideration when setting ULs. The UL is not a recommended level of intake and does not refer to 
single dose or short-term intakes of a nutrient (SCF, 2000). 
The derivation of ULs for the normal healthy population, divided into various life-stage groups, 
accounts for normally expected variability in sensitivity, but it excludes sub-populations with extreme 
and distinct vulnerabilities due to genetic predisposition or other conditions. Including these sub-
populations would result in ULs that are significantly lower than needed to protect most people against 
adverse effects of high intakes. Sub-populations needing special protection are better served through 
public health screening, health care providers, product labelling or other individualised strategies. The 
extent to which a sub-population becomes significant enough to be assumed to be representative of the 
general population is an area of judgement and of risk management (SCF, 2000). 
The Panel notes that several characteristics of nutrients are shared with caffeine, which distinguish 
both caffeine and nutrients from hazardous food chemicals (e.g. contaminants). Caffeine has a long 
history of human consumption and data on health effects are available from studies in humans. 
However, caffeine is not an essential nutrient, and thus ULs cannot be derived. In addition, advice on 
the safe/recommended timing of caffeine consumption prior to physical activity cannot be provided by 
the derivation of an UL. In this context, the Panel interprets the request from the European 
Commission as follows: 
 to provide advice on a daily intake of caffeine from all sources which, if consumed ad libitum 
and throughout the day for long periods of time, does not give rise to concerns about harmful 
effects to health for the healthy population, divided into various life-stage groups as 
appropriate, but excluding sub-populations with extreme and distinct vulnerabilities due to 
genetic predisposition or other conditions; 
                                                     
10 Defined as a pattern of drinking alcohol that brings blood alcohol concentration (BAC) to 0.08 % or above. For the typical 
adult, this pattern corresponds to consuming, in about two hours, five or more drinks (male) or four or more drinks 
(female) in the United States (US) (where a “drink” is standardised to 14 g of pure alcohol), or about eight or more drinks 
(male) or six or more drinks (female) in most European Union (EU) countries, including the United Kingdom (UK) (where 
a “drink” is standardised to 8 g of pure alcohol).  
 http://www.publications.parliament.uk/pa/cm201012/cmselect/cmsctech/writev/1536/ag22.htm 
http://www.cdc.gov/alcohol/fact-sheets/binge-drinking.htm 
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 for the specific group of individuals performing physical activity, to advise on caffeine 
consumption (dose and timing) prior to physical activity which does not give rise to concerns 
about harmful effects to health for this population subgroup; and 
 to advise on whether or not, and if so to what extent, the consumption of caffeine together 
with other food constituents (such as alcohol, substances found in energy drinks or  
p-synephrine) presents a health risk and if additional or different recommendations for 
caffeine intakes need to be provided, regarding either the dose of caffeine or the time interval 
between the consumption of caffeine and the aforementioned food constituents. 
Owing to the abundance of scientific literature available, previous risk assessments on the safety of 
caffeine consumption in humans conducted by authoritative bodies will be reviewed first in order to 
identify the major health concerns raised in relation to the consumption of caffeine, either alone or in 
combination with other components of “energy drinks”, alcohol or p-synephrine, and the specific 
population subgroups which are relevant for the assessment. 
2. Previous safety assessments 
2.1. Caffeine 
Safety assessments in relation to acute and chronic consumption of caffeine have been issued by a 
number of authoritative bodies around the world. 
In 1983, the Scientific Committee on Food (SCF) noted that caffeine in comparatively high doses 
showed weak teratogenic effects (slight delays in the mineralisation of sternebrae) in experimental 
animals and mutagenic effects in vitro, but not in vivo. The SCF concluded that there was no evidence 
for concerns about carcinogenic, teratogenic or mutagenic effects of caffeine in humans at observed 
levels of intake (between 2.0 and 4.5 mg/kg body weight (bw) per day) and that human 
epidemiological studies provided no evidence for any association between coffee consumption and 
congenital defects (SCF, 1983). 
In 1999, the SCF re-assessed the safety of caffeine by considering the contribution of “energy drinks” 
to caffeine intakes (SCF, 1999). In the absence of representative intake data for the European 
population, the SCF assumed that “energy drink” users would consume about 160 mg caffeine per day 
from this source (0.5 L; 320 mg caffeine/L). On the basis of a number of human observational studies, 
the SCF found that results were contradictory regarding the association between prenatal caffeine 
exposure and birth weight, and were inconsistent for pre-term delivery and congenital malformation. 
No clear association was established between caffeine intake in early pregnancy and spontaneous 
abortion or delayed conception; only one study showed an association between heavy caffeine intake 
in pregnancy and the risk of sudden infant death syndrome. The SCF concluded that, in general, 
maternal caffeine consumption during pregnancy did not appear to have any measurable adverse 
consequences for the human fetus at intakes up to 300 mg caffeine per day. Moderation of caffeine 
intakes from whatever source was advised for pregnant women. For children, the SCF considered 
seven publications reporting on intervention studies (Elkins et al., 1981; Rapoport et al., 1981a, 1984; 
Baer, 1987; Zahn and Rapoport, 1987; Leviton, 1992; Bernstein et al., 1994; Stein et al., 1996) 
conducted in pre-school and school children with caffeine doses up to 10 mg/kg bw (3, 5 or 10 mg/kg 
bw), either as a single dose or on a daily basis for periods of up to two weeks. In these studies, either 
no effect or small, inconsistent effects were noted on mood, behavioural, cognitive and motor 
functions. According to the SCF, “some of the studies indicated that a dose of 5 mg/kg bw increased 
arousal, irritability, nervousness or anxiety in some subjects, particularly if they were normally low 
consumers of caffeine”. 
A Food Standards Australia and New Zealand expert group (FSANZ, 2000), on the basis of available 
prospective cohort studies in humans, concluded that a causal relationship between habitual caffeine 
intakes from dietary sources and an increased risk of hypertension or cardiovascular disease (CVD) 
could not be established. FSANZ noted reports of increased anxiety levels in children (Bernstein et al., 
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1994) at doses of 2.5 mg/kg bw per day and in adults (Nickell and Uhde, 1994) at doses of 3 mg/kg 
bw per day when caffeine was administered intravenously, corresponding to 95 mg per day for a mean 
body weight of 32 kg in children aged 5–12 years and to 210 mg per day for a mean body weight of 
70 kg in adults. FSANZ also noted that doses of 100 mg of caffeine (1.4 mg/kg bw for a 70-kg adult) 
taken at bedtime had been reported to reduce the ability to sleep in adults (Landolt et al., 1995). 
In 2004, the Nordic Working Group on Food Toxicology and Risk Evaluation (NNT) assessed 
possible adverse health effects of the consumption of caffeine (and other methylxanthines) during 
pregnancy (NNT, 2004). Like the SCF in 1999, the NNT concluded that, on the basis of virtually the 
same human observational studies, results were contradictory regarding the association between 
prenatal caffeine exposure and birth weight (including fetal growth retardation). If present, the 
Committee judged that the effect of high caffeine intakes on birth weight would be small and of low 
clinical relevance. No clear association was found between caffeine intake in early pregnancy and 
increased risk of pre-term delivery or congenital malformations, or between caffeine intake in 
childbearing age and delayed conception. Different from the SCF, and on the basis of additional 
prospective cohort studies, the NNT concluded that the relationship between high caffeine intakes and 
increased risk of spontaneous abortion was probable. Recommendations were given to reduce caffeine 
intakes during pregnancy (e.g. as the SCF or the Food and Drug Administration (FDA)), but no cut off 
value was advised. 
Maximum daily caffeine intakes recommended by Health Canada in 2006 (Health Canada, 2006) for 
different population subgroups were based on a review of the literature published in 2003 (Nawrot et 
al., 2003). On the basis of the studies available at the time on the relationship between caffeine 
consumption and health outcomes in humans, the authors concluded that daily caffeine intakes of 
400 mg were not associated with adverse health effects such as general toxicity, cardiovascular effects, 
changes in adult behaviour, increased incidence of cancer, effects on male fertility or bone 
status/calcium balance if calcium intakes are adequate. In a review of the available observational 
studies on caffeine consumption during pregnancy and the risk of spontaneous abortion, pre-term 
delivery, fetal growth, congenital malformations and post-natal development, it was concluded that 
caffeine intake for women who plan to become pregnant and during gestation should not exceed 
300 mg per day. The publications reviewed concerning caffeine intakes in children mostly addressed 
the effects of caffeine on the central nervous system (CNS), and were those considered by the SCF 
(1999) together with three additional studies (Rapoport et al., 1981b; Hale et al., 1995; Davis and 
Osorio, 1998). The authors noted the small size of the studies available and the diversity of study 
designs. The authors also noted that the use of different endpoints or of different ways to assess similar 
endpoints hampered comparability among studies, and that most studies did not stratify children by 
their usual (pre-study) caffeine intake, a variable which could affect the way subjects respond to pre-
study caffeine withdrawal and to additional caffeine intakes. Nevertheless, findings of altered 
behaviour, including anxiety, were noted in some studies to the lowest level of administered caffeine 
used (2.5 mg/kg bw). In the absence of more robust data associated with low levels of administered 
caffeine in this population subgroup, an upper intake of 2.5 mg/kg bw per day based on the study by 
Bernstein et al. (1994) was derived for children, considering that the nervous system in children is 
continually developing and the lack of available information on the longer-term effects of caffeine 
consumption in this population subgroup. 
Based on the results from a prospective cohort study (CARE Study Group, 2008), the UK Committee 
on Toxicity of Chemicals in Food, Consumer Products and the Environment (COT) concluded in 2008 
that caffeine consumption during pregnancy was associated with an increased risk of fetal growth 
restriction (FGR), and that the risk at intakes < 200 mg per day may be low, even if a threshold level 
of caffeine intake below which there was no increased risk could not be identified (COT, 2008). Based 
on an extensive review of the literature, the COT also suggested a possible association between 
caffeine consumption and an increased risk of miscarriage, but considered that data on the relationship 
between caffeine consumption and other pregnancy outcomes (e.g. pre-term birth, congenital 
malformations) were inconclusive. 
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In 2008, the NNT focused on the safety of caffeine among children and adolescents in the Nordic 
countries (NNT, 2008). A no observed effect level (NOEL) of 0.3 mg/kg bw (Goldstein and Wallace, 
1997) and a lowest observed adverse effect level (LOAEL) of 1.0–1.3 mg/kg bw (Bernstein et al., 
2002; Heatherley et al., 2006) were established for tolerance development with withdrawal symptoms, 
whereas a LOAEL of 2.5 mg/kg bw (Bernstein et al., 1994) was established for anxiety and jitteriness. 
The NNT noted that the only study which assessed the relationship between habitual caffeine 
consumption and sleep patterns in adolescents (Pollak and Bright, 2003) did not allow conclusions to 
be drawn on a causal effect of caffeine on disturbed sleep (i.e. it was an observational study and 
reverse causality could not be excluded) and that no studies were available in children. The NNT 
concluded that there were no data to conclude that caffeine would not have the same sleep-depriving 
effect in children and adolescents as in adults, and that, in adults, doses less than 100 mg, equivalent to 
1.4 mg/kg bw, did not seem to have an effect on sleep (Dorfman and Jarvik, 1970). 
The Belgium Superior Health Council (SHC, 2012) based its recommendations on the assessments 
conducted by FSANZ (2000), Health Canada (Nawrot et al., 2003) and the COT (2008). The SHC 
considered that caffeine intakes of 5.7 mg/kg bw per day (400 mg per day for a 70-kg adult) were not 
linked to any adverse effects in relation to general toxicity, altered behaviour, decreased male fertility, 
CVD or cancer risk; recommended a maximum daily intake of caffeine of 2.5 mg/kg bw for children 
and adolescents based on the increased risk of anxiety and altered behaviour beyond this dose 
(Bernstein et al., 1994); and advised to women of childbearing age not to exceed 300 mg per day, or 
even 200 mg per day. The SHC noted a report (Nickell and Uhde, 1994) of increased anxiety levels in 
adults who received 3 mg/kg bw per day (210 mg per day for a 70-kg adult) of caffeine intravenously. 
2.2. Caffeine in combination with other constituents of “energy drinks” and in combination 
with alcohol 
A number of safety assessments have also been conducted in relation to the consumption of “energy 
drinks”, which most often contain combinations of caffeine (typically 300–320 mg/L), taurine (about 
4 000 mg/L) and D-glucurono-γ-lactone (about 2 400 mg/L) among other ingredients, and to the 
consumption of “energy drinks” or caffeine in combination with alcohol. 
In 1999, the SCF (1999) considered that the contribution of “energy drinks” to caffeine intakes in non-
pregnant adults was not of concern on the assumption that “energy drinks” would replace other 
caffeine sources, such as coffee or tea. For children, the SCF concluded that the consumption of 
160 mg caffeine per day from 0.5 L of “energy drinks”, equivalent to 5.3 mg/kg bw per day for a  
10-year-old, 30-kg child, could result in transient behavioural changes, such as increased arousal, 
irritability, nervousness or anxiety, based on the studies referred to in Section 2.1. 
In 2003, the SCF (2003) considered that it is unlikely that D-glucurono-γ-lactone would interact with 
caffeine, taurine, alcohol or the effects of exercise. Caffeine exerts stimulatory effects in the CNS and, 
although taurine generally acts as an inhibitory neuromodulator, the SCF could not rule out the 
possibility of stimulatory effects of caffeine and taurine on the CNS. This was based on a rat study 
showing a stimulatory action on locomotor activity after taurine consumption in all treated rat groups. 
Based on the antagonistic effects of caffeine and taurine on the cardiovascular system (CVS) observed 
in vitro in animal studies and in human studies conducted with either caffeine or taurine, the SCF 
considered that, if there are any cardiovascular interactions between caffeine and taurine, taurine might 
reduce the cardiovascular effects of caffeine. The SCF also noted the possibility of additive effects of 
taurine and caffeine on diuresis (acting via different mechanisms), which could be exacerbated by the 
consumption of alcohol and sweating during exercise. This could theoretically result in short-term 
dehydration, but no human studies investigating this possibility were available. The majority of studies 
suggested that caffeine would not exacerbate the adverse effects of alcohol on the CNS. 
In 2009, the Panel on Food Additives and Nutrient Sources Added to Food (ANS Panel) concluded 
that exposure to taurine and D-glucurono-γ-lactone at levels commonly used in “energy drinks” was 
not of safety concern, even for consumers of high levels (EFSA (European Food Safety Authority), 
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2009). Similarly to the SCF (2003), the ANS Panel considered that it is unlikely that D-glucurono-γ-
lactone would have any interaction with caffeine, taurine, alcohol or the effects of exercise. The ANS 
Panel concluded that additive interactions between taurine and caffeine on diuretic effects were 
unlikely, based on a human intervention study (Riesenhuber et al., 2006), and that a possible 
stimulatory effect from taurine on the CNS was improbable on the basis of a second rat study, from 
which a no observed adverse effect level (NOAEL) of 1 500 mg/kg bw per day was derived for 
behavioural effects. 
In 2008, the Federal Institute for Risk Assessment (BfR) assessed the safety of “energy drinks” in 
view of case reports on fatalities following reported consumption of these beverages, either alone or in 
combination with alcohol, which implicated, primarily, the CVS and CNS (BfR, 2008). The BfR 
considered that adverse health effects upon consumption of large amounts of “energy drink” in 
combination with intense physical exercise or alcohol could not be ruled out, and advised children, 
pregnant women, lactating women or individuals who are “sensitive” to caffeine (i.e. with cardiac 
arrhythmias or mental disorders) not to consume “energy drinks”, particularly in large amounts. 
Subsequently, the BfR (BfR, 2009) assessed health risks related to the consumption of “energy shots”, 
which contain higher concentrations of caffeine and taurine than “energy drinks” (50–200 mg caffeine 
and taurine 200–1 000 mg per portion). The BfR stated that the consumption of “energy shots” poses 
no risk to health if consumed in accordance with the suggested daily intake levels of 50–200 mg 
caffeine. 
In 2012, the UK COT (COT, 2012) assessed the health effects of consuming caffeine from all sources, 
including “energy drinks” in combination with alcohol. A number of human observational (mostly 
cross-sectional and retrospective) studies suggested that higher caffeine intakes were associated not 
only with higher alcohol intakes but also with use of other psychoactive substances. Similarly, high 
intakes of “energy drinks” were correlated with higher alcohol intakes in some individuals. However, 
the studies available did not allow conclusions to be drawn on “whether this is because consumption 
of energy drinks causes people to drink more alcohol, or because people who are inclined to more 
risky behaviour tend generally to consume larger quantities of psychoactive substances, including 
caffeine and alcohol”. Results from controlled human intervention studies, systematically reviewed by 
Verster et al. (2012), were conflicting with respect to the effects of caffeine (1.1 to 5.6 mg/kg bw) on 
mental performance (e.g. motor reaction time, mean tracking performance and memory reaction time) 
and subjective perception of alcohol intoxication when consumed together with alcohol (0.18 to 
1.07 g/kg bw). The COT concluded that the heterogeneity of methods and neurological endpoints in 
the intervention studies available prevented firm conclusions on whether or not caffeine counteracts 
the acute neurocognitive effects of alcohol, and that the available evidence did not support a 
toxicological or behavioural interaction between caffeine and alcohol. The COT also noted the 
limitations of the data available and the uncertainty linked to this statement. 
In 2013, Health Canada assessed the health risks associated with the consumption of “energy drinks” 
in Canada (Rotstein et al., 2013). The hazard assessment was based on individual ingredients. Caffeine 
was identified as the ingredient with the greatest potential for intakes of possible health concern. On 
this basis, excess consumption of energy drinks would be expected to result in health consequences 
similar to those from excess exposure to caffeine. Health Canada considered that the potential for 
taurine and glucuronolactone to interact with caffeine and the health effects of excessive intake of 
taurine and glucuronolactone were unknown. The hazard assessment concluded that the general adult 
population could consume two servings of a typical energy drink per day with no health consequences. 
This conclusion was based on the safety of the non-caffeine ingredients of energy drinks at the level of 
consumption, and the fact that caffeine from other dietary sources in addition to that in two servings of 
energy drink would not pose a health hazard to the general adult population. The consumption of 
energy drinks by sub-populations, such as children, adolescents and pregnant women, should be 
limited to their recommended maximum daily intakes of caffeine, as recommended by Health Canada 
(see Section 2.1). Health Canada concluded that the evidence did not conclusively indicate a harmful 
toxicological interaction between “energy drinks” and alcohol. 
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The French Agency for Food, Environmental and Occupational Health and Safety (ANSES, 2013) 
analysed 212 cases of adverse effects reported through the French Nutritional Vigilance Scheme and 
considered that a causal relationship between the consumption of “energy drinks” and the reported 
adverse effects was very likely or likely in 25 cases (12 %) and possible in 54 cases (24 %). The main 
signs and symptoms identified implicated the CVS (e.g. heart failure, feelings of tightness or pain in 
the chest, tachycardia, high blood pressure) and the CNS (e.g. irritability, nervousness, anxiety, panic 
attacks, hallucinations, epilepsy). Although most adverse effects were attributed to the consumption of 
high doses of caffeine, ANSES suggested that taurine could have additional effects in raising blood 
pressure and inducing vasospasm of the coronary arteries. ANSES warned about the chronic 
consumption of caffeinated beverages, including “energy drinks”, by certain subgroups of the 
population at higher risk of adverse effects, including pregnant (risk of impaired fetal growth) and 
lactating women (caffeine transferred to milk), children and adolescents (disruption of sleep patterns, 
risk of “addictive behaviour” later in life), “slow caffeine metabolisers” and subjects with cardiac, 
psychiatric or neurological disorders, kidney failure or severe liver diseases. ANSES also noted that 
additional risks could arise from the different pattern of consumption of “energy drinks” compared 
with other dietary sources of caffeine, e.g. very high acute intakes, concomitant alcohol use (increased 
risk of cardiac arrhythmias and masking of alcohol intoxication) and/or concomitant intense physical 
exercise (increased risk of cardiac events, dehydration and heat stroke). Similar concerns were raised 
by the Italian National Food Safety Committee in 2012 regarding the consumption of “energy drinks”, 
particularly in combination with alcohol
11
. 
2.3. Caffeine in combination with p-synephrine 
A number of authoritative bodies in different European Union (EU) Member States have conducted 
risk assessments (BfR, 2012; SLE, 2012) or issued warnings (Sundhedsstyrelsen, 2008; MHRA, 2012; 
Evira, 2013) in relation to p-synephrine-containing products intended for weight loss and improving 
sports performance which also contain caffeine. Concerns were raised on the basis of case reports and 
Rapid Alert System for Food and Feed (RASFF) notifications of adverse health effects. 
The BfR (2012) reviewed human intervention studies investigating the acute effects of p-synephrine 
on blood pressure and heart rate, either alone (Min et al., 2005; Bui et al., 2006; Stohs et al., 2011) or 
in combination with caffeine (Haller et al., 2005b, 2008; Seifert et al., 2011). Based on these studies, 
the BfR concluded that single doses of p-synephrine > 27 mg can be expected to significantly increase 
blood pressure in humans, and that the effect may be observed at lower doses (of about 5 mg) in 
combination with caffeine. The BfR (2012) considered a daily intake of 6.7 mg p-synephrine from 
food supplements to be safe, on the assumption that total intakes of p-synephrine (from conventional 
foods and food supplements) would remain < 25.7 mg (95
th
 percentile of p-synephrine intake from 
conventional foods), even in consumers with high intakes from the diet. On the basis of these and 
other human intervention studies (Penzak et al., 2001), the Swedish National Food Agency (SLE, 
2010) and (ANSES, 2014) concluded that the effects of single-ingredient preparations (p-synephrine) 
are seen from about 20 mg, that at 50 mg there is a clear effect on heart rate and systolic and diastolic 
blood pressure and that caffeine could potentiate the cardiovascular effects of synephrine. ANSES 
(2014) recommended not combining p-synephrine with caffeine, whereas (Health Canada, 2011) 
established a limit of 50 mg of synephrine in supplements as a single active ingredient for healthy 
adults and the combination of caffeine and p-synephrine at daily doses up to 320 mg and 40 mg, 
respectively. 
2.4. Summary of previous safety assessments 
2.4.1. Caffeine 
Recommendations on maximum levels of caffeine consumption for different population subgroups 
have been derived by different national and international bodies taking into account a variety of health 
                                                     
11 http://www.salute.gov.it/imgs/c_17_pubblicazioni_1790_allegato.pdf 
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outcomes. No health concerns in relation to acute toxicity, calcium balance (under adequate calcium 
intakes), cardiovascular health, cancer risk or male fertility have been raised for habitual caffeine 
intakes from all sources up to 400 mg per day in the general adult population. It has been noted, 
however, that single doses of 1.4 mg/kg bw and above, taken at bedtime, could impair sleep in some 
individuals (Landolt et al., 1995), and that single doses of 3 mg/kg bw and above could increase 
anxiety in some cases when caffeine is administered intravenously (Nickell and Uhde, 1994). Early 
recommendations for pregnant women and for women of childbearing age to not exceed 300 mg of 
caffeine per day are based on a number of cross-sectional and prospective cohort studies which 
assessed the relationship between habitual caffeine consumption and a variety of outcomes (e.g. 
spontaneous abortion, pre-term delivery, fetal growth, congenital malformations, post-natal 
development). A later evaluation advised against exceeding 200 mg of caffeine per day in the light of 
a new prospective cohort study, which identified FGR as the most sensitive adverse outcome of 
caffeine consumption during pregnancy (CARE Study Group, 2008). Recommendations on maximum 
daily intakes of caffeine in children have been based on its acute and short-term effects on the CNS. 
The SCF noted that, considering all the available human intervention studies conducted in this 
population subgroup, doses of 5 mg/kg bw of caffeine increased arousal, irritability, nervousness or 
anxiety in some subjects, particularly if they were normally consumers of low amounts of caffeine 
(SCF, 1999). Other bodies (FSANZ, 2000; Health Canada, 2006; NNT, 2008; SHC, 2012), however, 
have recommended that doses of 2.5 mg/kg bw per day not be exceeded, on the basis of a single study 
(Bernstein et al., 1994). 
2.4.2. Caffeine in combination with other constituents of “energy drinks” and in combination 
with alcohol 
Concerns have been raised in relation to the consumption of “energy drinks” and an increased risk of 
adverse health effects involving the CVS and the CNS from a number of case reports, particularly 
when they are consumed within short periods of time, at high doses and in combination with alcohol 
and/or physical exercise. Although it has been acknowledged that such adverse effects could be 
attributed to caffeine alone, additive and/or synergistic cardiovascular and psychological effects have 
been proposed for other components of “energy drinks” on various health outcomes, especially 
taurine. Concerns regarding the possibility of an interaction between caffeine and taurine regarding the 
stimulatory effect on the CNS based on a rat study were not confirmed in subsequent animal studies. 
Similarly, it was found that the theoretical additive diuretic effects of caffeine and taurine mentioned 
in previous assessments were unlikely, on the basis of a human intervention study designed to 
investigate that question (Riesenhuber et al., 2006). Interactions between caffeine and taurine on the 
CVS were found to be unlikely based on the antagonistic effects of caffeine and taurine observed in 
vitro in animal studies and in human studies conducted with either caffeine or taurine. Studies linking 
high levels of consumption of caffeine and “energy drinks” with high alcohol intakes, consumption of 
other psychotropic drugs and increased “risk-taking” behaviour were either cross-sectional or 
retrospective and did not allow a causal role to be attributed to either caffeine or “energy drinks” in 
this cluster. It was also found that alcohol consumption is unlikely to exacerbate the effects of caffeine 
on the CVS and/or the CNS. Concerns were, however, expressed regarding the antagonistic effects of 
caffeine and alcohol on the CNS, and the possibility that caffeine could mask the subjective perception 
of alcohol intoxication, leading to increased “risk-taking” behaviour. However, the human intervention 
studies that investigated this question were found to yield conflicting results (Verster et al., 2012). 
2.4.3. Caffeine in combination with p-synephrine 
Concerns related to the co-consumption of caffeine and p-synephrine arise from the potential 
synergistic effects of these two substances on the CVS, and particularly on blood pressure. On the 
basis of human intervention studies which have investigated the acute effects of p-synephrine on blood 
pressure and heart rate, either alone (Penzak et al., 2001; Min et al., 2005; Bui et al., 2006; Stohs et al., 
2011) or in combination with caffeine (Haller et al., 2005b, 2008; Seifert et al., 2011), authoritative 
bodies came to the conclusion that doses of p-synephrine between 20 and 27 mg increase blood 
pressure, and that this effect is enhanced by the concomitant consumption of caffeine. 
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3. Dietary intakes 
3.1. Dietary sources and occurrence data 
The main sources of caffeine in the diet include coffee, tea, caffeinated soft drinks (including “energy 
drinks”) and chocolate. Caffeine concentrations in these foods and beverages as reported in different 
publications and European dietary surveys are depicted in Table 1. 
In order to calculate dietary intakes of caffeine, data from a survey conducted in the UK were used 
whenever available (Fitt et al., 2013). Information on caffeine concentrations of 400 samples of teas 
(e.g. loose leaves, bags, vending machines and instant tea) and coffees (e.g. filter coffee, vending 
machines, espresso and instant coffee) prepared at home, prepared in workplaces or purchased in retail 
settings was collected. In addition, the survey checked websites of manufacturers for information on 
product- and brand-specific caffeine levels and used analytical data from a UK survey of 162 samples 
from various types of caffeine- and other methylxanthine-containing products (Ministry of 
Agriculture, Fisheries and Food, 1998). For foods for which the survey did not report caffeine levels, 
an average of mean values reported in other representative original surveys was used, except for 
“energy drinks”, for which the caffeine concentration (320 mg/L) of the most consumed brand was 
chosen. Products in which chocolate occurs as a minor constituent, e.g. “chocolate biscuits”, were not 
considered because of their relatively low and highly variable caffeine levels. 
The Panel notes that there were no major differences among surveys and publications from different 
countries regarding average caffeine levels in foods and beverages (Table 1). Average values reported 
in Table 1 were used to assess daily caffeine intakes and caffeine intakes on single days for all 
countries and surveys. 
Variability in caffeine levels for different foods and beverages, in particular for coffee drinks, espresso 
coffee and tea, have been noticed within the same product and for the same country. The highly 
variable caffeine concentrations in coffee beverages depend on the manufacturing process, on the type 
of coffee beans used and on the type of preparation (e.g. drip coffee, espresso) (Waizenegger et al., 
2011). Owing to personal choices, individual consumers might therefore have coffee beverages with 
lower or higher caffeine levels than those used in the present assessment. The use of an average 
concentration value has been adopted by the Panel to account for this variability. 
Cocoa-based beverages are another food product that might present significant variability in caffeine 
levels because of the amount and type of cocoa present in the different brands. The distinction 
between “cocoa beverages based on cocoa powder” and “cocoa beverages based on cocoa-beverage 
preparation powder”, the latter being consumed mainly by children and containing more sugar and 
significantly lower amounts of cocoa, was used to minimise this uncertainty. However, it is not 
possible to exclude that some of the brands of cocoa-beverage preparation powder consumed in 
particular by children contain lower levels of caffeine than those used in the present assessment. It is 
also possible that some of them are decaffeinated. 
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 Caffeine concentrations in food and beverages  Table 1: 
Groups Subgroups Caffeine concentrations (mg/L or mg/kg) 
Used in the 
intake 
assessment 
Fitt et al. 
(2013) 
Waizenegger 
et al. (2011) 
Heckman et 
al. (2010) 
Mayo Clinic 
Staff (2013) 
ANSES 
(2013) 
Austria 
Rudolph 
et al. 
(2012) 
Zucconi 
et al. 
(2013) 
Belgium 
SHC 
(2012) 
Denmark 
NNT 
(2008) 
Finland 
NNT 
(2008) 
Iceland 
NNT 
(2008) 
Norway 
NNT 
(2008) 
Sweden 
NNT 
(2008) 
Chocolate Chocolate bar 111 (a) 111 – – – – – 180 – – – – – 
150 Milk chocolate 
168 (a) 168 
– – – – – 183 – – – – – 
Chocolate snacks – – – – – 180 – – – – – 
Cocoa beverage based 
on cocoa powder (b) 
 
 
– – – – – 150 – 20 – 20 – 15 Cocoa beverage based 
on cocoa-beverage 
preparation powder 
42 (c) – 
Dark chocolate 525 (a) 525  – – – – 340 – – – – – 650 
Coffee Coffee drink 445 (a) 445 380 
(30–1 780) 
586 
(450–882) 
477 
(114–840) 
513 
(175–1 244) 
400 
(197–804) 
400 320 500 500 550 500 690 
Cappuccino 273 (d) – – – 315 – 250 
(194–310) 
250 – – – – – – 
Espresso coffee 1 340 (e) – – 1 411 
(1 058–3 175) 
1 897 
(1 320–2 475) 
713 
(250–2 140) 
– 1916 – – – – – – 
Decaffeinated and 
imitations 
21 (f) – – 22 
(13–53) 
29 
(8–50) 
21 
(15–120) 
– 11 – – – – – – 
Instant coffee, ready to 
drink  
445 (a) 445 210 
(80–500) 
410 
(119–763) 
477 
(113–840) 
484 
(201–856) 
300 
(201–485) 
400 320 500 500 550 500 690 
Tea Black tea 220 (a) 220 – 207 
(110–485) 
– 
272 
(90–500) 
150 
(122–183) 
100 320 160 150 170 160 240 
Green tea 151 (a) 151 – 198 
(132–220) 
– 
Tea (unspecified) 165 (a) 165 – 234 
(176–529) 
158 
(59–256) 
Tea, decaffeinated 25 – – – 25 
(0–50) 
– – 25 – – – – – – 
Cola beverages (caffeinated) 108 (a) 108 – 127 
(101–163) 
104 
(76–132) 
97 
(41–132) 
– – 79 130 130 130 130 130 
“Energy drinks” 320 (g) 300 – 335 
(317–353) 
– 300 
(120–320) 
300 
(267–665) 
– 300 150 320 150 150 320 
(a): Derived from Fitt et al. (2013). 
(b): Cocoa beverage products have been prepared or recorded differently in the different dietary surveys. When needed, a correction factor equal to 60 has been applied to transform “cocoa 
powder” and “cocoa mass” into cocoa beverage (assuming that 60 g of cocoa beverage contains 1 g of cocoa powder). 
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(c): “Cocoa-beverage preparation powder” was assumed to contain only 25 % of the cocoa contained in “cocoa powder” and, consequently, 25 % caffeine. 
(d): Mean value from Mayo Clinic Staff (2013) and Austria (Rudolph et al., 2012) (minimum and maximum). 
(e): Mean value from Heckman et al. (2010), Mayo Clinic Staff (2013) and ANSES (2013). 
(f): Derived from ANSES (2013). 
(g): Caffeine concentration of the most consumed “energy drink” considered. 
–, no value provided in the references. 
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3.2. Food consumption data 
3.2.1. EFSA Comprehensive European Food Consumption Database 
The EFSA Comprehensive European Food Consumption Database (Comprehensive Database) 
provides a compilation of existing national information on food consumption at the individual level. It 
was first created in 2010 (EFSA, 2011a; Huybrechts et al., 2011; Merten et al., 2011) and then updated 
in 2014
12
. Details on how the Comprehensive Database is used are published in the Guidance of EFSA 
(EFSA, 2011b). For dietary surveys included in the 2010 release, which was based on the FoodEx 
classification, products coded as “carbohydrate-rich energy food products for sports people” or 
“carbohydrate–electrolyte solutions for sports people” at the third level of FoodEx within the first-
level category of “Products for special nutritional use” were used to calculate caffeine consumption 
from “energy drinks”. Even using this conservative approach, the contribution of “energy drinks” to 
total caffeine intakes was very low in all surveys published before 2000. The 17 surveys from 11 
Member States added in 2014 used the FoodEx2 code classification, which allows accurate reporting 
of “energy drink” consumption (Appendix A). 
The database used to calculate caffeine intake included surveys conducted between 2005 and 2012, 
with two exceptions (DIPP 2001–2009, Finland; VELS 2001–2002, Germany). The database contains 
data from 39 surveys conducted in 22 different European countries for a total of 66 531 participants 
(Appendix A). Data from 11 surveys were available for toddlers (≥ 12 months to < 36 months old), 
from 19 surveys for other children (≥ 36 months to < 10 years old), from 19 surveys for adolescents 
(≥ 10 years to < 18 years old), from 21 surveys for adults (≥ 18 years to < 65 years old), from 
15 surveys for the elderly (≥ 65 years to < 75 years old) and from 13 surveys for the very elderly 
(≥ 75 years old). Two additional surveys provided information on specific population groups: pregnant 
women (Latvia) and lactating women (Greece). 
In the above-mentioned surveys, consumption data were collected using single or repeated 24- or 48-
hour dietary recalls or dietary records covering three to seven days per subject. Owing to the 
differences in the methods used for data collection, direct country-to-country comparisons must be 
taken with caution. These surveys do not provide information about the consumption of caffeine-
containing food supplements. 
3.2.2. EFSA report on “energy drinks” 
In 2011, EFSA commissioned a study to gather data on the prevalence of “energy drink” consumption 
among adults, adolescents and children in Europe (Zucconi et al., 2013). This study also aimed at 
estimating intakes of “energy drink” ingredients, including caffeine, in “energy drink consumers”, as 
well as the relative contribution of “energy drinks” to total caffeine intakes. “Energy drink consumers” 
were defined as subjects who had consumed at least one “energy drink” over the last year. 
Consumption of “energy drinks” on a “single session”, defined as a period of time of about two hours 
(e.g. a “night out”, a “study or sport session”), and consumption of “energy drinks” with alcohol or in 
relation to physical exercise in adolescents and adults was also investigated. The Panel notes, 
however, that a “night out”, “study session” or “sport session” could last more than two hours, and it is 
not possible from the report to precisely define the time frame covered by a “single session”. 
Consumption data were collected through a food frequency questionnaire (FFQ)-based survey, 
involving more than 52 000 participants from 16 different European Member States. 
The Panel notes that this study provides useful information about the prevalence of “energy drink” 
consumption in Europe, the number of “energy drinks” (and the amount of their constituents, 
including caffeine) consumed in a “single session” and the prevalence of “energy drink” consumption 
in combination with physical activity. However, the Panel notes that: (i) “energy drink consumers” 
may not be representative of the general population with respect to caffeine intake from all sources; 
                                                     
12 http://www.efsa.europa.eu/en/datexfoodcdb/datexfooddb.htm  
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(ii) FFQs specifically developed to assess consumption of specific foods tend to overestimate 
consumption of such foods; and (iii) the study contains information about the frequency of 
consumption of “energy drinks” in combination with alcohol, but not on the amount of alcohol 
consumed in combination with “energy drinks”. Therefore, the Panel considered that this study could 
be used to calculate caffeine intakes from “energy drinks” in a “single session”, either alone or in 
combination with physical exercise, but not to calculate total caffeine intakes from all sources or from 
sources other than “energy drinks”. 
3.3. Dietary intake 
3.3.1. Caffeine intake estimated from the EFSA Comprehensive European Food 
Consumption Database 
3.3.1.1. Daily caffeine intake 
Daily caffeine intake for an individual was calculated by finding the sum of the intakes reported on all 
survey days during the survey period for that individual and dividing by the number of days. Only 
surveys which collected data for at least two days were used. 
Individual daily caffeine intakes were used to estimate the mean and 95
th
 percentile of daily caffeine 
intake from all sources and for each food group (chocolate, coffee, cola beverages, energy drinks and 
tea) for “all subjects” in a survey. Mean and 95th percentile daily caffeine intakes were also estimated 
for “consumers only” of each food group. Consumers were defined as subjects who had consumed a 
food product of the concerned food groups at least once within the survey period. 
The mean and 95
th
 percentile of daily caffeine intake for each age class and food group across different 
dietary surveys are given below for all subjects (Table 2) and for consumers of a caffeine-containing 
specific food group only (Table 3). Detailed information by country can be found in Appendix B. 
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 Daily caffeine intakes of all subjects by age class and food group across different dietary Table 2: 
surveys 
Age class Food groups Mean caffeine intake 95
th
 percentile caffeine intake 
(a)
 
mg per day mg/kg bw  
per day 
mg per day mg/kg bw  
per day 
Min 
(b)
 Max 
(b)
 Min 
(b)
 Max 
(b)
 Min 
(b)
 Max 
(b)
 Min 
(b)
 Max 
(b)
 
Toddlers  
(12 to < 36 
months; 10 
surveys) 
Total intakes 
(c)
 0.3 30.3 0.0 2.1 0.8 45.4 0.1 3.5 
Chocolate 0.3 30.3 0.0 2.1 0.7 23.9 0.1 1.8 
Coffee 0.0 1.9 0.0 0.2 – – – – 
Cola beverages 0.0 8.5 0.0 0.6 – – – – 
“Energy drinks” 0.0 0.0 0.0 0.0 – – – – 
Tea 0.0 6.6 0.0 0.5 0.0 43.3 0.0 3.2 
Other 
children  
(3 to < 10 
years; 17 
surveys) 
Total intakes 3.5 47.1 0.2 2.0 19.8 102.6 1.2 4.6 
Chocolate 2.1 35.0 0.1 1.4 6.5 94.5 0.4 4.6 
Coffee 0.0 10.3 0.0 0.4 0.0 44.5 0.0 1.8 
Cola beverages 0.0 6.3 0.0 0.3 0.0 27.0 0.0 1.5 
“Energy drinks” 0.0 0.3 0.0 0.0 – – – – 
Tea 0.0 31.8 0.0 1.3 0.0 70.1 0.0 2.8 
Adolescents  
(10 to < 18 
years; 16 
surveys) 
Total intakes 17.6 69.5 0.4 1.4 60.5 211.6 1.5 4.1 
Chocolate 2.8 35.1 0.1 0.7 9.8 129.8 0.2 2.9 
Coffee 0.5 22.0 0.0 0.4 0.0 133.5 0.0 2.1 
Cola beverages 0.0 26.5 0.0 0.4 0.0 106.9 0.0 1.7 
“Energy drinks” (d)  0.0 5.7 0.0 0.1 0.0 40.0 0.0 0.8 
Tea 0.0 36.3 0.0 0.8 0.0 122.2 0.0 2.4 
Adults  
(18 to < 65 
years; 16 
surveys) 
Total intakes 36.5 319.4 0.5 4.3 108.6 742.4 1.5 10.0 
Chocolate 1.9 9.5 0.0 0.1 8.9 50.4 0.1 0.8 
Coffee 20.9 280.7 0.3 3.7 72.1 737.4 1.0 9.7 
Cola beverages 0.0 18.0 0.0 0.3 0.0 80.5 0.0 1.2 
“Energy drinks” (e)  0.0 4.4 0.0 0.1 0.0 34.4 0.0 0.4 
Tea 0.5 88.6 0.0 1.2 0.0 247.0 0.0 3.4 
Elderly  
(65 to < 75 
years; 13 
surveys) 
Total intakes 22.6 362.1 0.3 4.8 96.3 715.7 1.5 10.4 
Chocolate 1.0 5.0 0.0 0.1 4.2 30.2 0.1 0.4 
Coffee 18.9 330.6 0.3 4.4 93.8 712.0 1.4 10.3 
Cola beverages 0.0 3.4 0.0 0.0 0.0 22.8 0.0 0.3 
“Energy drinks” 0.0 0.7 0.0 0.0 – – – – 
Tea 1.4 124.0 0.0 1.7 14.9 297.4 0.2 4.0 
Very elderly 
(≥ 75 years; 
11 surveys) 
Total intakes 21.8 416.8 0.3 6.0 174.0 454.5 2.3 6.1 
Chocolate 1.5 9.3 0.0 0.1 4.4 36.6 0.1 0.6 
Coffee 16.8 382.6 0.2 5.5 134.1 446.8 1.8 6.1 
Cola beverages 0.0 1.8 0.0 0.0 0.0 13.5 0.0 0.2 
“Energy drinks” 0.0 1.0 0.0 0.0 – – – – 
Tea 0.8 125.7 0.0 1.8 47.7 283.3 0.7 4.2 
(a): The 95th percentile estimates obtained from dietary surveys and age classes with fewer than 60 subjects may not be 
statistically robust (EFSA, 2011b) and consequently were not considered in this table (“–”). 
(b): Minimum (min) and maximum (max) means and 95th percentiles of those calculated from individual surveys for each 
age class. 
(c): “Total intakes” are not derived by calculating the minimum and maximum values for the different food categories 
(values obtained from different subjects), but reflect the minimum and maximum intakes of caffeine from all sources for 
all subjects in the survey and age group across the different dietary surveys. 
(d): Only one study (the Netherlands) with a sufficient number (≥ 60) of subjects who had consumed “energy drinks”, was 
available to estimate a statistically robust 95th percentile. 
(e): Only two studies (the Netherlands and Ireland) with a sufficient number (≥ 60) of subjects who had consumed “energy 
drinks”, were available to estimate statistically robust 95th percentiles. 
  
Safety of caffeine 
 
EFSA Journal 2015;13(5):4102 26 
 Daily caffeine intakes from each food group by age class and food group for consumers of Table 3: 
that food group only across different dietary surveys 
Age class Food groups Mean caffeine intake 95
th
 percentile caffeine intake 
(a)
 
mg per day mg/kg bw  
per day 
mg per day mg/kg bw  
per day 
Min 
(b)
 Max 
(b)
 Min 
(b)
 Max 
(b)
 Min 
(b)
 Max 
(b)
 Min 
(b)
 Max 
(b)
 
Toddlers  
(12 to < 36 
months; 10 
surveys) 
Chocolate 1.6 46.8 0.1 3.2 6.2 26.3 0.5 2.2 
Coffee 0.7 67.5 0.1 6.1 – – – – 
Cola beverages 1.7 18.0 0.2 1.3 – – – – 
“Energy drinks” 8.0 8.0 0.8 0.8 – – – – 
Tea 6.8 24.8 0.5 1.9 20.6 61.9 1.7 5.1 
Other 
children  
(3 to < 10 
years; 17 
surveys) 
Chocolate 2.6 44.8 0.1 1.8 6.8 105.0 0.4 5.0 
Coffee 1.1 62.1 0.1 2.5 29.7 29.7 1.3 1.3 
Cola beverages 5.9 19.8 0.3 1.0 18.0 53.4 0.9 2.1 
“Energy drinks” 6.5 58.5 0.4 1.9 – – – – 
Tea 9.5 38.1 0.4 1.4 26.0 98.8 0.8 3.8 
Adolescents 
(10 to < 18 
years; 16 
surveys) 
Chocolate 4.0 46.4 0.1 1.0 14.1 165.4 0.3 3.2 
Coffee 14.1 93.1 0.3 1.5 103.5 246.1 1.9 4.4 
Cola beverages 13.4 46.5 0.3 0.8 36.0 124.7 0.7 2.0 
“Energy drinks” (c) 29.0 90.1 0.6 1.4 145.6 145.6 2.9 2.9 
Tea 9.0 72.0 0.2 1.2 43.3 216.7 1.2 3.5 
Adults  
(18 to < 65 
years; 16 
surveys) 
Chocolate 3.8 24.9 0.1 0.4 15.1 84.0 0.2 1.3 
Coffee 32.9 347.0 0.5 4.6 80.1 775.6 1.2 10.2 
Cola beverages 12.0 45.8 0.2 0.7 32.8 121.8 0.5 1.7 
“Energy drinks” (d) 23.5 98.5 0.3 1.2 152.0 200.0 2.0 2.8 
Tea 6.6 111.0 0.1 1.5 41.3 264.0 0.7 3.6 
Elderly  
(65 to < 75 
years; 13 
surveys) 
Chocolate 4.1 13.7 0.1 0.2 7.9 60.5 0.1 0.7 
Coffee 36.5 339.3 0.5 4.5 224.7 712.0 3.3 10.3 
Cola beverages 5.9 30.1 0.1 0.4 95.2 95.2 1.1 1.1 
“Energy drinks” 32.0 132.8 0.4 1.6 – – – – 
Tea 19.8 135.8 0.3 1.8 66.0 335.0 1.0 4.6 
Very 
elderly  
(≥ 75 years; 
11 surveys) 
Chocolate 5.1 22.3 0.1 0.4 21.8 34.1 0.3 0.5 
Coffee 34.3 382.6 0.5 5.5 247.0 446.8 3.7 6.1 
Cola beverages 3.9 26.5 0.1 0.3 43.2 43.2 0.6 0.6 
“Energy drinks” 24.0 113.1 0.4 1.7 – – – – 
Tea 19.0 130.8 0.2 1.9 55.0 283.5 0.9 4.2 
(a): The 95th percentile estimates obtained from dietary surveys and age classes with fewer than 60 subjects may not be 
statistically robust (EFSA, 2011b) and consequently were not considered in this table (“–”). 
(b): Minimum (min) and maximum (max) means and 95th percentiles of those calculated from individual surveys for each 
age class. Total caffeine intakes cannot be calculated for “consumers only” by calculating the sum of caffeine 
consumption from coffee, tea, colas and energy drink, because these figures reflect the intakes of different subjects 
(consumers of the food group). 
(c): Only one study (the Netherlands) with a sufficient number (≥ 60) of subjects who had consumed “energy drinks” was 
available to estimate a statistically robust 95th percentile. 
(d): Only two studies (the Netherlands and Ireland) with a sufficient number (≥ 60) of subjects who had consumed “energy 
drinks” were available to estimate statistically robust 95th percentiles. 
Adults, the elderly and the very elderly 
Daily caffeine intake from all sources could be estimated for adults from 16 Member States. Means 
and 95
th
 percentiles ranged from 37 to 319 mg and from 109 to 742 mg, respectively, among countries 
(Table 2, Appendix B). 
In most surveys, coffee was the predominant source of caffeine for the adult population and 
contributed between 40 and 94 % to total caffeine intake. In Ireland and the UK, tea was the main 
source of caffeine, which contributed 59 and 57 %, respectively, to total caffeine consumption 
(Appendix E). 
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Considering caffeine intake in consumers of the different caffeine-containing food groups, coffee 
consumers had the highest 95
th
 percentile of caffeine consumption per day (up to 776 mg of caffeine 
from coffee), followed by tea drinkers (up to 264 mg of caffeine from tea), “energy drink consumers” 
(up to 200 mg of caffeine from “energy drinks”) and consumers of cola beverages (up to 122 mg of 
caffeine from cola drinks) (Table 3). 
Daily intake estimates for the elderly and very elderly are of a similar magnitude, with a tendency for 
lower 95
th
 percentiles. Cola beverages and energy drinks were negligible as sources of caffeine in 
these population groups in all surveys. 
Pregnant women 
Data on pregnant women are available for Latvia only (n = 1 002). The mean and the 95
th
 percentile of 
the daily caffeine intake from all sources were 109 mg and 206 mg per day, respectively 
(Appendix B). 
Lactating women 
Data on lactating women are available from only a small survey in Greece (n = 65). The mean and the 
95
th
 percentile of the daily caffeine intake from all sources were 31 mg and 97 mg per day, 
respectively (Appendix B). 
Adolescents 
Daily caffeine intakes from all sources could be estimated for adolescents from 13 Member States. 
Means and 95
th
 percentiles ranged from 18 to 70 mg and from 61 to 212 mg, respectively, among 
countries (Table 2, Appendix B). On a per kg bw per day basis, the mean intakes ranged from 0.4 to 
1.4 mg/kg bw per day. The 95
th
 percentile varied between 1.5 and 4.1 mg/kg bw per day 
(Appendix B). 
There were large differences among countries regarding the contribution of different food sources to 
total caffeine intake (Appendix E). Chocolate was the main contributor to caffeine intake in six 
surveys, coffee was the main contributor in four surveys, cola beverages were the main contributors in 
three surveys and tea was the main contributor in two surveys. Differences between surveys regarding 
the contribution of different caffeine sources to total caffeine intakes could be explained, at least in 
part, by the different mean age of the adolescents studied in the different surveys and by dietary habits. 
The highest contribution to total caffeine intakes from “energy drinks” was found for adolescents in 
the UK (11 %), followed by those in the Netherlands (8.1 %) and Belgium (5.3 %). In only the first 
two was a specific code for “energy drinks” available in the database. 
Toddlers and other children 
For toddlers, 10 surveys were available. Mean daily intakes of caffeine ranged from 0 to 2.1 mg/kg bw 
per day (Table 2, Appendix B). The 95
th
 percentile ranged from 0.1 to 3.5 mg/kg bw per day. Tea or 
chocolate was the main caffeine source in all surveys except for Belgium, where cola drinks 
contributed the most to total caffeine intake (58 %; Appendix E). Mean daily caffeine intake was 
1.1 mg/kg bw per day in this country (Appendix B). 
For children aged 3 to < 10 years, 17 surveys were available. Mean daily intake of caffeine from all 
sources ranged from 0.2 to 2.0 mg/kg bw per day. The 95
th
 percentile ranged from 1.2 to 4.6 m/kg bw 
per day. 
In most countries, “chocolate” (which also includes cocoa drinks) was the predominant source of 
caffeine for children aged 3 to 10 years, followed by tea and cola drinks (Appendix E). “Energy 
drinks” were a negligible source of caffeine for children up to 10 years of age in the surveys 
considered. 
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3.3.1.2. Caffeine intake on a single day 
Ninety-fifth percentiles are also reported for total caffeine intakes on single survey days (considering 
all days available) and for caffeine intakes from a given caffeine source on single survey days on 
which that caffeine source was consumed (Appendices C and D). 
Data from multiple survey days for the same individual are considered independently, and data from 
all surveys, including those with a single survey day per individual, have been included. The 95
th
 
percentiles of caffeine intake on a single day have been calculated to gather information on days of 
particularly high caffeine consumption, but these do not provide information about the proportion of 
subjects with high caffeine consumption days. 
Adults, the elderly and the very elderly 
For adults, the highest 95
th
 percentile of caffeine intake on a single day was 809 mg (10.8 mg/kg bw) 
(Appendices C and D). 
When considering only coffee consumption days, the highest 95
th
 percentile of caffeine intake from 
coffee on a single day was 890 mg. The highest 95
th
 percentiles of caffeine intake from “energy 
drinks”, tea and cola on a single day were 330, 308 and 216 mg, respectively. 
Adolescents 
The highest 95
th
 percentiles of caffeine intake on a single day in absolute values and on a per kg bw 
basis were 240 mg and 4.3 mg/kg bw, respectively (Appendices C and D). 
When considering only coffee consumption days, the highest 95
th
 percentile of caffeine intake from 
coffee on a single day was 445 mg (Appendix C). The highest 95
th
 percentiles of caffeine intake from 
“energy drinks”, tea, chocolate and cola were 330, 308, 253 and 142 mg, respectively. On a per kg bw 
basis, the highest 95
th
 percentile of caffeine intake was from coffee (7.1 mg), followed by chocolate 
(5.4 mg), “energy drinks” (5.2 mg), tea (5.0 mg) and cola beverages (2.4 mg). 
Toddlers and other children 
For toddlers, the highest 95
th
 percentile of caffeine intake per kg bw on a single day when considering 
all days recorded was 7.1 mg/kg bw (Appendices C and D). Sufficient (n ≥ 60) days to obtain 
statistically robust 95
th
 percentiles for toddlers regarding caffeine intakes from different sources on 
consumption days were available only for chocolate and tea, for which the highest values across 
Member States were estimated to be 5.3 and 9.6 mg/kg bw per day of caffeine, respectively 
(Appendix C). 
For children aged 3 to 10 years, the highest 95
th
 percentile of caffeine intake from all sources on a 
single day was estimated to be 5.7 mg/kg bw (Appendices C and E). When considering only days with 
consumption of the different food categories, the 95
th
 percentile of caffeine intake from coffee 
provided the highest estimate (15 mg/kg bw per day), followed by chocolate (7.7 mg/kg bw per day) 
(Appendix C). 
3.3.2. Caffeine intake from “energy drinks” in a “single session” estimated from the EFSA 
report on “energy drinks” 
Table 4 summarises caffeine intakes from “energy drinks” consumed in a “single session” by adults 
and adolescents who were “energy drink consumers” (i.e. at least once in the previous year). The table 
also indicates the prevalence of subjects who declared that they consume three or more “energy 
drinks” per “single session”. Data were available from 16 Member States (Zucconi et al., 2013). 
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 Caffeine intakes from “energy drinks” in a “single session” by “energy drink consumers” Table 4: 
and prevalence of subjects consuming three or more cans of “energy drink” per single session 
  Caffeine intake per single session 
(a)
 Percentage of “energy 
drink consumers” 
consuming ≥ 3 cans 
per single session 
Percentage of 
total respondents 
consuming ≥ 3 
cans per single 
session 
Mean 95
th
 percentile 
mg mg/kg bw mg mg/kg bw 
Adolescents (10–
18 years) 
176 2.9 450 7.2 24 16.3 
Adults (18–65 
years) 
155 2.2 344 5.1 19 5.7 
(a): “Single session” was defined as a period of time of a couple of hours (e.g. a night out, study session or sport session); 
not studied in children. 
 
Adults 
The mean and 95
th
 percentile of caffeine intakes in a “single session” from “energy drinks” in adult 
“energy drink consumers” were 155 mg and 344 mg, respectively (Table 4). In this survey, 52, 29, 11, 
5 and 3 % of “energy drink consumers” declared that they consume one, two, three, four and five or 
more cans of “energy drinks” within a “single session”. 
Adolescents 
The mean and 95
th
 percentile of caffeine intakes in a “single session” from “energy drinks” in 
adolescent “energy drink consumers” were 176 mg and 450 mg, respectively (Table 4). On a per kg 
bw basis, these intakes were estimated to be 2.9 and 7.2 mg, respectively. In this survey, 51, 25, 11, 6 
and 7 % of “energy drink consumers” declared that they consume one, two, three, four and five or 
more cans of “energy drinks” within a “single session”. 
3.3.3. Prevalence of “energy drink” consumption 
3.3.3.1. EFSA Comprehensive European Food Consumption Database 
The prevalence of “energy drink consumers” (defined as subjects who consumed “energy drinks” at 
least on one day during the survey) among the 17 surveys introduced into the EFSA Comprehensive 
Database in 2014 using the FoodEx2 code for “energy drinks” was < 10 %. The highest prevalences of 
“energy drink consumers” were observed in adolescents (9 % in the Netherlands, 7 % in the UK and 
5 % in Finland) and adults (8 % in Ireland, 4 % in the Netherlands and 3 % in the UK). In these 
surveys, the prevalence of “energy drink consumers” was most often zero and never exceeded 1 % in 
toddlers (five surveys), children aged 3–10 years (seven surveys), the elderly (10 surveys) and very 
elderly (eight surveys), lactating women (one survey) and pregnant women (one survey). 
3.3.3.2. EFSA report on “energy drinks” 
Table 5 provides an overview of the prevalence of “energy drink consumers” (defined as consumers of 
“energy drinks” on at least one occasion during the previous year) alone and in combination with 
physical activity. 
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 Prevalence (%) of “energy drink consumers” and of consumers of “energy drinks” in Table 5: 
combination with physical activity expressed as minimum and maximum ranges among 16 Member 
States and as mean values for all surveys combined 
 Children  
(3–10 years) 
Adolescents  
(10–18 years) 
Adults  
(18–65 years) 
 Mean Min Max Mean Min Max Mean Min Max 
“Energy drink consumers” (a)  18 6 40 68 48 82 (b) 30 14 50 
Consumers of energy drinks plus physical 
activity 
(c)
 among “energy drink consumers”  
– – – 41 14 65 52 26 62 
Consumers of ≥ 3 “energy drinks” plus 
physical activity among “energy drink 
consumers” 
– – – 11 – – 14 – – 
Consumers of “energy drinks” plus physical 
activity 
(c)
 among total respondents 
– – – 28 – – 16 – – 
Consumers of ≥ 3 “energy drinks” plus 
physical activity among total respondents 
– – – 8 – – 4 – – 
(a): Percentage of “energy drink consumers” among total respondents. 
(b): The highest prevalence of “energy drink” consumption among total respondents was observed in Belgium (85 %), but 
these data were not considered owing to the small sample size available for that MS (sampling error of estimates 
exceeds 5 %). 
(c): Percentage of subjects who declared that they usually consume “energy drinks” before/in association with/after sports 
activities. Children were not studied. 
–, not available. 
The Panel notes that the prevalence of “energy drink consumers” in this survey is considerably higher 
than that calculated from the EFSA’s Comprehensive Database, mainly because of differences in the 
definition of “consumers” and in the methodology used to retrieve consumption data. 
Adults 
About 52 % of adult “energy drink consumers” (15 % of all respondents) declared that they usually 
consume “energy drinks” before/in association with/after sports activities (Table 5). According to this 
survey, 47, 26, 13, 9 and 5 % of this population declared that they consume one, two, three, four and 
five or more cans of “energy drinks” in relation to a single sport session. 
Adolescents 
About 41 % of adolescent “energy drink consumers” (about 28 % of all respondents) declared that 
they usually consume “energy drinks” in relation to sport activities (Table 5). In this survey, 48, 25, 
13, 7 and 7 % of this population declared that they consume one, two, three, four and five or more 
cans of “energy drinks” in relation to a single sport session. 
3.4. Limitations of the available caffeine intake data and data gaps 
The surveys included in the EFSA Comprehensive Database vary considerably regarding several 
aspects, e.g. the methodology used to retrieve food consumption data (e.g. number of survey days, 
dietary recalls versus dietary records), the number of subjects and age range of the subjects included, 
the sampling year(s). Such differences do not allow direct between-country comparisons, and thus 
ranges of means and 95
th
 percentiles across surveys should be interpreted with caution. Data are 
particularly scarce for pregnant and lactating women, and absent regarding the consumption of 
caffeine-containing supplements. The EFSA Comprehensive Database is useful to gather data on daily 
caffeine intakes from all sources from unselected populations and population subgroups, as well as on 
the contribution of different food groups to total caffeine intakes. 
The EFSA “energy drink” report provides information about caffeine intakes by adolescents and 
adults from “energy drinks” on a “single session”, also in relation to a “single session” of physical 
exercise. Although the time covered by the term “single session” is imprecise, these data give an idea 
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of the amounts of caffeine from “energy drinks” consumed as a single dose or during short periods of 
time. However, the same type of information is not available for consumers of other caffeine sources 
that may provide similar or higher doses of caffeine in short periods of time (e.g. coffee, caffeine 
supplements), or for other population subgroups (e.g. children, pregnant women). 
4. Hazard identification 
As indicated in the background provided by the European Commission and in Section 2.4 of this 
opinion, the health concerns expressed by national and international risk assessment bodies in relation 
to caffeine mostly refer to its effects on pregnancy outcomes, the cardiovascular system and the CNS. 
Concerns were also raised with respect to caffeine in so-called “energy drinks” (i.e. also containing 
taurine and D-glucurono-γ-lactone), particularly if combined with alcohol, and to food supplements 
containing caffeine and p-synephrine. As in previous risk assessments by, for example, the SCF and 
EU Member State Committees, the present opinion considers primarily human data and addresses 
specific subgroups of the population, such as pregnant and lactating women, children and subjects 
performing physical exercise. 
4.1. Absorption, distribution, metabolism and excretion 
4.1.1. Adults 
In humans, caffeine is rapidly (tmax 30–120 minutes) and completely absorbed after oral intake 
(Blanchard and Sawers, 1983). Once absorbed, it freely crosses the blood–brain, placental and blood–
testicular barriers (Weathersbee and Lodge, 1977; Arnaud, 1993). The volume of distribution is 
0.671 L/kg bw (Abernethy and Todd, 1985). 
The main route of metabolism in humans (70–80 %) is via N-3 demethylation to paraxanthine (also 
known as 1,7-dimethylxanthine or 17X) catalysed by cytochrome (CYP) 1A2 in the liver. Other 
primary metabolites are theophylline and theobromine. Activity of CYP1A2 accounts for about 95 % 
of caffeine clearance, a smaller proportion is metabolised by CYP3A4, xanthine oxidase and  
N-acetyltransferase 2 (Berthou et al., 1991; Miners and Birkett, 1996). Caffeine has a plasma half-life 
of about four hours with range of about two to eight hours (Knutti et al., 1981; Abernethy and Todd, 
1985; Abernethy et al., 1985; Balogh et al., 1995). The kinetics of caffeine have been reported to be 
linear in doses up to 10 mg/kg bw (Bonati et al., 1982), whereas a later study claimed non-linearity 
beginning at doses as high as 500 mg, corresponding to about 7.1 mg/kg bw (Kaplan et al., 1997). 
Paraxanthine, theophylline and theobromine are further metabolised and then excreted in the urine. 
Several studies investigated the effect of the genetic polymorphism of the CYP1A2 gene, smoking, 
coffee consumption, sex, pregnancy and oral contraceptives on caffeine metabolism and clearance. 
CYP1A2 polymorphism has been reported to be a source of variability in the metabolism of caffeine 
between individuals measured by caffeine metabolites in urine (Rasmussen et al., 2002). These authors 
also found a higher CYP1A2 activity in smokers and men than in non-smokers and women, 
respectively. A lower CYP1A2 activity was found in women taking oral contraceptives. A single base 
change of A to C at position 734 within intron 1 of the CYP1A2 gene decreases inducibility of the 
enzyme (Sachse et al., 1999; Han et al., 2001). This polymorphism is also referred to as CYP1A2*1F 
or -163C>A (AA, AC, CC) genotypes (Cornelis et al., 2006; Djordjevic et al., 2010) or as single 
nucleotide polymorphism (SNP) “rs762551” registered in the SNP Database of the US National 
Center for Biotechnology Information (http://www.ncbi.nlm.nih.gov/SNP). The homozygote AA 
genotype has been considered by some authors as a “fast metaboliser”, while the AC and CC 
genotypes were considered to be “slow metabolisers”. In four publications, the combined prevalence 
of the “slow” CC and AC genotypes was reported to be between 52 and 60 %, whereas the “fast” AA 
genotype was reported to be between 48 and 40 % (Sachse et al., 1999; Han et al., 2001; Cornelis et 
al., 2006; Wang et al., 2012). Djordjevic et al. (2010) and Rodenburg et al. (2012) reported a higher 
prevalence for the AA genotype (61 % in Serbs; 54 % in Dutch). 
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Tantcheva-Poor et al. (1999) studied the effect of genetic (CYP1A2, sex) and lifestyle (coffee 
consumption, smoking, intake of oral contraceptives) factors of 786 individuals on the clearance of 
caffeine with a single saliva sample taken five to seven hours after a test dose of about 145 mg 
caffeine. Overall, the geometric mean (geometric standard deviation (SD)) of caffeine clearance was 
1.34 mL/min/kg bw (1.65). Relevant factors influencing clearance were (i) daily coffee consumption, 
increasing clearance 1.45-fold per consumed litre; (ii) smoking, increasing clearance 1.22-fold, 1.47-
fold, 1.66-fold and 1.72-fold for 1–5, 6–10, 11–20 and > 20 cigarettes smoked per day, respectively; 
(iii) oral contraceptives, reducing clearance by 0.72-fold; and (iv) female gender, reducing clearance 
by 0.90-fold. These covariates explained 37 % of overall variation in clearance. The clearance data did 
not indicate a relevant functional polymorphism for CYP1A2 activity when adjusted for covariate 
effects. 
CYP1A2 enzyme induction and higher caffeine clearance in smokers have also been reported in other 
studies (Joeres et al., 1988; Ghotbi et al., 2007). Ghotbi et al. (2007) and Sachse et al. (1999) found 
significantly higher CYP1A2 activity in smokers of the CYP1A2 -163AA genotype (“fast”) than in 
smokers of the (“slow”) AC and CC genotypes. No difference was found in enzyme activity among 
the three genotypes in non-smokers in these two studies. 
In addition, coffee consumption of more than two cups per day was significantly associated with 
higher CYP1A2 activity in non-smoking Swedes and Serbs, but only in the CYP1A2 -163AA 
genotype (Djordjevic et al., 2010). No increased CYP1A2 activity was found for coffee consumers of 
less than three cups of coffee per day, irrespective of this SNP, and for the “slow” CC and AC 
genotypes, irrespective of their coffee consumption. 
More than 150 SNPs have been identified for CYP1A2 (dbSNP database: 
http://www.ncbi.nlm.nih.gov/SNP/) (Yang et al., 2010) with unknown functional relevance concerning 
caffeine metabolism. 
In a study with eight healthy individuals, two subjects who were taking oral contraceptives had 
significantly longer caffeine half-lives (15.5 ± 0.3 hours versus 5.6 ± 1.7 hours) and lower values for 
oral clearance (0.34 ± 0.01 mL/min/kg bw versus 0.99 ± 0.41 mL/min per kg bw) than subjects who 
were not taking oral contraceptives (Haller et al., 2002). These results are consistent with earlier 
studies on the influence of sex steroids on caffeine metabolism (Rietveld et al., 1984; Abernethy and 
Todd, 1985; Balogh et al., 1995). In addition, severe liver disorders (Arnaud, 1993) and some drugs 
(Carrillo and Benitez, 2000) have been reported to cause a significant inhibition of CYP1A2 activity. 
4.1.2. Pregnant women 
During pregnancy, the half-life of caffeine increased in 15 pregnant women to a range of 6–16 hours 
and returned to a range of two to eight hours within 4 and 15 weeks after delivery (Knutti et al., 1982). 
The reported prolonged half-life for pregnant women is consistent with results from other studies. For 
the end of pregnancy, the half-life of caffeine in non-smoking women was reported to be 11.5 hours 
(Arnaud, 1993) and 18 hours (Aldridge et al., 1981). This observation can be explained by the 
interaction of caffeine with oestrogens and gestagens which have been shown to inhibit the activity of 
CYP1A2 (Rietveld et al., 1984; Abernethy et al., 1985; Balogh et al., 1995). Tracy et al. (2005) 
reported that CYP1A2 activity was significantly and progressively lower during pregnancy  
(–32.8 ± 22.8 % for weeks 14–18), (–48.1 ± 27 % for weeks 24–28) and (–65.2 ± 15.3 % for weeks 
36–40) than during the postpartum period. Similar quantitative and progressive reductions of CYP1A2 
activity during pregnancy have been reported (Tsutsumi et al., 2001). The Panel notes that CYP1A2 
activity is reduced during pregnancy and, hence, the half-life of caffeine is increased. At the end of 
pregnancy, the half-life of caffeine is three to four times longer than in the non-pregnant state. This 
would lead to higher blood concentrations of caffeine at the end of pregnancy than in the non-pregnant 
state if caffeine intake is kept constant during pregnancy. 
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4.1.3. Fetus 
Caffeine readily crosses the placenta into the fetus. Amniotic fluid and maternal serum concentrations 
of caffeine are believed to be reliable indicators of fetal serum concentration. Given the prolonged 
half-life of caffeine during pregnancy and considering that neither the fetus nor the placenta can 
metabolise caffeine, fetuses of caffeine-consuming women are exposed to caffeine and its metabolites 
for a significantly prolonged time (Grosso et al., 2006). 
4.1.4. Breastfed infants 
In a study on 18 nursing mothers who abstained for 24 hours from eating and drinking caffeine-
containing food, the concentration of caffeine was measured in plasma and milk two and four hours 
after the intake of caffeine from coffee (148 ± 48 mg). The average milk/maternal plasma ratio was 
0.8 ± 0.07. Intake in the nursed infants (4 days to 19 weeks) was estimated to be between 0.03 and 
0.2 mg/kg bw per day. In eight of the infants, the caffeine concentration was measured in their saliva, 
which is close to the non-protein bound fraction of caffeine in plasma (90 %). The concentration in the 
saliva of infants was 0.38 ± 0.2 mg/L, whereas the peak concentration in the plasma of the mothers 
was about 3 mg/L, thus indicating low intakes of the infants (Hildebrandt and Gundert-Remy, 1983). 
In two studies (Steer et al., 2003, 2004), pre-term neonates were treated for extubation with caffeine 
doses of 3 mg/kg bw (n = 42), 5 mg/kg bw (n = 121), 15 mg/kg bw (n = 40) 20 mg/kg bw (n = 131) 
and 30 mg/kg bw (n = 45). Mean caffeine concentrations in the 3 mg/kg bw group, the 15 mg/kg bw 
group and the 30 mg/kg bw group were 6.7 mg/L, 31.4 mg/L and 59.9 mg/L, respectively. The 
observed side effects of caffeine administration were tachycardia (defined as heart rate > 200 bpm) 
and jitteriness. Tachycardia was observed in 1 out of 42 pre-term infants in the 3 mg/kg bw group, in 
1 out of 121 infants in the 5 mg/kg bw group, in 5 out of 40 infants in the 15 mg/kg bw group, in 4 out 
of 131 infants in the 20 mg/kg bw group and in 8 out of 45 infants in the 30 mg/kg bw group. 
Jitteriness was observed in 1 out of 42 infants in the 3 mg/kg bw group, 2 out of 121 infants in the 
5 mg/kg bw group, 1 out of 40 infants in the 15 mg/kg bw group, 2 out of 131 infants in the 20 mg/kg 
bw group and 0 out of 45 infants in the 30 mg/kg bw group. As pre-term neonates are considered an 
especially sensitive population subgroup, these results can be extrapolated to neonates and breastfed 
infants in general as the most conservative estimates of the prevalence of side effects. 
The half-life of caffeine in neonates who have no CYP1A2 activity has been reported to range from 50 
to 103 hours (Ginsberg et al., 2004; Grosso et al., 2006). However, the half-life of caffeine is rapidly 
reduced in the first months of life, decreasing to 14 hours at three to four months of age and to two to 
three hours at five to six months of age (Aranda et al., 1979). Caffeine’s half-life appears to remain 
stable at about two to three hours during childhood and increase thereafter in adolescents and adults. 
Caffeine clearance from plasma has been estimated to be 5 to 20 % faster in children than in adults 
(NNT, 2008). 
4.1.5. Conclusions 
The Panel notes that several genetic and non-genetic factors have been reported to significantly affect 
caffeine metabolism by CYP1A2 for various population groups. Considering the reduced maternal 
clearance and prolonged half-life during pregnancy, and the fetus’s exposure to maternal caffeine 
plasma levels, the Panel considers unborn children to be the most vulnerable group for adverse effects 
of caffeine among the general population. 
4.2. Pharmacodynamic effects 
The pharmacology of caffeine has been extensively studied. The effects of caffeine are predominantly 
related to its antagonistic activity at adenosine receptors. Of the four adenosine receptors (A1, A2A, A2B 
and A3), caffeine acts as an antagonist to adenosine A1 and A2A receptors that are expressed in the 
CNS, in particular at the basal ganglia, which are involved in motor activity. The psychomotor 
stimulant effect of caffeine is generated by affecting a particular group of projection neurons located 
in the striatum, the main receiving area of the basal ganglia expressing high levels of adenosine A2A 
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receptors. Caffeine acts, at least in part, by facilitating dopamine D2 receptor transmission. Its 
mechanism of action appears to be substantially different from that of “dopaminomimetic” 
psychostimulants, such as cocaine and amphetamine (Fisone et al., 2004; Ferre, 2008). Caffeine is also 
known as a non-specific phosphodiesterase inhibitor, with a Ki of 48 µM, corresponding to the peak 
concentration after a 450 mg dose (Aronsen et al., 2014). 
The diuretic activity of caffeine can be explained by an interaction with the adenosine receptor A1 in 
the kidney, leading to inhibition of renal re-absorption and causing diuresis and natriuresis (Rieg et al., 
2005). 
Tolerance to caffeine is observed after repeated administration. The mechanism is not well 
understood. It has been attributed to upregulation of adenosine receptors (Ammon, 1991). Fast 
tolerance development has been observed concerning the pressor effects of caffeine (Shi et al., 1993). 
Prolonged administration of an adenosine A2A receptor antagonist does not induce tolerance to its 
motor stimulant effect, suggesting that caffeine tolerance may be dependent on blockade of A1, rather 
than A2A, receptors (Ferre, 2008). Tolerance in humans develops to some, but not to all, effects of 
caffeine and the development of tolerance is highly variable among the population (Fredholm et al., 
1999). Tolerance to the effects of caffeine on blood pressure and heart rate usually develops within a 
couple of days and it is accompanied by lower release of adrenaline, noradrenaline and renin than in 
the non-tolerant state. It is uncertain if the development of tolerance may explain the difference in the 
sensitivity to the effects of coffee on sleep. Some authors consider that the difference instead reflects 
inter-individual variations in sensitivity to the effects of caffeine as well as intra-individual variability. 
Symptoms such as headache, fatigue, decreased energy and activeness, decreased alertness, 
drowsiness, decreased contentedness, depressed mood, difficulty concentrating, irritability and being 
not clear headed are observed 12–24 hours after abstinence and this clinical situation is called caffeine 
withdrawal syndrome (Juliano and Griffiths, 2004). 
Polymorphisms in adenosine receptors have also been described and for some effects of caffeine the 
effect size might be related to the polymorphic state (Alsene et al., 2003). 
4.3. Adverse effects of caffeine: methodological considerations 
In order to update the safety assessment of caffeine conducted in 1999 by the SCF (SCF, 1999), EFSA 
launched a procurement project (RC/EFSA/NUTRI/2013/01) to retrieve articles published from 1997 
onwards which addressed the effects of caffeine consumption in humans on different health outcomes 
(Bull et al., 2014). Previous risk assessments by other bodies and spontaneous submissions from 
stakeholders were also considered by the Panel when retrieving articles published up to June 2014 
which could be used as a source of data in the present assessment. 
The Panel considers that human intervention studies and human observational studies (prospective 
cohort, case–control and cross-sectional studies) with adequate control for confounding variables and 
which have been conducted in healthy subjects at recruitment are appropriate for evaluating potential 
adverse effects of caffeine consumption in humans. Moreover, studies conducted in subjects selected 
on the basis of a disease condition (e.g. established CVD, neurological or psychiatric diseases, 
behavioural or sleep disorders, diabetes mellitus and other metabolic disorders, renal or hepatic 
insufficiency, open angle glaucoma) do not allow conclusions to be drawn on the safety of caffeine for 
the general healthy population or subgroups thereof. Whenever available, human intervention studies 
and prospective cohort studies were preferred over case–control and cross-sectional studies because of 
the lower risk of reverse causality and recall bias. The Panel also considers that case reports of adverse 
health events following consumption of caffeine-containing foods or beverages are useful to identify 
health concerns for further investigation. However, “cases” are, by definition, not representative of the 
general population or subgroups thereof and case reports generally provide insufficient information to 
conclude on the doses of caffeine which may be considered as safe for the general population or 
subgroups thereof (e.g. they do not provide sufficient information to allow a comparison between the 
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incidence of adverse events associated with the consumption of caffeine-containing products and the 
background incidence of such adverse events in the general population). For these reasons, case 
reports of adverse reactions following consumption of caffeine-containing foods or beverages, 
including “energy drinks”, will not be considered in the derivation of caffeine levels of no concern. 
Whenever available, systematic reviews and meta-analyses were used to summarise the scientific 
evidence. 
On the basis of the human studies identified, the Panel addressed possible adverse health effects of 
caffeine as a result of single doses (acute) or repeated doses within a day of longer-term consumption 
(single or repeated doses within a day consumed daily for ≥ 7 days, after caffeine habituation takes 
place, but for ≤ 1 month), and of habitual caffeine consumption (doses of caffeine consumed 
throughout the day for longer periods of time, usually months or years, ad libitum). 
4.4. Adverse effects of a single dose and of repeated doses of caffeine consumed within a day 
With few exceptions, the effects of a single dose and of repeated doses of caffeine consumed within a 
day from a variety of sources (including “energy drinks”), either alone or in combination with alcohol 
or p-synephrine, have been addressed in human intervention studies. Among the variety of outcomes 
investigated in these studies, the Panel focuses on the main health concerns expressed by other bodies 
in previous safety assessments, i.e. adverse effects of caffeine on the CVS and the CNS (also 
considering that the CVS and the CNS are the target organs for the acute effects of caffeine), and on 
water–electrolyte balance and body temperature, primarily in relation to physical exercise. Studies 
which did not report on safety outcomes (i.e. investigating the effects of caffeine on outcomes which 
were deemed to be beneficial for the target population recruited, such as attention, alertness or 
physical performance, and studies addressing the beneficial effects of caffeine in the treatment of 
various diseases) were not considered by the Panel in this assessment. 
The Panel notes that an assessment of the health effects of components other than caffeine in foods 
and beverages which are common dietary sources of caffeine (e.g. coffee, tea, soft drinks other than 
“energy drinks”, chocolate) is outside the scope of this opinion, and therefore human intervention 
studies which do not provide information about the effects of caffeine on the above-mentioned health 
outcomes (e.g. studies using caffeinated coffee/tea and caffeine as control; studies using different 
doses of decaffeinated coffee/tea with no caffeine group; uncontrolled studies with a caffeine group 
only) are not considered specifically. 
4.4.1. Cardiovascular system 
Early metabolic studies found that single caffeine doses of 200–250 mg acutely increase plasma renin 
activity, catecholamine concentrations and blood pressure (BP), and are able to induce cardiac (mostly 
atrial) arrhythmias in healthy, caffeine-naive subjects (Robertson et al., 1978; Dobmeyer et al., 1983). 
Possible mechanisms for the acute cardiovascular effects of caffeine include antagonistic effects on 
adenosine receptors, activation of the sympathetic nervous system (release of catecholamines from 
adrenal medulla), stimulation of the adrenal cortex (release of corticosteroids), renal effects (diuresis, 
natriuresis, activation of the renin–angiotensin–aldosterone system) and inhibition of 
phosphodiesterases (increase in cyclic nucleotides), although the contribution of each of these 
mechanisms to the acute cardiovascular effects of caffeine are unclear (Nurminen et al., 1999). It has 
been suggested that the acute effects of caffeine on the CVS may depend on the source of caffeine, the 
dose administered and caffeine plasma concentrations prior to caffeine administration. 
4.4.1.1. Blood pressure, endothelial function and arterial compliance 
Caffeine: single dose 
Nurminen et al. (1999) reviewed 20 controlled human intervention studies in normotensive subjects 
and five intervention studies in hypertensive subjects which had investigated the effects of single 
doses of caffeine or caffeinated coffee on BP. A single dose of caffeine (200–250 mg, equivalent to 
two to three cups of coffee) was found to increase systolic blood pressure (SBP) by 3–14 mmHg and 
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diastolic blood pressure (DBP) by 4–13 mmHg in normotensive subjects. Lower doses of caffeine 
were not tested. Changes in BP paralleled changes in plasma concentrations of caffeine. BP started 
increasing 30 minutes after caffeine administration to reach a maximal effect at 60–120 minutes, and 
lasted for about two to four hours. The effect was more pronounced in older subjects, in caffeine 
abstainers, during “mental or physical stress” and in subjects with hypertension. In a more recent 
meta-analysis (Mesas et al., 2011) of five randomised control trials (RCTs) conducted in subjects with 
hypertension, single caffeine doses of 200 to 300 mg induced a mean increase in SBP and DBP of 
8.1 mmHg (95 % confidence interval (CI) = 5.7–10.6 mmHg) and 5.7 mmHg (95 % CI = 4.1–
7.4 mmHg), respectively, which was observed in the first 60 minutes after intake and persisted up to 
180 minutes afterwards. The effect of caffeine on BP did not change with the dose (only 200 to 
300 mg was tested), the time of caffeine abstinence before the trial (9–48 hours) or the use of 
antihypertensive medication. 
The effects of a single dose of caffeine on arterial BP were investigated in 182 men stratified in five 
groups by their risk of hypertension (Hartley et al., 2000). The study sample included 73 men with 
optimal BP, 28 men with normal BP, 36 men with high–normal BP, 27 men with stage 1 hypertension 
on the basis of resting BP and 18 men with diagnosed hypertension from a hypertension clinic. BP was 
measured after 20 minutes of rest and 45 to 60 minutes after the oral administration of caffeine 
(3.3 mg/kg bw or a fixed dose of 250 mg for an average dose of 260 mg). Caffeine significantly raised 
both SBP and DBP in all groups. However, the strongest response to caffeine was observed among 
diagnosed men (mean increase in SBP of 10 mmHg), followed by the stage 1 and high–normal groups 
and then by the normal and optimal groups, with a change 1.5 times greater in diagnosed hypertensive 
individuals than in the group with optimal BP. 
A number of controlled human intervention studies have been published on the effects of single 
caffeine doses (as supplements and in coffee, tea and “energy drinks”) on functional vascular 
outcomes, including endothelial function, arterial compliance and BP, in healthy subjects. The main 
characteristics of these studies are summarised in Appendix F. 
Acute increases in SBP, DBP or both, as well as in pulse pressure and mean arterial blood pressure 
(MABP), have been reported after single doses of caffeine ranging from 80 to 250 mg in coffee 
abstainers, in habitual caffeine consumers after 12–48 hours’ withdrawal and after caffeine habituation 
(300–600 mg per day for six days) (Hodgson et al., 1999; Lane et al., 2002; Farag et al., 2005a, b, 
2010; Arciero and Ormsbee, 2009; Worthley et al., 2010; Buscemi et al., 2011). The effect was 
inversely related to the level of physical activity in pre-menopausal women (Arciero and Ormsbee, 
2009), and did not translate into acute adverse changes in left ventricular repolarisation (corrected QT 
interval (QTc)) (Buscemi et al., 2011). 
In studies assessing endothelial function, compared with decaffeinated coffee, caffeinated coffee has 
been reported to significantly increase SBP (130 mg caffeine) and DBP (80 and 130 mg caffeine), as 
well as to decrease endothelium-dependent flow-mediated dilatation (FMD) in habitual moderate 
coffee consumers after 12–24 hours’ caffeine withdrawal (Papamichael et al., 2005; Buscemi et al., 
2010). A significant decrease in endothelial function (assessed by peripheral artery tomography) with 
concomitant increases in SBP and DBP was also reported after consumption of an “energy drink” 
containing 80 mg caffeine, 1 000 mg taurine and 600 mg D-glucurono-γ-lactone (Worthley et al., 
2010). Whether or not this effect could be explained by its content of caffeine was not addressed (no 
caffeine group). Conversely, a significant increase in acetylcholine-mediated, endothelium-dependent 
forearm blood flow (measured by brachial impedance plethysmography), which was reversible with 
the infusion of a nitric oxide synthetase inhibitor, was reported for a caffeine dose of 300 mg, which 
also induced a significant increase in both SBP and DBP (Umemura et al., 2006). 
All studies available in healthy individuals (Mahmud and Feely, 2001; Vlachopoulos et al., 2003, 
2006; Hartley et al., 2004; Karatzis et al., 2005; Swampillai et al., 2006) reported a significant adverse 
effect of caffeine (in supplements, coffee or tea) at doses of 100–250 mg on one or more measures of 
arterial compliance (e.g. forward compression and expansion waves or pulse wave velocity as 
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measures of stiffness; augmentation index and augmented pressure as measures of wave reflections), 
denoting an increase in arterial stiffness, which was accompanied by a simultaneous increase in one or 
more measures of BP (e.g. radial, aortic or brachial SBP and DBP, pulse pressure, MABP). The 
methods used to assess arterial compliance and BP, the arterial segments assessed and the indices 
derived as outcome variables differed among studies. Similar effects of caffeine on arterial compliance 
were found in men and women, although different mechanisms (increase in peripheral resistance 
versus increase in stroke volume and cardiac output, respectively) were proposed for each sex (Hartley 
et al., 2004). 
The clinical relevance of acute changes in endothelial function and arterial compliance following an 
intervention is unclear, particularly when simultaneous changes in BP occur (Anderson, 2006; McCall 
et al., 2011). Changes in BP, and therefore blood flow, are associated with changes in FMD and pulse-
wave velocity (PWV), which do not necessarily reflect an adverse change in the endothelial function 
or sustained stiffness of the artery (McCall et al., 2011). The acute changes in endothelial function and 
arterial compliance following caffeine consumption are vascular phenomena concordant with the acute 
increase in BP, which can be predicted from arterial physiology. Unlike for BP (see Section 4.5.1.2), 
there are no studies available on the longer-term effects of habitual caffeine consumption on these 
endpoints. 
Caffeine: repeated doses 
Two studies (Lane et al., 2002; Farag et al., 2005b) have investigated the effects of repeated doses of 
caffeine consumed within a day on 12- to 18-hour ambulatory BP in healthy habitual caffeine 
consumers (Appendix F). 
In a double-blind, randomised, placebo-controlled cross-over study (Lane et al., 2002), 47 healthy 
normotensive, non-smoking subjects (20 female) were given either placebo or two 250 mg doses of 
caffeine four hours apart (at 7.30–8.30 am and before 1.00 pm) on two separate trial days after an 
overnight fast. Ambulatory BP was monitored after the first caffeine dose until bedtime or 10.00 pm. 
Compared with placebo, caffeine significantly raised average SBP through the entire day by about 
4 mmHg and DBP by about 3 mmHg, whereas heart rate (HR) decreased by 2 bpm, with no significant 
interaction between treatment and location (at work, at home). Urinary free adrenaline levels were 
32 % higher with caffeine than with placebo, particularly at work. 
In a second study with a double-blind, randomised, placebo-controlled cross-over design (Farag et al., 
2005b), 85 healthy normotensive subjects (38 women) completed a four-week protocol. During each 
week, subjects consumed capsules containing 0, 100 or 200 mg of caffeine three times daily (daily 
doses of 0, 300 or 600 mg) for five days. On day 6, subjects consumed capsules at 9.00 am, 1.00 pm 
and 6.00 pm with either 0 or 250 mg caffeine after the placebo (P) maintenance dose and with 250 mg 
caffeine (C) after each caffeine maintenance dose (four interventions: P-P, P-C, C300-C and C600-C). 
Ambulatory BP was monitored on day 6 after the second caffeine dose until 7.00 am the following 
day. Subjects were dived into “high” and “low” tolerance groups on the basis of the median DBP 
response to the first two challenge caffeine doses (at 9.00 am and 1.00 pm) given after the highest 
caffeine maintenance dose (600 mg per day). The Panel notes that data were not analysed for all the 
study subjects combined. As expected, significant differences in daytime BP were observed across 
maintenance caffeine doses and tolerance groups. However, no significant week by tolerance group 
interactions were noted. Sleep BP also differed significantly across caffeine maintenance doses, but 
not between tolerance groups, with no significant week by tolerance group interactions for sleep SBP 
or DBP. Compared with P-P, daytime BP was significantly higher during P-C in both tolerance groups 
and during C300-C in the “low” tolerance group, with no differences during C600-C in either 
tolerance group or during 300-C in the “high” tolerance group. Similarly, sleep BP was significantly 
higher during P-C in both tolerance groups and during C300-C (only SBP) in the “low” tolerance 
group, with no differences during C600-C in either tolerance group or during C300-C in the “high” 
tolerance group. 
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These studies suggest that repeated doses of 250 mg caffeine taken four hours apart may induce a 
significant increase in daytime BP, that BP remains significantly elevated up to 9–12 hours after 
consumption of the last dose and that the effect, which depends on habitual caffeine consumption, is 
mostly observed after caffeine withdrawal. The Panel notes the high total caffeine intakes used in 
these studies (500–750 mg per day), that lower repeated doses of caffeine (< 250 mg) have not been 
tested and that the time between doses (four hours), about one half-life, is likely to induce an increase 
in plasma caffeine concentrations throughout the day. 
Caffeine and physical exercise 
Three randomised, placebo-controlled, human intervention studies assessed the effects of caffeine  
(4–6 mg/kg bw) ingested 45–60 minutes pre-exercise on BP before (n = 3), during (n = 2) and after 
(n = 2) resistance exercise in recreational resistance-trained, normotensive men (except for three 
women in Souza et al., 2014) who were habitual caffeine consumers after 48–72 hours of caffeine 
withdrawal (Astorino et al., 2007, 2013; Souza et al., 2014). The study by Astorino et al. (2013) 
included seven subjects with either high–normal or stage 1 hypertension, although the number of 
subjects with hypertension was not specified. Sample size ranged from 14 to 22. BP variables and 
exercise programmes varied among studies. In the study by Astorino et al. (2007), SBP, HR and rate-
pressure product (but not DBP) significantly increased during exercise with caffeine and placebo and 
were significantly higher before and during exercise with caffeine than with placebo, but no time by 
treatment interaction was observed, suggesting an additive (but not synergistic) effect of caffeine and 
exercise on BP. In the study by Astorino et al. (2013), in which four resistance exercise protocols were 
tested, SBP significantly increased during all exercise protocols and significantly decreased post 
exercise with caffeine and placebo. SBP was significantly higher before and two hours after exercise 
with caffeine than with placebo, whereas HR and DBP were not different between treatments. SBP 
was higher with caffeine than with placebo during only one (out of four) type of exercise and in the 
“pre-hypertensive” group only. Souza et al. (2014) reported a significant decrease in SBP and MABP 
and a significant increase in HR after exercise with caffeine and placebo. DPB and HR (but not SPB) 
were significantly higher at rest with caffeine than with placebo, as was peripheral vascular resistance 
(SBP, DBP, HR, stroke volume or cardiac output) in the nine hours post exercise. The Panel considers 
that, although these studies have small sample sizes and are difficult to compare, they suggest an 
additive effect of caffeine and resistance training on BP during exercise, and that caffeine could 
attenuate the decrease in BP observed after resistance training. 
Caffeine and other components of “energy drinks” 
Two randomised cross-over studies (Worthley et al., 2010; Grasser et al., 2014) assessed the effects of 
two “energy drinks” containing caffeine, taurine and D-glucurono-γ-lactone on BP and endothelial 
function compared with the same volume of water. One study (Bischoff, 2013)
13
 conducted at the 
University of Hohenheim and submitted to EFSA investigated the effects of an “energy drink” 
containing caffeine, taurine and D-glucurono-γ-lactone, with and without 75 g of alcohol, on multiple 
outcomes (including heart rate and BP) compared with the same volume of a caffeine-free soft drink. 
The Panel notes that these studies do not allow conclusions to be drawn on whether or not “energy 
drinks” have a BP-raising effect over and above what could be expected from their caffeine content. 
One open-label, randomised, two-period cross-over study investigated the effects of a single dose of 
an “energy drink” on BP compared with caffeine alone (Franks et al., 2012). Twelve healthy, non-
smoking, normotensive volunteers aged 18–45 years consumed one serving of “energy drink” (80 mg 
caffeine and 1 000 mg taurine per serving) four times at 8.00 am, 11.00 am, 3.00 pm and 7.00 pm, 
giving a total consumption of 320 mg caffeine and 4 000 mg of taurine. Subjects underwent the same 
protocol with caffeine alone (80 mg per serving in a similar volume) 4–30 days apart. The order of the 
intervention was randomised. During the interventions, 24-hour ambulatory BP was monitored. Data 
from nine subjects were available for analysis. The analysis showed that 24-hour SBP, DBP and mean 
                                                     
13 http://download.ble.de/09HS022/09HS022_AB.pdf  
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arterial BP were significantly higher with the consumption of “energy drinks” than with the 
consumption of caffeine alone (by 5.8, 5.3 and 5.3 mmHg, respectively), whereas HR and nocturnal 
dipping (SBP and DBP) did not differ. The Panel considers that, although this study suggests a greater 
BP-raising effect associated with the consumption of “energy drinks” than with caffeine alone, the 
small number of subjects included in the study, the high dropout rate (25 %) and the absence of 
blinding all limit the conclusions which can be drawn in relation to the effects of “energy drink” 
components other than caffeine on BP. 
The aforementioned study (Bischoff, 2013) contains information on a “pre-study” using a cross-over 
design conducted in 19 healthy subjects who received a single dose (1 000 mL) of a sports drink 
(control, free of caffeine, taurine or D-glucurono-γ-lactone), the sports drink plus taurine (4 000 mg), 
the sports drink plus caffeine (320 mg) and an “energy drink” (containing 4 000 mg of taurine, 320 mg 
of caffeine and 240 mg of D-glucurono-γ-lactone) on four separate occasions. The same preliminary 
testing was conducted in 19 other subjects using 750 mL (as a single dose) of the same beverages. A 
significant increase in SBP (by about 7–8 mmHg) was reported following consumption of the sports 
drink plus caffeine in both preliminary tests, whereas consumption of the other beverages did not 
increase SBP significantly. No significant changes in DBP were noted. The increase in SBP was 
significantly higher with the consumption of the sports drink plus caffeine than with the consumption 
of the control sports drink or the sports drink plus taurine, whereas no significant differences were 
observed compared with the “energy drink”. The Panel notes that the acute consumption of an “energy 
drink” did not increase BP over and above what could be expected from its caffeine content in this 
study. 
Caffeine and p-synephrine 
p-Synephrine has direct stimulant effects on the sympathetic nervous system, primarily via the α1- and 
β-adrenoreceptors. In contrast with ephedrine and amphetamines, which have known psycho-
stimulating effects in the CNS, synephrine is more hydrophilic, which leads to a lower transit across 
the blood–brain barrier and consequently to lower, or no, CNS stimulation. Therefore, any additive or 
synergistic effects of p-synephrine when consumed in combination with caffeine should be expected 
in the CVS. 
The effects of single doses of p-synephrine in food supplements containing C. aurantium extracts on 
BP have been investigated in a number of controlled human interventions as safety outcomes, which 
have been recently reviewed (Stohs et al., 2012). The main characteristics of these studies are 
summarised in Appendix G. Most studies used C. aurantium extracts only, and some used 
combinations of C. aurantium, guarana and/or green tea, among other botanical preparations, in which 
p-synephrine and caffeine were the main active ingredients (Haller et al., 2005a; Sale et al., 2006; 
Seifert et al., 2011). Studies with caffeinated coffee as the control (dose of caffeine not reported; 
Hoffman et al., 2006) or an unclear study design (Gougeon et al., 2005) will not be considered. 
The studies are generally small and the results difficult to interpret. Significant increases in SBP and 
DBP were reported for p-synephrine from C. aurantium extracts when consumed at doses of 54 mg, 
but not at lower doses (13.5–50 mg). Significant increases in SBP and DBP were also reported for a 
combination of 5.5 mg p-synephrine and 5.7 mg octopamine and caffeine (239.2 mg), and a significant 
increase in DBP, but not in SPB, was observed with 21 mg p-synephrine and 304 mg caffeine. 
Conversely, no significant changes in BP were found with p-synephrine (12–13 mg) and lower doses 
of caffeine (150–176 mg). However, similar doses of caffeine, on their own, have been consistently 
reported to increase BP significantly in other studies (Appendix F). The Panel notes that none of the 
available studies has investigated the effects on BP of single doses of caffeine alone, of p-synephrine 
alone or of their combination. The Panel considers that, from the information available, no conclusions 
can be drawn on whether or not the simultaneous consumption of p-synephrine modulates the pressor 
effects of caffeine, and if so to what extent or at what doses this occurs. 
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Conclusions 
The Panel notes that caffeine consumption acutely increases BP in virtually all adult population 
subgroups tested, regardless of baseline BP, regular caffeine consumption/time of caffeine withdrawal, 
age, sex or hormonal status. The effect was observed at single doses of caffeine ranging from 80 to 
300 mg, although most studies tested doses of about 200–300 mg, which induced a mean increase in 
SBP of about 3–8 mmHg and in DBP of about 4–6 mmHg, with high inter-individual variability. The 
available data suggest that BP generally increases 30 minutes after caffeine consumption, reaches a 
peak after 60–90 minutes and returns to baseline after about two to four hours, which is consistent 
with the pharmacokinetics of caffeine. The effect may be more pronounced in subjects with high BP 
and after caffeine withdrawal. The dose range tested in the majority of studies is tight and the dose–
response relationship has not been systematically assessed. The Panel also notes that repeated doses of 
caffeine (250 mg) taken four hours apart also induce an increase in BP (of about 3–4 mmHg) which 
may last up to 9–12 hours, particularly after caffeine withdrawal. The acute effects of lower caffeine 
doses and/or taken at longer time intervals on BP have not been tested in the studies available. High 
doses of caffeine (4–6 mg/kg bw, corresponding to about 280–420 mg for a 70-kg adult) ingested 45–
60 minutes prior to exercise could add to the BP-raising effect of resistance training and attenuate the 
decrease in BP observed after resistance training. Lower caffeine doses were not tested. The studies 
available do not provide sufficient information to conclude on whether consumption of p-synephrine, 
or of substances commonly found in “energy drinks” other than caffeine, modifies the acute effects of 
caffeine on BP. 
4.4.1.2. Myocardial blood flow 
Caffeine (like other methylxanthines) is a non-selective competitive A2A receptor antagonist which 
counteracts the vasodilator effect of adenosine and other A2A receptor agonists in the coronary arteries, 
where the density of such receptors is particularly high. The cardiac hyperaemic response to physical 
exercise is primarily mediated by the endogenous production of adenosine by myocytes as a 
consequence of hypoxia, which induces vasodilation of the coronary arteries. 
Physical exercise protocols are used to induce maximal vasodilation of the coronary arteries in nuclear 
stress myocardial perfusion imaging tests (MPI) for the diagnosis of (and risk stratification of patients 
with) coronary artery disease (CAD). When adequate exercise workloads cannot be achieved, non-
selective (i.e. adenosine, dipyridamole) and selective (i.e. regadenoson) agonists of the A2A receptor 
are used. The consumption of caffeine (and other methylxanthines) has been contraindicated 24 hours 
before vasodilator MPI tests (Henzlova et al., 2006) because it attenuates the coronary hyperaemia 
induced by adenosine and dipyridamole in a dose-dependent manner. 
A recent narrative review summarises the mechanisms by which caffeine could reduce myocardial 
blood flow (MBF) during exercise (Higgins and Babu, 2013). 
Few studies have investigated the effects of single doses of caffeine on MBF at rest and under stress 
(hyperaemic MBF), and on the myocardial blood flow reserve (MFR) calculated as the difference 
between MBF at rest and under stress, using nuclear imaging techniques. These studies have been 
conducted in young healthy subjects or in patients with CAD. Physical exercise protocols and 
regadenoson have been used as stressors to induce maximal coronary vasodilation. 
15
O-labelled water and positron emission tomography (PET) were used to assess the effects of caffeine 
on resting and exercise-induced hyperaemic MBF and the resulting MFR in conditions of normoxia 
and hypoxia (to simulate CAD states of oxygen deprivation) in 18 (seven female) healthy habitual 
coffee drinkers after 36 hours of caffeine withdrawal (Namdar et al., 2006). A minimum clinically 
relevant difference in coronary resistance of 20 % between baseline and caffeine consumption was 
considered for power calculations. In 10 subjects (mean age 27 ± 6 years), MBF was measured at rest 
and after a five-minute supine bicycle exercise of increasing intensity after the target workload was 
achieved at normoxia, corresponding to environmental conditions at 4 500 m above sea level. Then 
subjects consumed a 200-mg caffeine tablet and the same measurements were repeated 50 minutes 
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later. Caffeine did not affect resting MBF but induced a significant decrease in exercise-induced 
hyperaemic MBF (2.51 ± 0.58 mL/min per g tissue versus 2.15 ± 0.47 mL/min per g tissue; p < 0.05), 
leading to a decrease in MFR of 22 % (2.53 ± 0.69 to 1.90 ± 0.49 mL/min per g tissue; p < 0.01). In 
eight subjects (mean age 29 ± 4 years), MBF was measured following the same protocol as above but 
in conditions of hypoxia, simulating an altitude of 4 500 m by inhalation of a mixture of 12.5 % 
oxygen. Caffeine significantly increased resting MBF (1.71 ± 0.41 mL/min per g tissue versus 
2.22 ± 0.49 mL/min per g tissue; p < 0.001) and significantly decreased exercise-induced hyperaemic 
MBF (5.15 ± 0.79 mL/min per g tissue versus 3.98 ± 0.83 mL/min per g tissue; p < 0.005), leading to 
a decrease in MFR of 39 % (3.13 ± 0.60 to 1.87 ± 0.45; p < 0.005). The Panel notes that the decrease 
in MFR in healthy subjects following consumption of 200 mg of caffeine under normal environmental 
conditions was not considered clinically relevant by the authors for that population group. The Panel 
also notes that the effect could be considered clinically relevant for healthy subjects under extreme 
environmental conditions where oxygen partial pressure in the air is low (e.g. high altitude). 
The effects of caffeine on resting and exercise-induced hyperaemic MBF and the resulting MFR in 
conditions of normoxia were also assessed in 15 patients with CAD and 15 age-matched healthy 
controls by the same research group using an identical protocol and the same dose of caffeine 
(200 mg) (Namdar et al., 2009). Subjects refrained from caffeine for 24 hours prior to the tests. A 
minimum clinically relevant difference in hyperaemic MBF of 20 % between baseline and caffeine 
was considered for power calculations. Resting MBF was not significantly affected by caffeine 
consumption in either group. Exercise-induced hyperaemic MBF and MFR significantly decreased 50 
minutes after caffeine ingestion compared with baseline measurements without caffeine. MFR 
significantly decreased in healthy subjects by 14 % (p < 0.05) and in CAD patients by 18 % (p < 0.05) 
in remote segments and by 25 % (p < 0.01) in stenotic segments. The Panel notes that the decrease in 
MFR in healthy subjects following consumption of 200 mg of caffeine was not considered clinically 
relevant by the authors for that population group under normal environmental conditions. 
The Panel notes that the order in which resting and exercise-induced MBF were measured in relation 
to caffeine consumption was not randomised in these studies, so that caffeine measurements were 
always performed following an exercise test whereas non-caffeine measurements were not, and thus 
the physiological condition of the subjects in relation to the outcome variables tested may not have 
been comparable. 
15
O-labelled water and PET were also used to assess the effects of caffeine on resting and 
regadenoson-induced hyperaemic MBF, and the resulting MFR, in a double-blind, randomised, 
placebo-controlled cross-over study (Gaemperli et al., 2008). A total of 41 healthy volunteers (15 
female) aged ≥ 18 years who were non-smokers and regular coffee drinkers received, in a blinded 
fashion, either a 200 mg caffeine capsule on day 1 and placebo on day 2 (2–14 days washout) or the 
inverse after refraining from methylxanthine-containing products for at least 24 hours. MBF was 
measured each day two hours after capsule ingestion at rest and after intravenous administration of 
regadenoson. The MBF (mean ± standard error of the mean (SEM)) was not significantly different 
between caffeine and placebo at rest (1.13 ± 0.04 mL/min per g versus 1.06 ± 0.05 mL/min per g) or 
under stress (2.98 ± 0.14 mL/min per g versus 3.05 ± 0.14 mL/min per g). There was no difference in 
MFR between caffeine and placebo (2.75 ± 0.16 mL/min per g versus 2.97 ± 0.16 mL/min per g). The 
data show with one-sided 95 % confidence that any MFR reduction associated with caffeine intake 
was < 20 %. However, a similar study using regadenoson stress- single-photon emission computed 
tomography (SPECT) MPI in patients with CAD showed that doses of caffeine of 200 mg and 400 mg 
significantly decreased the number of cardiac segments with reversible vascularisation defects, 
suggesting that caffeine at doses of 200 mg or greater could significantly counteract the vasodilator 
effect of regadenoson in the coronary arteries in these patients (Tejani et al., 2014). 
The Panel notes that caffeine antagonises the vasodilator effect of adenosine and other A2A receptor 
agonists in the coronary arteries in a dose-dependent manner and this effect leads to a reduction of 
MBF and MFR during intense physical exercise, primarily in subjects with CAD, but also in healthy 
subjects to some degree. However, on the basis of the data available, the Panel considers that caffeine 
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at doses of 200 mg consumed one to two hours prior to exercise does not induce clinically relevant 
reductions of the coronary flow reserve in healthy adult subjects under normal environmental 
conditions. The Panel notes that the effect of higher doses of caffeine has not been tested. 
4.4.1.3. Cardiovascular disease risk 
There is marked diurnal variation in the onset time of cardiovascular events, with a peak in the early 
morning, which parallels the significant diurnal variation in BP observed in hypertensive subjects, 
with a decrease during sleep and a surge in the morning (Kario, 2010). It has been hypothesised that 
the morning surge in BP could trigger cardiovascular events in subjects with underlying 
atherosclerosis. Similarly, it has been hypothesised that the transient increase in BP induced by acute 
caffeine intake could increase the risk of cardiovascular events in the first hour after consumption, 
when BP reaches its peak. 
The effect of transient exposure to coffee on the risk of onset of acute cardiovascular events, including 
myocardial infarction (MI) and ischaemic stroke, has been investigated using case cross-over study 
designs (Baylin et al., 2006; Mostofsky et al., 2010a, b). Control information for each case was based 
on the subject’s past exposure experience, and a self-matched analysis was conducted (Maclure, 
1991). The effect of transient exposure to coffee on the risk of onset of sudden cardiac death (SCD) 
was also investigated in a case–control study (Selb Semerl and Selb, 2004). 
In one study (Baylin et al., 2006), 530 first incident cases of non-fatal MI between 1994 and 1998 
were recruited in Costa Rica. Information on habitual coffee intake was retrieved by a FFQ, which 
showed high correlation with seven 24-hour recalls for caffeine intake (0.83) and took into account 
serving size and type of coffee as well as nine possible frequencies of consumption. Intake of coffee 
during the time prior to the MI was collected by asking “when was the last time you had coffee before 
your heart attack?” The number of cups consumed was also recorded. The median time between 
hospital discharge and data collection was 11 days, with most people (82 %) completing the interview 
within two weeks after discharge. Out of the 530 incident cases of non-fatal MI recruited, complete 
and consistent information was available for 503 cases regarding intake of coffee during the 24 hours 
before the event and regarding habitual intake of coffee. Most patients reported drinking two to three 
cups of coffee per day and only 37 patients (7 %) reported no intake of coffee. All coffee consumed 
was caffeinated coffee; 93 % of respondents reported drinking filtered coffee. 
A hazard period of one hour was selected based on the absorption and bioavailability of caffeine in 
blood. Of the 503 patients for which complete data on coffee intake was available, 80 had at least one 
cup of coffee in the hour before the onset of MI (69 had one cup, nine had two cups and two had three 
cups). The relative risk (RR) of MI in the hour after drinking coffee was 1.49 (95 % CI = 1.17–1.89). 
The RR after coffee intake was not significantly increased when two or three hours were selected as 
the hazard period, suggesting that the risk dropped to basal conditions between one and two hours 
after drinking coffee. When stratifying by usual intake of coffee, patients with light/occasional intake 
of coffee (up to one cup per day; n = 66) had a RR of MI in the hour after taking coffee of 4.14 (95 % 
CI = 2.03– 8.42), those with moderate consumption of coffee (two to three cups per day; n = 280) had 
a RR of 1.60 (95 % CI = 1.16–2.21), and heavy drinkers (four or more cups per day; n = 120) had a 
RR of 1.06 (95 % CI = 0.69–1.63; p = 0.006, test for interaction). This was the only variable that 
significantly modified the risk; age, sex or physical activity, history of diabetes, 
hypercholesterolaemia, hypertension, smoking status or having at least three (n = 101) or less than 
three of these risk factors for disease did not significantly modify the risk. 
In the Stroke Onset Study, the relationship between coffee and alcohol consumption and the onset of 
ischaemic stroke was reported in two publications (Mostofsky et al., 2010 a, b). Between January 2001 
and November 2006, 390 subjects (209 men, 181 women) were interviewed a median of three days 
(range 0–14) after acute ischaemic stroke. Subjects were asked about their caffeinated coffee and 
alcohol intake the year prior to the stroke, and consumers were asked about the frequency of 
consumption and the last time that they consumed coffee or alcohol before the event. The same 
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questions were asked for caffeinated tea and cola. Each subject’s coffee consumption in the hour 
before stroke symptoms occurred was compared with his or her usual frequency of consumption in the 
prior year. Of the 390 subjects, 304 (78 %) drank coffee in the year prior to stroke, 232 drank coffee 
within 24 hours of the stroke and 35 drank coffee within one hour of stroke onset; of the 248 subjects 
who drank alcohol in the previous year, 169 subjects reported alcohol exposure during the week before 
stroke, 104 subjects drank alcohol within 24 hours of the stroke and 14 drank coffee within one hour 
of stroke onset. Of the 35 people exposed to coffee in the hour prior to stroke onset, three were also 
exposed to vigorous physical activity, one experienced feelings of anger, one smoked a cigarette and 
one drank an alcoholic beverage. Of the 14 people exposed to alcohol in the hour before stroke onset, 
four were also exposed to vigorous physical activity and one drank coffee. 
The RR of stroke in the hour after consuming coffee was 2.0 (95 % CI = 1.4–2.8; p < 0.001). There 
was no apparent increase in risk in the hour following consumption of caffeinated tea (RR = 0.9; 95 % 
CI = 0.4–2.0; p = 0.85) or cola (RR = 1.0; 95 % CI = 0.4–2.4; p = 0.95), possibly because of the lower 
caffeine content of these beverages or their lower consumption. The association between ischaemic 
stroke in the hour after coffee consumption was apparent only among those consuming at most one 
cup per day but not for patients who consumed coffee more regularly (p for trend = 0.002). RRs were 
similar when the sample was restricted to those who were not simultaneously exposed to other 
potential triggers (such as vigorous physical activity, feelings of anger, smoking of a cigarette, 
drinking an alcoholic beverage) and the results remained significant after stratifying by time of day. 
The risk of stroke onset was 2.3-fold higher (95 % CI = 1.4–4.0; p = 0.002) within one hour of stroke 
and RR was 1.6 (95 % CI = 1.0–2.5; p = 0.05) in the second hour after alcohol use compared with 
periods of non-use. The RR returned to baseline thereafter. Results remained similar when analyses 
were limited to subjects with no prior MI (n = 283) or were conducted excluding the 75 people 
exposed to any potential stroke trigger in the hour preceding stroke onset. 
The case–control study (Selb Semerl and Selb, 2004) was conducted in Slovenia among the 309 out-
of-hospital SCD victims who died in the period from January 2000 to March 2001 in that country 
(253 men and 56 women, median age at death 57.1 and 57.7 years, respectively). Information on 
exposure to coffee and alcohol, as well as on lifestyle, health and several socio-demographic variables, 
were obtained by posting one questionnaire to the family members of the deceased and one to the 
attending physician. Cases were those who died of SCD within one hour after coffee consumption or 
within two hours after ingesting alcohol; controls were those who died in the hours when they were 
not exposed to coffee or alcohol. The RR of dying within exposed hours compared with in non-
exposed hours was the parameter estimated for each risk factor. On average, each subject had 2.8 risk 
factors for ischaemic heart disease. The estimated RR of dying within one hour after coffee 
consumption was 1.73 (95 % CI = 1.13–2.65) and was 3.00 (95 % CI = 1.61–5.68) within two hours 
after alcohol consumption. Alcohol drinking did not appear to influence the risk in coffee drinkers. 
The Panel notes that these studies suggest an increased risk of acute cardiovascular events in the hour 
following consumption of caffeinated coffee, particularly in subjects with low habitual coffee intake. 
The Panel also notes that these studies conducted in subjects with an established (fatal or non-fatal) 
cardiovascular event included few cases, which may limit the value of the sensitivity and subgroup 
analyses conducted to explore modifying factors (e.g. influence of other risk factors of the event, such 
as disease conditions or physical activity prior to the event), and do not provide information about the 
risk of acute cardiovascular events following caffeine consumption in the general population, or on the 
dose of caffeine which could trigger such events. 
4.4.1.4. Conclusions on the cardiovascular system 
A single dose of 200 mg of caffeine consumed one to two hours pre-exercise significantly increases 
BP during resistance training in caffeine-naive subjects as well as in habitual coffee consumers after 
24–48 hours of caffeine withdrawal. A single dose of 200 mg of caffeine also decreases MBF if 
consumed approximately one hour prior to endurance exercise (i.e. when the BP-raising effect of 
caffeine reaches its peak). Although such changes could increase the risk of acute cardiovascular 
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events in subjects with an increased risk of CVD (e.g. with underlying hypertension and/or advanced 
atherosclerosis), the Panel considers the effect to be of low clinical relevance for healthy individuals in 
the general population under normal environmental conditions. Although not formally tested, the 
Panel considers that changes in BP and MBF induced by repeated intakes of caffeine at doses and time 
intervals which would not exceed the maximum plasma concentrations achieved with a single dose of 
200 mg of caffeine would also be of low clinical relevance for healthy individuals in the general 
population under normal environmental conditions. The studies available do not provide sufficient 
information to conclude on whether co-consumption of p-synephrine or of substances commonly 
found in “energy drinks” other than caffeine may affect the risk associated with caffeine consumption 
alone. 
4.4.2. Hydration status and body temperature 
Caffeine 
It is well established that caffeine has a diuretic effect (SCF, 1983; EFSA, 2009). However, any 
diuretic effects resulting from chronic caffeine consumption are unlikely to have adverse health 
consequences for healthy individuals in the general population. In addition, doses of caffeine up to 
6 mg/kg bw per day consumed for four days by habitual caffeine consumers (one week run-in with 
doses of 3 mg/kg bw per day) did not lead to significant changes in body mass, urine osmolality, urine 
specific gravity, urine colour, 24-hour urine volume, 24-hour Na
+
 and K
+
 excretion, 24-hour 
creatinine, blood urea nitrogen, serum Na
+
 and K
+
, serum osmolality, haematocrit or total plasma 
protein compared with placebo (Armstrong et al., 2005). Similar results were obtained in two studies 
with a similar design conduced in healthy males, in which 5 mg/kg bw of caffeine were consumed 
daily for four consecutive days by low habitual caffeine consumers (< 100 mg/day) (Silva et al., 2013) 
and 4 mg/kg bw per day of caffeine from coffee were consumed for three consecutive days by habitual 
coffee consumers (three to six cups of coffee per day) (Killer et al., 2014). 
It has been suggested, however, that single doses of caffeine consumed prior to exercise, and 
particularly at high temperatures, could increase body temperature and sweating as well as diuresis, 
leading to water–electrolyte imbalances which may pose a risk to health. Single doses of caffeine of 
about 100–600 mg consumed prior to exercise, however, did not lead to a significant increase in 
urinary volume or a significantly different water retention during dehydration, and did not induce 
adverse water–electrolyte imbalances compared with water or placebo, particularly in habitual caffeine 
consumers (Armstrong, 2002). 
A number of studies have investigated the effects of single doses of caffeine of 3–9 mg/kg bw on 
hydration status and/or body temperature before and during endurance exercise under different 
conditions of temperature and humidity. 
In a double-blind randomised cross-over study (Kim et al., 2011), 13 male students who were non-
habitual caffeine consumers, who followed daily aerobic training, completed two experimental trials 
(i.e. running for 30 minutes at 60 % of VO2max) in thermo-neutral conditions (24 C, 40 % relative 
humidity) one week apart, in which they received caffeine (3 mg/kg bw and 200 mL of water) or water 
only (200 mL) 40 minutes before the test. Core (tympanic) and skin temperature were measured after 
caffeine consumption at rest, pre-exercise (40 minutes after caffeine/placebo consumption) and post 
exercise (after 30 minutes of running at 60 % VO2max). Mean body temperature (calculated from 
tympanic and skin temperatures) was significantly higher in pre- (by 0.08 C) and post exercise (by 
0.14 C) following caffeine consumption than following water consumption, whereas tympanic body 
temperature increased significantly pre-exercise only (by 0.12 C). After caffeine consumption, 
sweating rate was significantly higher and the onset of sweating was significantly delayed during 
exercise. 
In a double-blind, randomised cross-over study (Millard-Stafford et al., 2007) which used higher doses 
of caffeine, 16 cyclists completed three trials consisting of cycling for 120 minutes at 60–75 % VO2max 
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followed by 15 minutes of maximal effort cycling at 28.5 C and 60 % relative humidity. During each 
trial, subjects consumed either placebo (artificially sweetened water), a carbohydrate–electrolyte drink 
(CE) containing 6 % carbohydrates or a carbohydrate–electrolyte drink containing 7 % carbohydrates 
and 46 mg/L carnitine, 1.92 mg/L taurine and 195 mg/L caffeine (CAF + CE). Total caffeine intake 
during the trial was 5.3 mg/kg bw. No significant differences among trials were found regarding 
measures of hydration status, relative dehydration, fluid retention, urine output or sweat rate. Exercise 
intensity during the last 15 minutes was significantly higher in the CAF + CE trials than in the CE or 
placebo trials, which is consistent with a higher increase in heart rate. Rectal temperature in the 
CAF + CE trials was significantly higher than in the placebo trials (by 0.19 to 0.29 C) after 60 
minutes, but was significantly higher than in the CE trials only in the last 15 minutes, which is 
consistent with a higher relative exercise intensity for the CAF + CE trial. The Panel notes that this 
study does not show a clinically significant effect of caffeine on core (rectal) temperature or hydration 
status at doses of 5.3 mg/kg bw consumed during physical exercise and hot and humid conditions. 
In another double-blind, randomised cross-over study (Del Coso et al., 2008), seven endurance-trained 
cyclists pedalled for 120 minutes at 63 % of VO2max in a hot-dry environment (36 C, 29 % humidity) 
under six different testing conditions: no fluid, water (WAT) to replace 97 % fluid losses, the same 
volume of a 6 % carbohydrate–electrolyte solution (CES) or each of these treatments along with 
caffeine at 6 mg/kg bw. Caffeine or placebo capsules were ingested about 50 minutes prior to the trial. 
Core (rectal) temperature and serum osmolality as an indicator of fluid balance were measured 
throughout the six trials. Rehydration with WAT or CES, with or without caffeine, prevented the 
significant losses of body fluid, the increase in serum osmolality and the significant rise in core 
temperature observed with no fluid replacement, with or without caffeine. No significant differences 
in fluid losses, serum osmolality or core temperature were observed between the WAT and CES 
groups with caffeine and without caffeine. This is consistent with the results from a more recent study 
(Ping et al., 2010) conducted in nine male recreational runners (normally non-caffeine users) who 
consumed caffeine (5 mg/kg bw) one hour prior to a running exercise (at 70 % of VO2max) in a hot 
environment (31 C, 70 % relative humidity) but received regular hydration (3 mL of cool water/kg 
bw every 20 minutes) during the trial. No significant differences in core temperature were observed 
between the caffeine and placebo conditions. 
The same dose of caffeine (6 mg/kg bw) was tested by Roelands et al. (2011) in a double-blind 
randomised cross-over study, in which eight healthy trained male cyclists who were habitual “mild” 
caffeine consumers completed two experimental trials (at 30 C). Subjects ingested either placebo or 
caffeine one hour prior to exercise, which consisted of cycling for 60 minutes at 55 % of Wmax 
immediately before a time trial to measure performance. Compared with placebo, caffeine 
significantly increased core (rectal) temperature during exercise by up to about 0.5 C, whereas it had 
no significant effect on skin temperature, heart rate, loss of body mass or sweat rate. 
Compared with placebo, single doses of 9 mg/kg bw caffeine consumed after four days of caffeine 
abstinence also increased core (rectal) body temperature (by 0.20–0.30 C), but not skin temperature, 
in 10 healthy men performing 30 minutes of cycle ergometry at 50 % VO2peak followed by a 15-minute 
performance time trial at 40 C and 20–30 % relative humidity (Cheuvront et al., 2009). “Caffeine 
sensitive” and heavy caffeine drinkers (> 400 mg per day) were excluded from this study. Conversely, 
in another study using the same caffeine dose, mean body temperature was significantly higher (by 
0.27 C) one hour after caffeine consumption than with placebo only at the beginning of the exercise 
(cycling for 30 minutes at 50 % of VO2peak in a 40 °C and 25 % relative humidity environment), 
whereas no differences between caffeine and placebo were observed with respect to core, skin or mean 
temperature during exercise (Ely et al., 2011). 
Caffeine in combination with taurine 
The acute diuretic effects of caffeine do not appear to be modified by the concomitant ingestion of 
taurine or by any other component of “energy drinks” (EFSA, 2009). 
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In a human intervention study (Riesenhuber et al., 2006), 12 participants received, in a random order, 
each of four different test drinks at weekly intervals in a blinded fashion (750 mL of each fluid) 
containing: (i) 80 mg caffeine and 1 g taurine per 250 mL, (ii) 80 mg caffeine per 250 mL, (iii) 1 g 
taurine per 250 mL and (iv) neither caffeine nor taurine. Caffeine significantly increased urinary 
output and natriuresis, whereas taurine had no effect on either of these outcomes and did not appear to 
modify the diuretic effects of caffeine when administered simultaneously. 
4.4.2.1. Conclusions on hydration status and body temperature 
The Panel notes that caffeine at doses of 3 mg/kg bw (equivalent to 210 mg for a 70-kg adult) ingested 
about one hour prior to endurance exercise appear to induce only a modest increase in body 
temperature compared with placebo. The Panel also notes that higher doses of caffeine (5–6 mg/kg 
bw) ingested one hour before and during prolonged endurance exercise in a hot environment do not 
affect body temperature or hydration status significantly beyond what could be expected from the 
testing conditions. 
4.4.3. Central nervous system 
4.4.3.1. Sleep, anxiety and behavioural changes 
Adults 
In adults, single doses of caffeine of about 100 mg (1.4 mg/kg bw per day in a 70-kg adult) have been 
shown to increase sleep latency and reduce sleep duration when consumed close to bedtime (Landolt 
et al., 1995), whereas doses < 100 mg do not appear to have such an effect on sleep (Dorfman and 
Jarvik, 1970). 
Higher doses (≥ 400–500 mg) consumed either on a single occasion or within short periods of time 
have been reported to increase anxiety upon oral consumption, mostly in patients with psychiatric 
anxiety disorders, but also in healthy adults, particularly if they are non-habitual caffeine consumers 
(FSANZ, 2000; Nawrot et al., 2003; Childs and de Wit, 2006; NNT, 2008; SHC, 2012). The study by 
Nickell and Uhde (1994) has been referred to by other bodies (FSANZ, 2000; SHC, 2012) to conclude 
that lower doses of caffeine (3 mg/kg bw) could increase anxiety in adult subjects. The Panel notes 
that Nickell and Uhde (1994) investigated the effects of caffeine (3, 5 and 7 mg/kg bw) versus placebo 
given intravenously in 10 subjects, who experienced olfactory hallucinations immediately following 
intravenous caffeine infusion. The Panel considers that this route of administration is not appropriate 
to investigate the effects of oral caffeine consumption on anxiety. 
Polymorphisms of the adenosine receptor gene ADORA2A have been suggested as the cause of some 
of the inter-individual variability observed in the anxiogenic response to caffeine (Childs et al., 2008; 
Rogers et al., 2010) and in the effects of caffeine on sleep (Retey et al., 2007; Byrne et al., 2012). 
Children and adolescents 
A number of human intervention studies (Elkins et al., 1981; Rapoport et al., 1981a, b, 1984; Baer, 
1987; Leviton, 1992; Bernstein et al., 1994; Hale et al., 1995; Davis and Osorio, 1998) and a 
systematic review and meta-analysis of human studies (Stein et al., 1996) which investigated the 
effects of caffeine on behaviour in children and adolescents have already been considered by other 
assessment bodies. No new studies have become available since then in this population subgroup. 
Stein et al. (1996) searched for human studies reporting cognitive, behavioural, sleep or psychological 
effects of caffeine that included a caffeine comparison (either placebo, alternative drug treatment, 
baseline or matched control group). Nine studies were identified, of which five were in children with 
attention deficit hyperactivity disorders (ADHD) and four were in healthy children. The Panel 
considers that results obtained in children with ADHD cannot be extrapolated to children in the 
general population and will not be further considered in this opinion (e.g. Leviton, 1992). 
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Of the studies mentioned above, only two (three publications) have assesed the effects of single doses 
of caffeine in healthy children (Elkins et al., 1981; Rapoport et al., 1981b; Bernstein et al., 1994). Both 
studies investigated two caffeine doses using randomised, placebo-controlled cross-over designs. 
The behavioural and cognitive effects of single doses of caffeine (3 and 10 mg/kg bw) were 
investigated in 19 prepubertal boys (mean age 10.6 ± 2.5 years) and 20 young men (mean age 
21.7 ± 3.4 years) (Elkins et al., 1981; Rapoport et al., 1981b). Children were not recruited on the basis 
of their habitual caffeine consumption, which was on average 125 ± 160 mg per day. Subjects were 
asked to complete the anxiety scale “What I think I feel” and an 11-item caffeine side-effect 
questionnaire (headache, stomach ache, nausea, chest pain, heart pounding, feeling flush, feeling faint, 
feeling nervous, feeling jittery, increased diuresis, difficulty sleeping) one hour after caffeine 
administration. Items were rated on a three-point scale. Nine items of behaviour (fidgety, distractible, 
tense, hypoactive, pressured speech, physical complaints, euphoria-elation, nervous habits, and 
mannerisms) from a Psychiatric Rating Scale were rated (on a seven-point scale) by a research 
assistant. No significant differences in self-reported side effects were observed in children for any 
caffeine dose compared with placebo, with the exception of feeling “nervous/jittery”. Scores for this 
side effect were significantly higher for the 3 mg/kg bw dose than for placebo, and for the 10 mg/kg 
bw dose than for the 3 mg/kg bw dose. No significant differences in self-rated anxiety or investigator-
rated items of behaviour were found between placebo and caffeine at any dose. 
The study by Berstein et al. (1994) investigated the effects of two single doses of caffeine (2.5 and 
5 mg/kg bw) on self-reported anxiety in 21 children (mean age 10.6 ± 1.3 years) after 12–15 hours of 
abstinence from caffeine. Self-reported anxiety was evaluated using the Visual Analogue Scale for 
Anxiety Revised (VAA-R), which assessed how anxious the child was at the time of testing (anxiety 
state) and how anxious the child was most of the time (anxiety trait); the State-Trait Anxiety Inventory 
for Children (STAIC), which assessed anxiety trait and anxiety state; and the Revised Children’s 
Manifest Anxiety Scale (RCMAS). Caffeine intake was not significantly associated with any of these 
measures of self-reported anxiety, whereas a significant linear association was reported between 
caffeine concentrations in saliva and the anxiety state item in the VAA-R scale only. The Panel notes 
that caffeine intakes were not significantly associated with anxiety, and that caffeine concentrations in 
saliva were generally not associated with self-reported measures of anxiety in this study. The Panel 
also notes that the above-mentioned tools to assess self-reported anxiety have been developed to 
discriminate between children with high and low anxiety levels, rather than to assess changes in 
anxiety. 
The Panel notes that these studies (Elkins et al., 1981; Rapoport et al., 1981b; Bernstein et al., 1994) 
do not show an effect of single doses of caffeine ranging from 2.5 to 10 mg/kg bw on most self-
reported measures of anxiety in children. However, the Panel also notes the scarcity of studies 
available and the low number of children enrolled, as well as the heterogeneity of the studies regarding 
the testing conditions (e.g. with respect to the tools used to assess anxiety and behavioural changes, 
and to the caffeine status before testing), which hampers the comparability of the results. The Panel 
considers that the results of these studies cannot be used on their own to derive single doses of caffeine 
of no concern for children or adolescents. 
4.4.3.2. Perceived exertion during exercise 
In 2011, health claims on caffeine and endurance capacity, endurance performance and reduction in 
the rated perceived exertion/effort during exercise were evaluated by the NDA Panel with a positive 
outcome. The conditions of use for these claims were that caffeine should be consumed one hour prior 
to exercise at doses of 3 mg/kg bw for claims on endurance capacity and performance and of 4 mg/kg 
bw for claims on reduction in the rated perceived exertion/effort during exercise (EFSA NDA Panel, 
2011a). The target population was adults performing endurance exercise. 
The scientific substantiation of the claim on the reduction in the rated perceived exertion/effort during 
exercise was based on a meta-analysis of 22 laboratory-based, double-blind, fully randomised (and 
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mostly cross-over), placebo-controlled intervention studies which examined the effects of caffeine 
ingestion on ratings of perceived exertion (RPE) during exercise (Doherty and Smith, 2005). 
Compared with placebo, caffeine significantly reduced RPE during exercise (in 20 out of the 22 
studies) by 5.6 % (95 % CI = –6.7 to –4.5 %). RPE could account for 29 % of the variance in the 
improved exercise performance (based on 16 studies where changes in exercise performance were 
tested). This analysis comprised studies from 1975 to 2004, representing over 200 subjects (74 % 
men) who were 20 to 35 years of age, ranging from physically active individuals to extremely well-
trained elite athletes, and included both habitual caffeine users and non-users (half of the studies did 
not provide information on coffee use). The protocols varied, including work intensities from 50 % to 
125 % (mean = 80 %) of VO2max. The caffeine doses ranged from 4 to 10 mg/kg bw (median 6 mg/kg 
bw) and were typically given one hour before the start of the exercise test after a period of caffeine 
withdrawal. The caffeine abstinence of the subjects varied from 12 to 240 hours (median = 24 hours). 
As only the effect-size difference between caffeine and placebo was calculated in the meta-analysis, it 
was unclear whether the between-group difference observed was a result of an increased perception of 
fatigue due to caffeine deprivation, to a decreased perception of fatigue due to caffeine consumption or 
both. The effect of a single dose of caffeine on fatigue perception in either caffeine abstainers or 
caffeine consumers who are not caffeine deprived was not investigated. 
These conclusions were supported by the results of a double-blind, cross-over, placebo-controlled 
intervention study published after the meta-analysis by Doherty and Smith (2005), where nine 
competitive male rugby players ingested either caffeine (6 mg/kg bw) or placebo (dextrose) 
70 minutes before performing a rugby test consisting of seven circuits in each of two 40-minute halves 
with a 10-minute half-time rest (Stuart et al., 2005). The development of fatigue during the test was 
significantly reduced after caffeine consumption compared with placebo. 
In the health claim opinion (EFSA NDA Panel, 2011b), a reduction in the rated perceived 
exertion/effort during exercise was considered by the Panel as a plausible mechanism by which single 
doses of caffeine administered after at least 12–24 hours of caffeine deprivation could increase 
endurance capacity and performance. In this context, the Panel considered this to be a beneficial 
physiological effect for adults performing endurance exercise willing to obtain such an effect. 
In the context of this opinion, however, a reduction in the perceived exertion/effort during exercise can 
be considered a potential adverse health effect for the general population (not limited to adults 
performing endurance exercise willing to obtain such an effect) under the assumption that the 
perception of fatigue is a physiological mechanism leading to the spontaneous ending of physical 
activities that, because of their high intensity, extended duration or both, may compromise the 
cardiovascular and/or musculoskeletal systems. The Panel notes that single doses of caffeine which 
have been observed to reduce the rated perceived exertion/effort during exercise (≥ 4 mg/kg bw) are 
equivalent to 280 mg of caffeine for a 70-kg adult. 
4.4.3.3. Subjective perception of alcohol intoxication 
It has been suggested that consumption of caffeinated beverages (including “energy drinks”) together 
with alcohol may “mask” or alter the subjective perception of alcohol intoxication, which could 
increase the likelihood of engaging in potentially dangerous activities while intoxicated (i.e. risk-
taking behaviour). 
In addition to the review of the literature (Verster et al., 2012) considered by the UK COT (COT, 
2012), a recent systematic review and meta-analysis of RCTs, which includes all the studies identified 
by Verster et al. (2012), has addressed this question (Benson et al., 2014). Studies were included if 
they had assessed the effects of alcohol with and without any type of caffeinated beverage (including, 
but not limited to, “energy drinks”) on a direct measure of subjective intoxication and provided 
enough data to be included in a meta-analysis. Of the 16 publications identified by the literature 
search, nine met these criteria (Fillmore and Vogel-Sprott, 1999; Fillmore et al., 2002; Marczinski and 
Fillmore, 2006; Howland et al., 2011; Marczinski et al., 2011, 2012, 2013; Heinz et al., 2013; Peacock 
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et al., 2013). Alcohol doses were typically 0.65 g/kg bw (in six studies) and ranged from 0.29 to 
1.068 g/kg bw, typically producing peak blood alcohol concentrations (BAC) between 0.068 and 
0.088 % (in seven studies) and ranging from 0.032 to 0.12 %. Caffeine doses ranged from 0.6 to 
5.5 mg/kg bw. Four studies used “energy drinks” as a source of caffeine. Three had a cross-over 
design and six had a parallel design. Sample size (per arm) varied between 7 and 74 subjects. 
Subjective intoxication was measured using the Beverage Rating Scale (BRS) in six studies, a self-
estimate BAC in one study, a Subjective Intoxication Scale (SIS) in one study and a “feel any effects” 
visual analogue scale (VAS) in one study. A meta-analysis of all studies combined showed no 
masking effect of caffeine when combined with alcohol relative to alcohol alone on direct measures of 
subjective intoxication. The only individual study reporting a significant masking effect of caffeine 
was Heinz et al. (2013), which had the biggest sample size (BAC 0.088 %, caffeine 5.0 mg/kg bw for 
females and 5.5 mg/kg bw for males). Marczinski and Fillmore (2006) reported no masking effect of 
caffeine at the highest caffeine dose tested (4 mg/kg bw), whereas Howland et al. (2011), who tested 
the highest dose of alcohol (target BAC 0.12 %) and caffeine (5.0 mg/kg bw) in heavy alcohol 
drinkers and used the second biggest sample (n = 35 alcohol plus caffeine, n = 28 caffeine) showed no 
significant masking effect of caffeine. 
Seven studies addressing the research question were excluded from the meta-analysis because they did 
not address subjective intoxication directly (Liguori and Robinson, 2001; Ferreira et al., 2006; Alford 
et al., 2012) or the publication did not contain sufficient detail to calculate the effect size for pooling in 
a meta-analysis (Rush et al., 1989; Azcona et al., 1995; Marczinski and Fillmore, 2003; Attwood et al., 
2012). Doses of alcohol had a target BAC between 0.03 and 0.10 % and caffeine doses were between 
1.14 and 7 mg/kg bw (80–500 mg). Two studies used “energy drinks” as sources of caffeine. No 
significant differences between the alcohol and the alcohol plus caffeine groups were reported in these 
studies in relation to direct or indirect measures of subjective intoxication. 
Another systematic review (Peacock et al., 2013) restricted the question to the consumption of alcohol 
together with “energy drinks” (rather than with caffeine from any source) and addressed a wide variety 
of (physiological and psychological) outcomes, mostly using cross-sectional studies. All of the RCTs 
on the combination of “energy drinks” with caffeine reviewed in this publication were already 
considered in the systematic review by Benson et al. (2014). 
The Panel considers that caffeine consumed at doses up to 3 mg/kg bw (corresponding to 210 mg in a 
70-kg adult) from all sources, including “energy drinks”, is unlikely to mask the subjective perception 
of alcohol intoxication which could lead to increased risk-taking behaviour when alcohol is consumed 
at doses of about 0.65 g/kg bw. Higher doses of alcohol have not been systematically investigated. 
4.4.3.4. Conclusions on the central nervous system 
Single doses of caffeine up to about 200 mg (3 mg/kg/bw for a 70-kg adult) do not appear to induce 
anxiety in unselected adult subjects from the general population, reduce the perceived exertion/effort 
during exercise when consumed one hour prior to exercise after 12–24 hours of caffeine withdrawal or 
alter the subjective perception of alcohol intoxication when alcohol is consumed at doses of about 
0.65 g/kg bw. In children, similar single doses of caffeine on a weight basis (3 mg/kg bw) do not 
appear to induce anxiety or behavioural changes, although inter-individual variability in relation to 
habitual caffeine intakes has not been studied. The Panel notes that 100 mg of caffeine (about 
1.4 mg/kg bw for a 70-kg adult) may increase sleep latency and reduce sleep duration in some 
individuals, particularly when consumed close to bedtime. 
4.5. Adverse effects of longer-term and habitual caffeine consumption 
Adverse effects of daily caffeine consumption over longer periods of time (> 7 days) on the CNS and 
the CVS have been reported in human intervention studies. These concern sustained changes in BP 
and children’s behaviour. 
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Data on the relationship between habitual consumption of caffeine in foods and beverages and the risk 
of chronic diseases (e.g. CVD, cancer, type 2 diabetes mellitus, Parkinson disease, Alzheimer disease, 
bone fractures), adverse pregnancy outcomes, male fertility and birth defects (neural tube defects, oral 
clefts) mostly come from human observational studies. With the exception of CVD risk and adverse 
pregnancy outcomes, the scientific publications identified almost exclusively reported no relationship 
or an inverse relationship between caffeine intake and adverse health effects in relation to these 
outcomes. Therefore, the Panel will focus on CVD risk and adverse pregnancy outcomes (e.g. pre-
term delivery, FGR or SGA, miscarriage or spontaneous abortion, stillbirth) to assess the safety of 
habitual caffeine consumption in adults. 
4.5.1. Central nervous system 
In adults, tolerance to the anxiogenic effect of caffeine develops with frequent consumption, even in 
genetically susceptible individuals (Rogers et al., 2010). 
In children, four studies have investigated the effects of caffeine consumed for longer periods of time 
(up to two weeks) using randomised, placebo-controlled, parallel or cross-over designs (Rapoport et 
al., 1981a, 1984; Baer, 1987; Hale et al., 1995). 
In the study by Hale et al. (1995), 18 adolescents (11–15 years of age) underwent six independent 
randomised, double-blind, placebo-controlled trials. In each trial, participants were given a non-
caffeinated and a caffeinated soft drink (providing 33 mg of caffeine) in a two-day cross-over, 
followed by two days in which subjects were given concurrent access to the two drinks, which were 
consumed ad libitum. No behavioural symptoms were reported by any participant. Average caffeine 
intake among the four subjects who tended to select caffeinated soft drinks repeatedly was 167 mg per 
day (about 3.3 mg/kg bw per day). 
In the placebo-controlled, cross-over study by Baer (1987), six five-year-old children were 
administered daily a caffeine-free or a caffeinated soft drink (providing 1.6–2.5 mg/kg bw of caffeine 
per day) for two weeks, at the end of which the drink conditions were reversed. No consistent effects 
on behavioural outcomes such as off-task behaviour or motor activity were noted. Anxiety was not 
assessed. 
Two studies by the same authors have investigated daily caffeine consumption (10 mg/kg bw per day) 
for two weeks in relation to self-reported anxiety, parent/teacher ratings of children’s behaviour and 
side effects in prepubertal children (mean age about 10 years, age range 6–13 years). These studies 
were either planned (Rapoport et al., 1984) or analysed considering habitual caffeine intakes and used 
a randomised, double-blind, placebo-controlled cross-over design. In the first study (Rapoport et al., 
1981a), data from 19 children were analysed depending on whether they were “low” (< 50 mg per 
day) or “high” (> 300 mg per day) caffeine consumers. In the second study, 19 “high” habitual 
caffeine consumers (> 500 mg per day) and 19 “low” habitual caffeine consumers (< 50 mg per day) 
matched by age, gender and teacher were recruited and separately randomised. Collectively, these two 
studies provide evidence that “high” habitual caffeine consumers (and their parents) tend to report 
more side effects during the caffeine withdrawal period, whereas the reverse is observed in “low” 
caffeine consumers, suggesting the development of tolerance and withdrawal symptoms in “high” 
habitual consumers. 
The Panel notes that regular consumption of caffeine up to about 3 mg/kg bw per day does not appear 
to induce behavioural changes in children and adolescents, whereas higher intakes (10 mg/kg bw per 
day) may increase anxiety and adversely affect behaviour and sleep in habitual low caffeine 
consumers. Children appear to develop tolerance to the central effects of caffeine at high habitual 
intakes (> 300 mg per day) and show withdrawal symptoms. The Panel also notes that the studies 
available at doses of ≤ 3 mg/kg bw have small sample sizes and are heterogeneous in design, and that 
doses between 3 and 10 mg/kg bw per day have not been investigated. 
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4.5.2. Cardiovascular system 
4.5.2.1. Methodological considerations 
There is a wealth of human prospective cohort studies which have investigated the relationship 
between caffeine-containing foods and beverages (e.g. coffee, tea, soft drinks, chocolate) and the risk 
of a number of CVD-related outcomes, including incident hypertension (fatal, non-fatal, total), 
coronary heart disease (CHD) (total, non-fatal), MI (total, fatal and non-fatal), stroke (all types, 
haemorrhagic, ischaemic), arrhythmias (mostly atrial fibrillation) and total CVD risk. There is also a 
wealth of meta-analyses published in relation to these outcomes which will be used to summarise the 
evidence available. 
Case–control and cross-sectional studies will not be considered specifically in this section. Previous 
meta-analyses have consistently reported positive associations between habitual consumption of 
caffeine-containing foods and beverages (mostly coffee) and the risk of CVD from case–control 
studies, but not from prospective cohort studies (Greenland, 1993; Kawachi et al., 1994; Sofi et al., 
2007). Possible explanations for this discrepancy include recall bias for exposure in cases (over-
reporting), low caffeine consumption in controls recruited from inpatients with chronic conditions, 
differences in outcome measures (case–control studies usually report on non-fatal events only) and 
lack or inappropriate control for confounding variables in case–control studies (Wilhelmsen et al., 
1977; Kawachi et al., 1994; Sofi et al., 2007). 
The prospective cohort studies available are heterogeneous with respect to the exposure used as an 
independent variable. Coffee (unspecified), caffeinated coffee, decaffeinated coffee, tea (unspecified), 
green tea, oolong tea, black tea (sugar-containing and sugar-free), caffeinated soft drinks and 
chocolate, as well as caffeine from all sources, have been investigated in relation to CVD-related 
outcomes in one or more of these studies. In some, tea has been assessed but used as a confounding 
variable only to adjust models on coffee. 
Appendix I provides an overview of the prospective cohort studies considered in the most recently 
published systematic reviews and meta-analyses which have investigated the association between 
habitual consumption of coffee or caffeine from all sources and CVD-related outcomes. Meta-analyses 
of prospective cohort studies investigating only tea in relation to CVD-related outcomes do not appear 
in the table, but will be discussed in the sections below where appropriate. Individual prospective 
cohort studies investigating only tea in relation to CVD-related outcomes will not be considered 
specifically because tea contains less caffeine than coffee, coffee is the major source of caffeine for 
adults in the majority of European countries and caffeine intakes in countries where tea is the major 
source of caffeine are generally lower than caffeine intakes in “coffee-drinking” countries (see 
Section 3 on dietary intake). 
Although some of the meta-analyses in Appendix I occasionally include one or more prospective 
cohort studies where the study population has been selected on the basis of a disease condition or a 
risk factor for disease (hypertension, previous MI, type 2 diabetes mellitus), the vast majority of the 
studies included were conducted in unselected samples from the general population. Individual studies 
(Martin et al., 1988; Hakim et al., 1998; Bidel et al., 2006; Palatini, 2007; Silletta et al., 2007; 
Mukamal et al., 2009; Zhang et al., 2009a, b) and meta-analyses (Mesas et al., 2011) focusing on 
particular population subgroups with a disease condition or a risk factor for disease will not be 
considered specifically. 
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4.5.2.2. Blood pressure 
Caffeine 
Prospective cohort studies 
A systematic review (Zhang et al., 2011) identified four prospective cohort studies which investigated 
the association between coffee drinking and long-term changes in BP measured in fasting conditions. 
Two were conducted in the Netherlands (Uiterwaal et al., 2007; Driessen et al., 2009), one was 
conducted in the US (Klag et al., 2002) and one was conducted in Australia (Jenner et al., 1988). 
Sample size varied from 340 to 5 189 subjects and follow-up varied between 6 and 33 years. Data 
from these studies could not be pooled in a meta-analysis because different BP variables were used as 
outcomes (e.g. residuals of BP, mean arterial BP, SBP and DBP) and the results were mixed: although 
the Australian study found a negative association between coffee drinking and long-term changes in 
BP, the Dutch studies found no association and the US study found a positive association. An 
additional prospective cohort study published thereafter (Giggey et al., 2011) investigated the 
relationship between habitual caffeinated coffee consumption and long-term changes in resting BP and 
pulse pressure in 2 442 participants (865 women and 1 577 men) from the Baltimore Longitudinal 
Study of Aging. In men, significant quadratic (non-linear) interactions were observed between coffee 
consumption, age and time since baseline on SBP and pulse pressure, but these were not observed in 
women. The models predicted an increase in SBP and pulse pressure with age which, beyond 70 years, 
would be potentiated by the intake of six or more cups of coffee per day. The Panel notes that the 
results from prospective cohort studies on the association between habitual caffeine consumption and 
long-term changes in BP are mixed. 
Randomised controlled trials lasting ≥ 7 days 
Three meta-analyses of RCTs (Jee et al., 1999; Noordzij et al., 2005; Steffen et al., 2012) have 
investigated the effects of caffeine or coffee consumption for ≥ 7 days (after habituation to caffeine 
takes place) on fasting BP in unselected populations. The characteristics of the studies included in 
each meta-analysis are summarised in Appendix H. 
Noordzij et al. (2005) selected RCTs in humans that had investigated the effects of caffeinated coffee 
or caffeine consumption for ≥ 7 days on fasting BP and HR. Studies using co-interventions (e.g. 
caffeine plus adrenaline) which did not allow conclusions on caffeine or coffee were excluded. The 
meta-analysis included 11 trials on coffee (18 strata) and five trials on caffeine (seven strata) 
published between 1984 and 2000, which varied in sample size from 10 to 123 participants (median: 
45) for a total of 1 010 subjects, of which ≥ 50 % were men in 17 strata. All trials were in adults (aged 
23 to 77 years) and lasted 7 to 84 days (median: 42 days). Six strata (24 %) included study populations 
with high–normal BP or hypertension, with two strata having subjects on antihypertensive treatment. 
The coffee trials were conducted using instant coffee (n = 8), filtered coffee (n = 7), boiled coffee 
(n = 2) or coffee that was boiled and subsequently filtered (n = 1). Daily coffee dose in active 
treatment groups varied from 450 to 1 235 mL, which corresponds to a caffeine dose of 225 to 798 mg 
per day (one cup of coffee was assumed to contain 150 mL and 90 mg of caffeine when not reported in 
the original publication). In caffeine trials, caffeine was administered in tablets at doses ranging from 
295 to 750 mg per day. In coffee and caffeine trials combined, the median caffeine dose was 410 mg 
per day. The control groups of coffee trials received either no coffee (11 strata) or decaffeinated coffee 
(seven strata). In the caffeine trials, all control groups received placebo tablets. 
Average pre-treatment BP ranged from 109 to 143 mmHg for SBP (median 122 mmHg) and from 65 
to 94 mmHg for DBP (median 74 mmHg). Mean pre-treatment HR ranged from 61 to 78 bpm (median 
71 bpm). Net BP changes in coffee and caffeine trials ranged from –1.6 to 12.0 mmHg for SBP and 
from –2.4 to 5.0 mmHg for DBP. Combining all caffeine and coffee studies, SBP significantly 
increased by 2.04 mmHg (95 % CI = 1.10–2.99 mmHg) and DBP significantly increased by 
0.73 mmHg (95 % CI = 0.14–1.31 mmHg). After excluding nine coffee trials with an open design, 
changes in SBP were 2.81 mmHg (95 % CI = 1.08–4.53 mmHg) and in DBP were 1.17 mmHg (95 % 
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CI = 0.54–1.81 mmHg). HR did not change significantly. In stratified analyses adjusted for type of 
intervention (coffee or caffeine), age (< 40 or ≥ 40 years), sex (proportion of males < 50 % or ≥ 50 %), 
baseline BP (< 130/85 or ≥ 130/8 mmHg), baseline caffeine intake (< 400 or ≥ 400 mg per day) and 
caffeine dose (median intake < 410 or ≥ 410 mg per day in all the coffee and caffeine studies 
combined), except when used as stratification factor, the type of intervention, sex and caffeine dose 
significantly affected changes in BP, whereas age, baseline BP, baseline caffeine intake and study 
duration (< 6 weeks or ≥ 6 weeks) did not. Changes (mean and 95 % CI) in SBP and DBP for coffee 
(18 strata) were 1.22 mmHg (0.52–1.92 mmHg) and 0.49 mmHg (–0.06 to 1.04 mmHg), and for 
caffeine (seven strata) were 4.16 mmHg (2.13–6.20 mmHg) and 2.41 mmHg (0.98–3.84 mmHg). 
Caffeine from any source at doses ≥ 410 mg per day significantly increased SBP (mean 2.98, 95 % 
CI = 2.15–3.80) and DBP (mean 1.96, 95 % CI = 1.19–2.73), whereas caffeine doses < 410 mg per 
day did not (change in SBP = mean 0.72, 95 % CI = –0.35 to 1.78; change in DBP = mean –0.52, 
95 % CI = –1.62 to 0.57). Caffeine significantly increased SBP and DBP in studies with a majority of 
women (n = 8), but not in those with a majority of men (n = 17). The Panel notes that this meta-
analysis shows a sustained BP-raising effect of continuous (≥ 7 days) caffeine consumption at doses of 
about 400 mg per day, but not at lower doses. 
The meta-analysis by Steffen et al. (2012) aimed to assess the effects of daily coffee consumption 
(> 7 days) on fasting BP. The effects of caffeine per se, and the effects of caffeine in coffee, were not 
assessed. The search targeted RCTs which included an intervention group that consumed coffee and a 
control group that consumed either no coffee or less coffee, which lasted > 7 days to eliminate any 
acute pressor effect of coffee. Studies (or intervention arms within a study) which used decaffeinated 
coffee as the control were excluded. Of the 10 RCTs included (Appendix H), 6 had been considered in 
the meta-analysis by Noordzij et al. (2005). Five studies had a parallel design and five had a cross-
over design, and the duration of the intervention was between 2 and 11 weeks. Seven trials included 
two strata and six used the same control group to compare the two interventions. Of these, only one 
intervention group with coffee was selected for inclusion in the meta-analysis, giving preference to the 
most common types of coffee consumed (caffeinated, filtered), so that only the effects of caffeinated 
coffee compared with no coffee were explored in the meta-analysis. Most of the study populations 
were healthy, normotensive individuals. Coffee consumption varied between trials and ranged from 
three to over six cups daily. Only four trials used a standard amount of coffee in the intervention, 
whereas the other trials defined a minimum amount of consumption, but no maximum. The pooled 
weighted difference in mean change of SBP was –0.55 mmHg (95 % CI = –2.46 to 1.36 mmHg) and 
of DBP was –0.45 mmHg (95 % CI = –1.52 to 0.61 mmHg). Heterogeneity in the pooled SBP 
(I2 = 72 %) and DBP (I2 = 41 %) analysis was explored by considering type of coffee, sex and pre-
study BP in subgroup analyses, but no significant interactions were found. The Panel notes that this 
meta-analysis does not show a significant increase in fasting BP following consumption of caffeinated 
coffee for > 7 days at doses of about three to six cups per day. 
A previous meta-analysis of RCTs on the effects of caffeinated coffee on fasting BP (Jee et al., 1999) 
included nine studies with durations of the intervention ranging between 2 and 11 weeks. Eight had 
been considered by Noordzij et al. (2005) and four by Steffen et al. (2012). The overall pooled 
estimates of treatment effect associated with coffee drinking were 2.4 mmHg (95 % CI = 1.0–
3.7 mmHg) for SBP and 1.2 mmHg for DBP (95 % CI = 0.4–2.1 mmHg). Duration of run-in and 
coffee dose significantly modified the effect of coffee on BP. Studies with shorter run-ins and the 
highest doses of coffee showed the biggest effect on BP. A significant effect of caffeinated coffee on 
BP was observed only by pooling studies using five or more cups of coffee, but not in studies using 
≤ 4.5 cups. 
One study not included in the meta-analyses above (Hodgson et al., 1999) assessed the effects of 
consuming 250 mg of caffeine in hot water, black tea or green tea (five cups per day) for seven days 
on 24-hour ambulatory SBP and DBP in 13 subjects with high–normal SBP and DBP in a cross-over 
design. Changes in 24-hour ambulatory BP did not differ significantly among interventions with 
respect to baseline. Consistent with the finding by Noordzij et al. (2005), this study suggests that 
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caffeine intake for one week at doses of 250 mg per day (< 400 mg per day) does not increase fasting 
BP significantly, regardless of the caffeine source. 
Caffeine and p-synephrine 
The majority of human intervention studies available which have investigated the effects of daily 
consumption (> 7 days) of p-synephrine in food supplements containing C. aurantium extracts have 
addressed energy metabolism, body weight and body composition as measures of efficacy (reviewed 
in Stohs et al. (2012)). Cardiovascular outcomes (SBP, DBP, HR) have only been evaluated in one 
study using 98 mg per day of p-synephrine (in two doses of 49 mg each) for 60 days (Kaats et al., 
2013) and in one study using a combination of p-synephrine (10 mg per day) and caffeine (400 mg per 
day) for 14 days (Kalman et al., 2002). None of these studies found a significant effect of the 
intervention on BP compared with placebo. The Panel notes that these studies provide no information 
on whether or not the co-consumption of p-synephrine modifies the effects of daily caffeine 
consumption on fasting BP. 
The Panel notes that caffeine intakes at doses of about 400 mg per day did not raise fasting BP 
significantly after caffeine habituation in human intervention studies. The studies available do not 
provide sufficient information to conclude on whether or not consumption of p-synephrine modifies 
the effects of daily caffeine consumption on fasting BP. 
4.5.2.3. Hypertension 
Two systematic reviews and meta-analyses of prospective cohort studies have addressed the 
association between coffee consumption and the risk of incident hypertension (Zhang et al., 2011; 
Steffen et al., 2012). They considered the same six cohort studies reported in five publications 
(Appendix I), which included a total of 172 567 participants and 37 135 incident cases of 
hypertension. Mean follow-up ranged from 6.4 to 33 years. Three studies reported in two publications 
were conducted in the US (Klag et al., 2002; Winkelmayer et al., 2005) and three were conducted in 
Europe: one in Finland (Hu et al., 2007), one in Italy (Palatini et al., 2007) and one in the Netherlands 
(Uiterwaal et al., 2007). 
Two studies used drug-treated hypertension as the outcome: one recruited only untreated hypertensive 
individuals at baseline (Palatini, 2007) and the second recruited both normotensive individuals and 
untreated hypertensive individuals (Hu et al., 2007). The remaining studies were conducted in 
normotensive individuals at baseline and used either diagnosis of hypertension or drug treatment for 
hypertension at follow-up as the outcome (Klag et al., 2002; Winkelmayer et al., 2005; Uiterwaal et 
al., 2007). Two studies assessed the intake of caffeinated coffee only (Klag et al., 2002; Palatini et al., 
2007); the Finnish study did not discriminate between caffeinated and decaffeinated coffee, but the use 
of the latter was very low (about 0.8 %) (Hu et al., 2007); one study assessed both caffeinated and 
decaffeinated coffee (Uiterwaal et al., 2007); and two studies reported in one publication 
(Winkelmayer et al., 2005) assessed caffeine intake from all sources, including caffeinated and 
decaffeinated coffee. Both meta-analyses assessed the relationship between habitual consumption of 
(any) coffee and incident hypertension, and stratified analyses by type of coffee were not possible with 
the data available. 
In both of the meta-analyses, data from original studies were grouped into four categories of coffee 
consumption: reference (less than one cup per day), low (one to three cups per day), moderate (three to 
five or three to six cups per day) and high (five or more or six or more cups per day). In the meta-
analysis by Zhang et al. (2011), the group consuming more than  zero to three cups per day was used 
as a reference category for the study by Uiterwaal et al. (2007) instead of coffee abstainers because of 
the low number of coffee abstainers, and the group consuming three to six cups per day was used as 
the second category. For the study by Palatini et al. (2007), the group consuming three or more cups 
per day (highest category) was taken as the high category and the group consuming one to three cups 
per day was used as the low category. Compared with the reference category, the pooled RRs (95 % 
CI) for hypertension were 1.09 (1.01–1.18) for the low category (one to three cups per day), 1.07 
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(0.96–1.20) for the moderate category (three to five cups per day) and 1.08 (0.96–1.21) for the highest 
category. In a dose–response meta-analysis, the best-fitting model showed an inverse “J-shaped” curve 
(p for quadratic term < 0.001), with the risk of hypertension increasing up to three cups per day (RR 
for the comparison of three cups with zero cups per day: 1.07, 95 % CI = 0.97–1.20) and decreasing 
with higher intake (RR for the comparison of six cups with zero cups per day: 0.99, 95 % CI = 0.89–
1.10). The Panel notes that the risk of hypertension did not increase significantly at any dose of coffee 
consumption in this dose–response analysis. In the meta-analysis by Steffen et al. (2012), the study by 
Uiterwaal et al. (2007) was excluded from the combined analysis because it used more than zero to 
three cups of coffee per day as the reference category. Coffee drinking was not significantly associated 
with an increased risk of hypertension at any category of coffee intake compared with the reference 
category. 
Among the individual studies considered, the study by Palatini et al. (2007) reported an increased risk 
of developing sustained hypertension associated with caffeinated coffee consumption compared with 
no consumption, with no significant difference in risk among categories of coffee intake (zero, one to 
three and three or more cups per day). A subsequent study by the same authors (Palatini et al., 2009) 
reported an increased risk of developing sustained hypertension requiring pharmacological treatment 
with increasing caffeinated coffee consumption in carriers of the slow CC or CA allele (59 %) of the 
CYP1A2 gene, but not in carriers of the fast AA allele, suggesting that the risk of developing 
hypertension associated with caffeine consumption may depend on the genetic background. However, 
these two studies exclusively enrolled subjects with never-treated stage 1 hypertension at baseline 
(incidence of hypertension requiring medication of 50.7 % in the six-year follow-up) and do not 
provide information about the general (unselected) adult population. Caffeinated coffee drinking was 
also positively associated with initiation of antihypertensive treatment (p for trend = 0.024 across 
categories of coffee intake: zero to one cup per day, two to three cups per day, four to five cups per 
day, six to seven cups per day and eight or more cups per day) in the study by Hu et al. (2007), which 
enrolled never-treated hypertensive and normotensive subjects, but the association was no longer 
significant when baseline BP was considered in the analysis. No association between caffeinated 
coffee consumption and the risk of incident hypertension was observed after adjusting for confounding 
variables in the study by Klag et al. (2002) in normotensive young males. In the study by Uiterwaal et 
al. (2007), where the category of more than zero to three cups per day was taken as the reference, 
higher coffee intake was not associated with an increased risk of hypertension, whereas coffee 
abstainers showed a decreased risk compared with the reference category. The Panel notes the low 
number of coffee abstainers included in the study and the low number of incident cases of 
hypertension in this group. The Panel also notes that the interaction between coffee intake and sex on 
the incidence of hypertension was not statistically significant, and thus subgroup analyses by sex were 
not statistically justified. 
In the Nurses’ Health Studies (NHSs) I and II of 155 594 US women free from physician-diagnosed 
hypertension were followed up over 12 years (Winkelmayer et al., 2005). FFQs were used to measure 
dietary intake and were completed in 1990, 1994 and 1998 for NHS I (30 to 55 years of age at 
recruitment) and in 1991, 1995 and 1999 for NHS II (25 to 42 years of age) and referred to the 
previous year. Relevant beverages included on the questionnaire were low-calorie and regular cola 
drinks, and caffeinated and decaffeinated tea and coffee. Caffeine content was assumed to be 137 mg 
per cup of coffee, 47 mg per cup of tea, 46 mg per can or bottle of cola beverage and 7 mg per serving 
of chocolate candy. A total of 19 541 (32 %) incident cases of physician-diagnosed hypertension were 
reported in NHS I and 13 536 (14.3 %) cases were reported in NHS II. In both cohorts, no linear 
association between caffeine consumption and the risk of incident hypertension was observed after 
multivariate adjustment. Using categorical analysis, an inverse U-shaped association between caffeine 
consumption and incident hypertension was found. Compared with participants in the lowest quintile 
of caffeine consumption (mean intakes 14.8 and 19.6 mg per day), those in the third quintile (209.3 
and 174.7 mg per day) had a significant 14 % and 15 % increased risk of hypertension in NHS I and 
NHS II, respectively, whereas no increased risk was observed in the highest quintile (608.1 and 
597.4 mg per day). In multivariate models including beverage type, rather than actual caffeine intake, 
significant inverse associations between intake of caffeinated coffee (p for trend = 0.02 and 0.03 in 
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NHS I and NHS II, respectively) and the risk of hypertension was observed in both cohorts, but an 
association was not found with decaffeinated coffee (p for trend = 0.08 and 0.67 in NHS I and NHS II, 
respectively). A significant association between caffeinated tea intake and incident hypertension was 
found in the cohort of younger women in NHS II (p for trend = 0.01), but not in NHS I (p for 
trend = 0.79). A significant positive association between the intake of sugar-containing (p for 
trend = 0.03 and < 0.001 in NHS I and NHS II, respectively) and sugar-free (p for trend = 0.03 and 
< 0.001 in NHS I and NHS II, respectively) caffeinated cola drinks and incident hypertension was 
observed in both cohorts. The Panel notes that this study shows an inverse U-shaped relationship 
between total caffeine intake from dietary sources and incident hypertension. An increased risk of 
hypertension was reported for women with mean caffeine intake of about 200 mg per day compared 
with women with very low (about 15–20 mg per day) or high (about 600 mg per day) intakes. The 
Panel also notes that different types of caffeinated beverages were differently associated with the risk 
of incident hypertension. Whereas caffeinated (but not decaffeinated) coffee was inversely associated 
with the risk of hypertension, caffeinated tea (in one cohort) and cola beverages (in both cohorts) were 
directly associated with that risk. 
The Panel notes that BP values are used for CVD risk stratification and as a therapeutic target in 
prevention studies, and that hypertension is an independent risk factor for CVD, including CHD and 
stroke, so that studies on the relationship between caffeine intake and risk of CVD may help to define 
habitual caffeine intakes which pose no concern in relation to the CVS. The Panel also notes that data 
from prospective cohort studies on the relationship between habitual caffeine intake and the risk of 
incident hypertension are conflicting. An increased risk at any level of intake, an inverse U-shaped 
relationship and no relationship have all been reported in the individual studies, whereas the meta-
analyses which combined data from all the studies available do not find an increased risk of 
hypertension at any level of caffeine intake. Although it has been suggested that polymorphisms of the 
CYP1A2 gene may affect the risk of hypertension associated with caffeine consumption and explain in 
part the different findings among studies, this hypothesis has not been tested prospectively in 
unselected populations. 
4.5.2.4. Coronary heart disease 
The dose–response meta-analysis by Ding et al. (2014) assessed prospective cohort studies on the 
relationship between coffee consumption and CVD risk (i.e. CHD, stroke, heart failure, CVD 
mortality). The 36 studies included (Appendix I) comprised ≈1 283 685 study participants and 47 779 
CVD cases, including 28 347 CHD cases, 12 030 stroke cases and 7 402 other CVD cases. Duration of 
follow-up for incident CVD ranged from 6 to 44 years, with a median follow-up of 10 years. Twenty-
one studies were conducted in Europe, 12 were conducted in the US and three were conducted in 
Japan. Nine studies assessed the association of caffeinated coffee consumption with CVD risk, and 
four studies assessed the association of decaffeinated coffee consumption with CVD risk. The 
outcome in 17 studies was risk of stroke, whereas the outcome in 22 studies was risk of CHD. 
Compared with the lowest category of coffee consumption (median zero cups per day), the RRs of 
CHD were 0.89 (95 % CI = 0.85–0.94) for the first category (median 1.5 cups per day), 0.90 (95 % 
CI = 0.84–0.97) for the second category (median 3.5 cups per day) and 0.93 (95 % CI = 0.84–1.02) for 
the third category of coffee consumption (median five cups per day). A significant heterogeneity 
between studies was found for the second and third categories. In the dose–response analysis, a non-
linear (p < 0.001) association between coffee consumption and CHD risk with significant trend 
(p < 0.001) and significant heterogeneity (p = 0.001) was reported. Coffee consumption was inversely 
associated with the risk of CVD up to eight cups per day. No association was observed between coffee 
consumption and CHD risk at higher intake. Caffeinated and decaffeinated coffee were not analysed 
separately for this outcome. 
Two meta-analyses of prospective cohort studies have specifically addressed the association between 
coffee consumption and CHD risk (Sofi et al., 2007; Wu et al., 2009). 
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Sofi et al. (2007) searched for articles published between 1966 and April 2006 and included 10 
independent prospective cohort studies (nine publications) with a total of 403 631 participants that 
were followed for between 3 and 44 years. Studies were excluded if they included a category other 
than that of very low consumption as a reference, if subjects were selected on the basis of a disease 
condition (hypertension), if categories of coffee consumption were not reported or if only 
decaffeinated coffee was studied. The cumulative RR for all cohort studies was 1.04 (95 % CI = 0.90–
1.19) for the first category of coffee consumption (one to two cups per day), 1.05 (95 % CI = 0.90–
1.22) for the second category (three to four cups per day) and 1.16 (95 % CI = 0.95–1.41) for the third 
category (four or more cups per day) compared with the reference category (none or less than one cup 
per day). Sensitivity analyses removing for each category the studies contributing more to 
heterogeneity gave similar results. Stratified analyses by region (US and Europe), publication year 
(before or after the median of 1995), fatal versus non-fatal events and number of years of follow-up 
(more or less than the median of 15 years) showed that only the publication year had an influence on 
the outcome (i.e. coffee consumption was associated with an increased risk of CHD in studies 
published before or in 1995 but not in studies published after 1995). 
In the meta-analysis by Wu et al. (2009), the literature search was limited to articles in English 
published between 1966 and 2008. Studies were excluded if they had only two categories of coffee 
consumption, if subjects had type 2 diabetes or CVD at baseline or if only caffeine intake (and not 
coffee) was reported. A total of 21 independent prospective cohort studies (20 publications) were 
included in the analysis, 8 of which had already been considered by Sofi et al. (2007). The 21 studies 
included 433 054 participants and 17 149 cases. Categories of coffee consumption were defined as 
follows: 
i. light (reference): US studies, one or less cups per day; European studies, two or less cups per 
day; 
ii. moderate: US studies, one to three cups per day; European studies, three to four cups per day; 
iii. heavy: US studies four to five cups per day; European studies, five to six cups per day; and 
iv. very heavy: US studies, six or more cups per day; European study, seven or more cups per 
day. 
The pooled RRs of CHD for all studies combined were 0.96 (95 % CI = 0.87–1.06) for the moderate, 
1.04 (95 % CI = 0.92–1.17) for the heavy and 1.07 (95 % CI = 0.87–1.32) for the very heavy 
categories of coffee consumption. Stratified analyses by sex, region, study quality and duration of 
follow-up and adjustment for confounding variables did not affect the results significantly. 
Among the 56 prospective cohort studies included in the meta-analyses above, eight studies, seven of 
which were published in or before 1995, reported a positive association between coffee consumption 
and the risk of CHD, including fatal and non-fatal CAD, fatal ischaemic heart disease and fatal and 
non-fatal MI. The risk increased significantly at one to four cups per day (Murray et al., 1981), three 
or more cups per day (Lindsted et al., 1992), three to four cups per day (Klag et al., 1994), four to six 
cups per day for non-fatal MI but not for other coronary cases (Klatsky et al., 1990), five to six cups 
per day (Stensvold and Tverdal, 1995), and six or more cups per day (LeGrady et al., 1987). In the 
study by Tverdal et al. (1990), only nine or more cups per day were compared with less than one cup. 
In the study by Happonen et al. (2004), the reference category was 376 to 813 mL per day of coffee, 
and thus did not allow conclusions to be drawn on the amount of coffee associated with an increased 
risk compared with no coffee consumption. Two studies (Murray et al., 1981; Stensvold and Tverdal, 
1995) were not adjusted for any confounding variable. All these studies investigated coffee except 
Klatsky et al. (1990), who also investigated tea and found no increased risk of CHD in relation to tea 
consumption. 
Four studies investigated the relationship between total caffeine intake (from various sources) and risk 
of CHD. 
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Grobbee et al. (1990) assessed caffeine intake from coffee, brownies, candies, chocolate and chocolate 
cookies, cocoa, cola beverages and tea in 45 589 men participating in the US Health Professionals 
Follow-up Study. Mean caffeine intakes were 236.7 mg per day in the sample, 52.6 mg per day in non-
coffee consumers, 268.6 mg per day in consumers of any coffee, 312.3 mg per day in caffeinated 
coffee consumers and 211.1 mg per day in decaffeinated coffee consumers. The risk of CHD (total, 
non-fatal MI and fatal CHD), coronary artery bypass grafting (CABG) and percutaneous transluminal 
coronary angioplasty (PTCA), stroke or total CVD did not increase significantly across categories of 
caffeinated or decaffeinated coffee consumption (one or less cup, two to three cups and four or more 
cups per day compared with none) or of total caffeine intake (quintiles: 0–74 mg per day, 74–148 mg 
per day, 149–285 mg per day, 286–491 mg per day and 492–1 796 mg per day), except for a 
significant p per tend (0.04) for an increased risk of CABG and PTCA in the highest category of 
decaffeinated coffee consumption. 
The publication by Lopez-Garcia et al. (2006) reports on two independent cohorts: the Health 
Professionals Follow-up Study (44 005 men) and the Nurses’ Health Study (84 488 women). 
Documented events were 2 173 incident cases of CHD (1 449 non-fatal MI and 724 fatal cases of 
CHD) among men and 2 254 cases (1 561 non-fatal MI and 693 fatal cases of CHD) among women. 
Total caffeine intake was estimated from caffeinated beverages (coffee, tea, soft drinks) and chocolate 
candies. Total caffeine intake from all sources across categories of coffee consumption (in cups: < one 
per month, one per month to four per week, five to seven per week, two to three per day, four to five 
per day, six or more per day) were 51, 91, 194, 418, 691 and 885 mg per day in men and 118, 134, 
218, 418, 751 and 881 mg per day in women, respectively. After adjustment for confounders, neither 
coffee nor total caffeine intake were significantly associated with the risk of CHD in either men or 
women. The results did not change when only the most recent information on coffee consumption 
before the event was considered in the analyses to assess short-term effects. Stratification by smoking 
status, alcohol consumption, history of type 2 diabetes mellitus and body mass index gave similar 
results. 
Using data from 6 594 men and women participating in the first National Health and Nutrition 
Examination Survey (NHANES I) Epidemiologic Follow-Up Study (NHEFS), Greenberg et al. (2008) 
studied the relationship between caffeine intake from caffeinated beverages (ground and instant 
caffeinated coffee, tea, cola drinks), chocolate snacks and all caffeinated beverages combined, and the 
risk of CHD, stroke and total CVD. Analyses were given for subjects < 65 years and ≥ 65 years of age 
separately, and were also stratified by history of hypertension. The risk of CHD, stroke and total CVD 
did not increase significantly across categories of total caffeine intake (> 30, 30–100, 100–350 and 
≥ 350 mg per day) or of caffeinated beverages consumed (< 0.5, 0.5 to < 2, 2 to < 4 and ≥ 4 servings 
per day). The risk of CVD and CHD mortality significantly decreased across categories of caffeine 
and caffeinated beverages consumption in subjects ≥ 65 years of age, in normotensive individuals and 
in subjects with untreated (stage 1) hypertension, whereas consumption of decaffeinated beverages did 
not affect the risk. 
One prospective study not included in the meta-analyses above (Bertoia et al., 2013) used data from 
93 676 postmenopausal women who participated in the Women’s Health Initiative Observational 
Study to assess the association between habitual alcohol and caffeine consumption and the risk of 
SCD. FFQs were completed at baseline and after three years. A total of 239 women experienced SCD 
after an average of 11 years of follow-up. No alcohol intake, moderate alcohol intake (15–30 g per 
day) and heavy alcohol intake (> 30 g per day) were not associated with risk of SCD compared with 
very light alcohol intake (0.1–5 g per day), whereas light alcohol intake (one drink or 5.1–15 g per 
day) was associated with a reduced risk of SCD only when recent alcohol exposure was used in the 
model. No association between total caffeine, caffeinated (regular) coffee, decaffeinated coffee or 
caffeinated tea and the risk of SCD was found. Caffeine analyses were not adjusted for alcohol and 
vice versa and alcohol–caffeine interactions were not addressed because no correlation between 
alcohol intake and caffeine intake (r = 0.08) was found in this population. 
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One case–control study aimed to determine whether or not polymorphisms of the CYP1A2 gene 
(Cornelis et al., 2006) and polymorphisms of the adenosine receptor gene ADORA2A, the serotonin 
receptor gene HTR2A and the dopamine receptor gene DRD2 (DaCosta, 2011) modify the association 
between coffee consumption and the risk of acute non-fatal MI. Cases (n = 2 014) and population-
based controls (n = 2 014) living in Costa Rica matched for age, sex and area of residence were 
genotyped (CYP1A2 gene) and answered a FFQ to assess coffee intake. In total, 55 % of cases 
(n = 1 114) and 54 % of controls (n = 1 082) were carriers of the slow *1F allele, for which the 
multivariate-adjusted odds ratios (ORs) and 95 % CIs for non-fatal MI associated with the 
consumption of less than one, one, two to three and four or more cups of coffee per day were 1.00 
(reference), 0.99 (0.69–1.44), 1.36 (1.01–1.83) and 1.64 (1.14–2.34), respectively. Corresponding ORs 
(95 % CIs) for individuals with the rapid *1A/*1A genotype were 1.00, 0.75 (0.51–1.12), 0.78 (0.56–
1.09) and 0.99 (0.66–1.48) (p = 0.04 for gene by coffee interaction). In sensitivity analysis stratified by 
age and smoking status, a significant gene by coffee interaction (p = 0.003) was observed among the 
younger participants only (< 59 years, the median age of the sample). An increased risk of non-fatal 
MI with increasing coffee consumption in carriers of the slow *1F allele was also observed among 
non-smokers, although the gene by coffee interaction did not reach significance in either smokers or 
non-smokers. The DRD2 genotype was associated with caffeine consumption among non-smokers and 
the slow *1F allele carriers of the CYP1A2 gene. HTR2A genotype was associated with caffeine 
consumption among non-smokers and subjects with the ADORA2A TT genotype. Neither of the 
polymorphisms modified the association between coffee consumption and the risk of MI, although a 
significant coffee by HTR2A interaction was seen among subjects with the slow *1F allele. The Panel 
notes that, although this case–control study suggests that polymorphisms of the CYP1A2 gene may 
affect the risk of MI in relation to caffeine consumption, which may be further affected by 
polymorphisms of the serotonin receptor gene HTR2A, the results have not yet been replicated and the 
hypothesis has not been tested in prospective cohort studies. 
The Panel notes that three meta-analyses and the vast majority of the 56 prospective cohort studies 
included in these review publications reported no increased risk of CHD associated with habitual 
coffee consumption at any level of intake. The Panel also notes that almost no study reported an 
increased risk of CHD associated with habitual coffee consumption of four or less cups per day, 
corresponding to about 400 mg per day of caffeine, which may be an underestimation of total caffeine 
intake considering that other sources of caffeine were not taken into account in the majority of the 
studies (e.g. mean caffeine intake from all sources in the category of subjects drinking four to five 
cups of coffee per day were 751 mg per day in the study by Lopez-Garcia et al. (2006), and 286–
491 mg per day in subjects drinking three to four cups of coffee per day in the study by Grobbee et al. 
(1990)). 
4.5.2.5. Atrial fibrillation 
Two systematic reviews and meta-analyses of prospective cohort studies have specifically addressed 
the association between habitual caffeine consumption and risk of atrial fibrillation (AF) (Caldeira et 
al., 2013; Cheng et al., 2014). Both considered the same six prospective cohorts (Appendix I), which 
included a total of 228 465 adult participants (mean age 51–62 years) and 4 261 cases of AF during a 
mean follow-up between 4 and 25.2 years. The meta-analysis by Caldeira et al. (2013) used, in 
addition, data from one case–control study (Mattioli et al., 2005). 
Three prospective cohort studies (two in the US and one in Denmark) assessed caffeine from all 
sources (i.e. coffee, tea, soft drinks, chocolate) and three assessed coffee as a source of caffeine. To 
calculate caffeine intake in the coffee studies, it was assumed in both meta-analyses that a cup of 
coffee contained 140 mg of caffeine in Sweden (two studies) and 85 mg in the US (one study). 
Caldeira et al. (2013) assumed 50 mg of caffeine per cup of coffee in the Italian case–control study 
(Mattioli et al., 2005). There was no significant association between caffeine exposure and AF risk in 
primary or subgroup analyses, considering age, sex, race, study quality, caffeine from coffee versus 
caffeine from all sources, caffeine dose or duration of follow-up. An inverse relationship was found 
between habitual caffeine intake and the risk of AF in a dose–response analysis (Cheng et al., 2014). 
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Incidence of AF decreased by 6 % (RR = 0.94, 95 % CI = 0.90–0.99) for every 300 mg per day 
increment in habitual caffeine intake up to about 1 000 mg per day. No single prospective cohort study 
reported an increased risk of AF associated with habitual caffeine or coffee consumption. 
The Panel notes that habitual caffeine consumption from all sources up to about 1 000 mg per day was 
not significantly associated with an increased risk of AF in these two meta-analyses. The Panel also 
notes that no single prospective cohort study reported an increased risk of AF associated with habitual 
caffeine consumption. 
4.5.2.6. Heart failure 
A systematic review and a dose–response meta-analysis of prospective studies assessed the 
relationship between habitual caffeinated coffee consumption and the risk of heart failure (Mostofsky 
et al., 2012). The meta-analysis selected five independent prospective studies published between 2001 
and 2011, which included, combined, 6 522 heart failure events among 140 220 participants. Four 
studies were conducted in Sweden (Wilhelmsen et al., 2001b; Ahmed et al., 2009; Mukamal et al., 
2009; Levitan et al., 2011), where a standard cup of coffee is 150 mL, and one was conducted in 
Finland (Wang et al., 2011), where a serving was defined as 100 mL. Three of the studies consisted of 
participants with no history of MI, one study consisted of patients with MI and one included separate 
analyses for people with and without a history of diabetes or MI. Two studies were in men, one was in 
women and two included both sexes. A non-linear association between coffee consumption and heart 
failure risk was found (p for non-linearity = 0.02; p for overall significance of curve = 0.02). 
Compared with no coffee consumption, the pooled RR (95 % CI) for heart failure was 0.96 (0.90– 
0.99) for 1 to 2 servings per day, 0.93 (0.86–0.99) for 2 to 3 servings per day, 0.90 (0.82–0.99) for 3 to 
4 servings per day, 0.89 (0.81–0.99) for 4 to 5 servings per day, 0.91 (0.83–1.01) for 5 to 6 servings 
per day, 0.93 (0.85–1.02) for 6 to 7 servings per day, 0.95 (0.87–1.05) for 7 to 8 servings per day, 0.97 
(0.89–1.07) for 8 to 9 servings per day, 0.99 (0.90–1.10) for 9 to 10 servings per day, 1.01 (0.90–1.14) 
for 10 to 11 servings per day and 1.03 (0.89–1.19) for 11 servings per day. With the exception of the 
study by Mukamal et al. (2009), which was conducted in subjects with a history of MI, the only source 
of caffeine studied was coffee. 
The Panel notes that coffee intake up to 11 cups per day, corresponding to about 1 100 mg of caffeine, 
were not significantly associated with an increased risk of heart failure in this meta-analysis. The 
Panel also notes that no single prospective cohort study reported an increased risk of heart failure 
associated with habitual coffee consumption. 
4.5.2.7. Stroke 
In the dose–response meta-analysis by Ding et al. (2014), the risk of stroke was assessed in 17 studies. 
Compared with the lowest category of coffee consumption, the RRs of stroke were 0.89 (95 % 
CI = 0.84–0.94) for the first category, 0.80 (95 % CI = 0.75–0.86) for the second category and 0.95 
(95 % CI = 0.84–1.07) for the highest category of coffee consumption. No significant heterogeneity 
between studies was found for any category of coffee consumption. In the dose–response analysis, a 
non-linear (p < 0.001) association between coffee consumption and CHD risk with significant trend 
(p < 0.001) and non-significant heterogeneity (p = 0.07) was reported. Coffee consumption up to about 
four cups per day was inversely associated with the risk of stroke. No association was observed 
between coffee consumption of higher intakes and the risk of stroke. Caffeinated and decaffeinated 
coffee were not analysed separately for this outcome. 
Two meta-analyses of prospective cohort studies have specifically addressed the association between 
coffee consumption and the risk of stroke (Larsson and Orsini, 2011; Kim et al., 2012). 
The meta-analysis by Larsson and Orsini (2011) searched for prospective cohort studies published 
between 1966 and 2011 which reported the risk of stroke for three or more categories of coffee 
consumption. The meta-analysis included 11 prospective studies, with 479 689 participants and 10 003 
cases of stroke. A non-linear inverse association between coffee consumption and stroke risk was 
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observed (p for non-linearity = 0.005). Compared with no coffee consumption, the pooled RRs of total 
stroke were 0.92 (95 % CI = 0.89–0.96) for one cup of coffee per day, 0.86 (95 % CI = 0.78–0.94) for 
two cups per day, 0.83 (95 % CI = 0.74–0.92) for three to four cups per day, 0.87 (95 % CI = 0.77–
0.97) for six cups per day and 0.93 (95 % CI = 0.79–1.08) for eight cups per day. When the RRs for 
comparable categories of coffee consumption were pooled, the RRs of stroke were 0.88 (95 % 
CI = 0.86–0.90) for < 3 cups per day, 0.88 (95 % CI = 0.77–1.01) for 3 to < 5 cups per day, 0.87 (95 % 
CI = 0.75–1.02) for 5 to < 7 cups per day and 0.93 (95 % CI = 0.76–1.12) for ≥ 7 cups per day. In 
stratified analyses by sex (men, five studies; women, five studies; both sexes, four studies), 
geographical region (Europe, seven studies; US, two studies; Japan, two studies), duration of follow-
up (≤ 10 years, four studies; > 10 years, seven studies) or stroke type (ischaemic, four studies; 
haemorrhagic, four studies), coffee consumption was not associated with an increased risk of stroke in 
any strata. Similar results were obtained in the meta-analysis by Kim et al. (2012), in which the 
literature search was limited to articles in English published between 2001 and July 2011. The meta-
analysis included nine prospective cohort studies, six of which had also been considered by Larsson 
and Orsini (2011). One meta-analysis (Arab et al., 2009) of prospective cohort studies which assessed 
the relationship between green and black tea consumption and the risk of stroke and included data 
from nine individual studies involving 4 378 strokes among 194 965 individuals in total found similar 
results. The risk of stroke was assessed for three cups per day compared with low intake or no tea. 
Among the prospective cohort studies included in the meta-analyses above, none reported a positive 
association (increased risk) between coffee consumption and the risk of stroke of any type. The only 
exception was the study by Hakim et al. (1998), which was conducted in a population of middle-aged 
(45–68 years) men with hypertension at baseline and it is not considered by the Panel as pertinent to 
this evaluation. 
Four studies investigated the relationship between total caffeine intake (from various sources) and risk 
of stroke. 
In addition to the studies by Grobbee et al. (1990) and Greenberg et al. (2007) described above in 
relation to CHD risk, two studies investigated the relationship between total caffeine intake from 
coffee and tea (Larsson et al., 2008), or from coffee, tea, caffeinated soft drinks and chocolate candy 
(Lopez-Garcia et al., 2009), and the risk of stroke. In the study by Larsson et al. (2008), caffeine 
contents of 80 mg per 100 mL of coffee and of 26 mg per 100 mL of tea were assumed to calculate 
total caffeine intake. Median caffeine intake was 186 mg per day. Consumption of caffeinated coffee, 
caffeinated tea or total caffeine (from coffee and tea) was not associated with an increased risk of 
ischaemic or haemorrhagic stroke. In the study by Lopez-Garcia et al. (2009), consumption of 
caffeinated beverages (cups) of less than one cup per month, one cup per month to four cups per week, 
five to seven cups per week, two to three cups per day and four or more cups per day corresponded to 
median total caffeine intakes of 71, 191, 318, 423 and 687 mg per day. Total caffeine intake, 
consumption of caffeinated beverages (tea, caffeinated soft drink and caffeinated coffee) and 
consumption of decaffeinated coffee were not significantly associated with an increased risk of stroke. 
The Panel notes that coffee intake up to 8–11 cups per day, corresponding to about 800–1 100 mg of 
caffeine per day, were not significantly associated with an increased risk of stroke in the meta-analyses 
considered. The Panel also notes that no single prospective cohort study reported an increased risk of 
stroke associated with habitual coffee or tea consumption in the general adult population. 
4.5.2.8. Cardiovascular disease risk (all outcomes combined) 
In the dose–response meta-analysis by Ding et al. (2014), compared with the lowest category of coffee 
consumption (median zero cups per day), the RR (mean, 95 % CI) of CVD (all outcomes combined) 
was 0.89 (0.84–0.94) for the first category (median 1.5 cups per day), 0.85 (0.80–0.90) for the second 
category (median 3.5 cups per day) and 0.95 (0.87–1.03) for the third (highest) category (median five 
cups per day). No significant interactions were found between coffee intake and baseline hypertension 
or MI when the analyses were stratified for the following variables: smoking status, publication year, 
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study quality score, dietary assessment method (24-hour diet recall/diet record/FFQ versus other 
methods), stroke versus CHD as the outcome, country (US, Europe, Japan), sex and type of coffee 
(caffeinated coffee or decaffeinated coffee). Compared with the lowest category of coffee 
consumption, the RRs (mean, 95 % CI) for caffeinated (11 comparisons) and decaffeinated (five 
comparisons) coffee consumption were 0.89 (0.81–0.91) and 0.99 (0.93–1.05) for the first category, 
0.83 (0.79–0.88) and 0.98 (0.87–1.15) for the second category and 0.91 (0.81–1.03) and 1.00 (0.88–
1.14) and third category, respectively. In the dose–response analysis, coffee consumption was 
inversely associated with the risk of CVD up to six cups per day. No association was observed 
between coffee consumption and CVD risk at higher intake. 
An additional prospective cohort study published thereafter (Loomba et al., 2014) using data from the 
US National Health and Nutrition Examination Survey III (NHANES III) reported no association 
between coffee consumption and CVD mortality (including stroke, congestive heart failure and 
ischaemia-related mortality) in multivariate analysis adjusted for confounding variables at any level of 
intake among 8 608 subjects > 45 years of age. 
A few studies investigated whether or not genetic polymorphisms have an effect on caffeine 
consumption. Rodenburg et al. (2012) studied the effect of this CYP1A2-163C>A polymorphism on 
coffee and tea intake in 6 689 subjects in the Netherlands. Hetero- and homozygote “slow” 
metabolisers (AC/CC) consumed 0.19 and 0.34 cups of coffee per day less, respectively, than subjects 
of the “fast” AA genotype (p < 0.0005); no difference was found for tea consumers. Cornelis et al. 
(2006) found no statistically significant effect of this SNP on habitual caffeine consumption in 2 735 
subjects. A meta-analysis of four genome-wide association studies of coffee consumption (in the 
Netherlands, Germany, US and Iceland) found two sequence variants (one locus between CYP1A1 
and CYP1A2 gene and one in the aryl-hydrocarbon receptor (AHR) gene) which were associated with 
a difference in coffee consumption (Sulem et al., 2011). The difference was about 0.2 cups of coffee 
per day. No significant effect of the CYP1A2-163C>A polymorphism on coffee consumption was 
found in this meta-analysis. The Panel notes that genetic polymorphisms for genes involved in 
caffeine metabolism may explain only a small proportion of the inter-individual variability in caffeine 
intake. 
4.5.2.9. Conclusions on the cardiovascular system 
Data from RCTs suggest that caffeine intake (from coffee or supplements) at doses ≤ 400 mg per day 
does not raise fasting BP significantly after caffeine habituation takes place. Prospective cohort studies 
on the relationship between habitual caffeine intake and long-term changes in BP and on the risk of 
incident hypertension are conflicting and difficult to interpret. An equal number of studies reporting 
positive, negative and no association between habitual caffeinated coffee consumption and long-term 
changes in BP are available. Although meta-analyses combining data form all the prospective studies 
available do not find an increased risk of hypertension at any level of caffeine intake, an increased risk 
for any level of intake, an inverse U-shaped relationship and no relationship have been reported in the 
individual studies. 
Hypertension is an established risk factor for CVD, and in particular for stroke, CHD and heart failure. 
A wealth of prospective cohort studies investigating the relationship between caffeinated coffee 
consumption (the type of coffee most often consumed and the main source of caffeine intake in most 
European populations) and the risk of total CVD and CVD subtypes (fatal and non-fatal CHD 
including MI and SCD, stroke and stroke subtypes, arrhythmias (mostly AF)), as well as systematic 
reviews and dose–response meta-analyses summarising their results, are available. Habitual 
caffeinated coffee consumption has not been associated with an increased risk of total CVD or CVD 
subtypes in the general adult population at any level of intake in any summary publication. Among the 
individual studies, a positive association between habitual caffeinated coffee consumption and CVD 
risk has been reported only for CHD (but not for stroke, AF or heart failure) in 8 out of the 56 studies 
reviewed, only 6 of which had any type of adjustment for confounding variables. Of these, only two 
reported an increased risk of CHD associated with habitual coffee consumption of four or less cups per 
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day (one for three or more cups per day, one for three to four cups per day), corresponding to about 
400 mg per day of caffeine, which may be an underestimation of total caffeine intake considering that 
other sources of caffeine were not taken into account in these studies. 
It has been suggested that certain substances in coffee (and tea) other than caffeine may decrease the 
risk of CVD and thus counteract any adverse effects of caffeine in the CVS which may become 
evident if the same amounts of caffeine are consumed from other sources (e.g. supplements, 
caffeinated soft drinks, “energy drinks”). However, total caffeine intake was not associated with an 
increased CVD risk in any of the studies that investigated all sources of caffeine. In addition, the 
individual studies and meta-analysis available that investigated the relationship between the 
consumption of caffeinated and decaffeinated beverages and CVD risk separately have reported either 
no association for any type of beverage (caffeinated or decaffeinated) or a J-shaped relationship 
(decreased risk of up to three to five cups per day and no increased risk thereafter compared with low 
or no consumption) for caffeinated beverages (mostly coffee, but also tea), which was not observed for 
decaffeinated beverages (mostly coffee, no change in risk across levels of intake). Although no firm 
conclusions can be drawn from these observations because of the low intake and/or low percentage of 
consumers of decaffeinated beverages and of caffeinated beverages other than coffee (except in the 
US) in these studies, the Panel considers that, on the basis of the data available, habitual caffeine 
intake up to about 400 mg per day from all sources does not increase the risk of CVD in the general 
adult population. 
Some case–control and one prospective cohort study in hypertensive subjects suggest that 
polymorphisms of genes involved in caffeine metabolism could affect the relationship between 
caffeine intakes and CVD-related outcomes. The Panel notes that genetic polymorphisms for genes 
involved in caffeine metabolism may explain only a small proportion of the inter-individual variability 
in caffeine intake, and that there is no evidence that such polymorphisms influence the risk of CVD-
related outcomes in the general population, although prospective cohort or human intervention studies 
investigating this hypothesis are currently not available for any subgroup of the general population. 
The Panel also notes that, considering that the distribution of “fast” and “slow” caffeine metabolisers 
in the general population is roughly 50:50, both phenotypes may have been equally represented in the 
human studies considered. 
The vast majority of prospective cohort studies assessed habitual alcohol intake (alcohol consumers 
were not excluded) and used this variable to adjust multivariate models, rather than to explore 
interactions between alcohol and coffee or caffeine intake on CHD risk. In addition, the intervention 
study which assessed the effect of coffee on longer-term BP in habitual alcohol drinkers did not 
control for (or report on) caffeine intake. Despite the scarcity of data available on the combined effects 
of habitual caffeine and alcohol consumption on CVD risk, the Panel considers that habitual caffeine 
intake up to about 400 mg per day from all sources does not increase the risk of CVD in habitual 
alcohol drinkers from the general adult population. 
4.5.3. Pregnancy outcomes 
Different mechanisms have been proposed by which caffeine consumption during pregnancy could 
adversely affect fetal development. Caffeine is rapidly absorbed, passes freely across the placenta and 
is poorly metabolised by the fetus (Aldridge et al., 1979, 1981). By increasing the levels of circulating 
catecholamines, caffeine could induce uteroplacental vasoconstriction and fetal hypoxia (Kirkinen et 
al., 1983), as well as impair normal cell development by increasing cellular cyclic adenosine 
monophosphate (Weathersbee and Lodge, 1977). 
Pregnancy outcomes that have been investigated in relation to the potential adverse health effects of 
caffeine consumption during pregnancy include length of gestation and related outcomes (e.g. pre-
term delivery), birth weight and related outcomes (e.g. FGR, SGA), fetal death-related outcomes 
(miscarriage or spontaneous abortion, stillbirth) and infant death. The Panel focuses on birth weight-
related outcomes (e.g. FGR, SGA), as these have been identified in previous assessments (COT, 2012) 
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as the most sensitive to the potential adverse health effects of caffeine consumption during pregnancy. 
FGR and SGA are associated with increased risk of perinatal morbidity and mortality. FGR has been 
found to be correlated with increased risk of metabolic diseases later in life. 
4.5.3.1. Human intervention studies 
Two Cochrane systematic reviews addressing the effects of maternal caffeine consumption during 
pregnancy on fetal, neonatal and/or pregnancy outcomes, conducted four years apart (Jahanfar and 
Sharifah, 2009; Jahanfar and Jaafar, 2013), identified only one human intervention study which 
addressed this topic (Bech et al., 2007). No other human intervention studies have been identified by 
the Panel. 
In a double-blind RCT, 1 207 Danish women who were less than 20 weeks’ pregnant were recruited 
either from those booked for delivery at Aarhus University Hospital or from a national birth cohort 
(Bech et al., 2007). Data on inclusion and exclusion criteria (pre-enrolment) were retrieved through a 
postal questionnaire at 16 weeks of pregnancy and by a telephone interview at about 12 weeks of 
pregnancy. Eligibility criteria included regular consumption of at least three cups of coffee per day and 
no history of a low birth weight baby (< 2 500 g), pre-term delivery, kidney diseases, epilepsy, 
diabetes or metabolic disorders. Eligible women were randomised to receive caffeinated instant coffee 
(n = 568) or decaffeinated instant coffee (n = 629) in identical boxes provided by the same 
manufacturer and were asked to replace their regular coffee with that provided, but were not advised 
on how much to drink and were not asked to avoid regular coffee offered by others or intake of other 
caffeinated beverages such as tea, cocoa or cola. Women were interviewed about daily consumption of 
the study coffee, of other caffeinated beverages (coffee, tea, cola or cocoa) and smoking status at 
weeks 20, 25 and 34 of gestation and at week 4 after the expected date of delivery. Caffeine intake 
from all sources during the study in both groups were calculated from data collected during the 
interviews, assuming a caffeine content per cup of 65 mg and 0 mg for caffeinated and decaffeinated 
study coffees, respectively (according to manufacturer), 100 mg for other caffeinated coffees, 50 mg 
for tea, and 5 mg and 20 mg per glass (2 dL) of drinking chocolate and cola drinks, respectively. 
Assuming a standard deviation of birth weight of 500 g, a sample size of 800 women was needed to 
detect a difference in birth weight of at least 100 g with 80 % power at a 5 % two-sided significance. 
Total median daily caffeine intake (interquartile range (IQR)) was 317 mg (229–461 mg) and 117 mg 
(56–228 mg) in the caffeinated and decaffeinated coffee groups, respectively. Data on birth weight and 
length of gestation were obtained for 1 150 and 1 153 live-born singletons, respectively. The adjusted 
difference in length of gestation between the decaffeinated and caffeinated coffee groups was –1.31 
days (–2.87 to 0.25). After adjustment for length of gestation, parity, pre-pregnancy body mass index 
and smoking at baseline, the mean birth weight of babies born to women in the decaffeinated coffee 
group was 16 g (95 % CI = –40 to 73 g), which was higher than those born to women in the 
caffeinated group. The Panel notes that this study did not report an effect of decreasing caffeine 
consumption from about 300 mg per day to about 100 mg per day in the last four months of pregnancy 
on length of gestation or birth weight. 
4.5.3.2. Prospective cohort studies 
Three prospective cohort studies have investigated the relationship between maternal intake of 
caffeine from caffeinated beverages and pregnancy and birth weight-related outcomes (i.e. FGR, 
SGA). In these studies, statistical analyses have been adjusted for a number of potentially confounding 
variables, including alcohol drinking and smoking during pregnancy, parity and socio-economic 
status. Maternal age, height and weight, maternal education, the baby’s sex, length of gestation, 
outcome of previous pregnancies and occasionally pregnancy-related symptoms (e.g. nausea, 
vomiting) were also generally considered. 
The CARE Study Group examined the relationship between maternal caffeine intake and birth weight, 
FGR (primary outcome, defined as birth weight < 10
th
 centile on a customised centile chart), late 
miscarriage (spontaneous pregnancy loss between 12 and 24 weeks), pre-term delivery (delivery at 
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< 37 completed weeks) and stillbirth (CARE Study Group, 2008; Greenwood et al., 2010). A total of 
2 635 low-risk pregnant women (out of the 13 071 invited: 20 %) aged 18–45 years living in the UK 
were recruited between weeks 8 and 12 of pregnancy. Caffeine intakes were estimated using a 
validated questionnaire designed to record habitual caffeine intake before and during pregnancy from 
all sources, including over-the-counter medications. The questionnaire was administered three times: 
the first at recruitment, when women were asked to recall caffeine intake from 4 weeks before 
pregnancy to 8–12 weeks of pregnancy; the second covered weeks 13–28 of pregnancy; and the third 
covered weeks 29–40 of pregnancy. The prevalence of FGR in the cohort was 343 out of 2 635 
(13 %). The women’s mean caffeine intake during pregnancy was 159 mg per day, which decreased 
from 238 mg per day before pregnancy to 139 mg per day between weeks 5 and 12 of pregnancy, 
remained almost unchanged during the second trimester and gradually increased to 153 mg per day in 
the third trimester. The main sources of caffeine were tea (62 %), coffee (14 %), cola drinks (12 %), 
chocolate (8 %) and soft drinks (2 %). Hot chocolate, “energy drinks” and alcoholic drinks contributed 
2, 1 and < 1 % to caffeine intake, respectively. 
After adjustment for confounding variables, the relationship between total caffeine intake in 
pregnancy and FGR showed a significant trend with increasing caffeine intake (p for trend = 0.02). 
Compared with caffeine intake of < 100 mg/day, the ORs (95 % CI) of having a baby with FGR were 
1.2 (0.9–1.6) for intakes of 100–199 mg per day, 1.5 (1.1–2.1) for intakes of 200–299 mg per day and 
1.4 (1.0–2.0) for intakes of ≥ 300 mg per day. Caffeine consumption of > 200 mg per day during 
pregnancy was associated with a reduction in birth weight of about 60–70 g, with a significant trend 
for greater reduction in birth weight with higher caffeine intake (p = 0.004). These relationships were 
consistent across all three trimesters. When caffeine intake was analysed as a continuous variable, the 
risk of FGR increased exponentially up to 30 mg per day and linearly thereafter, and no threshold was 
identified (CARE Study Group, 2008). The association between caffeine intake and FGR did not 
appear to be mediated by nausea and vomiting during pregnancy (Boylan et al., 2013). Caffeine intake 
was also associated with an increased risk of late miscarriage or stillbirth (Greenwood et al., 2010). 
Compared with women consuming < 100 mg per day of caffeine, ORs (95 % CI) were 2.2 (0.7–7.1) 
for 100–199 mg per day, 1.7 (0.4–7.1) for 200–299 mg per day and 5.1 (1.6–16.4) for ≥ 300 mg per 
day (p per trend = 0.004). 
The Panel notes that this study shows a dose-dependent positive association between caffeine intake 
during pregnancy and adverse birth weight- and fetal death-related outcomes, and that the risk 
becomes significant at caffeine doses ≥ 200 mg per day for FGR and at ≥ 300 mg per day for late 
miscarriage or stillbirth. 
The association between maternal caffeine intake from different sources (coffee, black tea, cola, 
“energy drinks”, chocolate milk) and gestational length, the risk of spontaneous pre-term delivery, 
birth weight and the risk of a baby being SGA was investigated in 59 123 Norwegian women with 
uncomplicated pregnancies giving birth to a live singleton (Sengpiel et al., 2013). SGA was diagnosed 
using three different growth curves and two definitions: < –2 SD or < 10th percentile of the growth 
curve distribution. Caffeine intake in the first four to five months of pregnancy was assessed using a 
semi-quantitative FFQ at week 22 of pregnancy, which was validated using four-day weighed food 
diaries. The way in which coffee was prepared was considered in calculating caffeine intake from this 
source. At weeks 15–17 and 30 of pregnancy, women also reported their current and pre-pregnancy 
consumption of coffee, tea and caffeinated soft drinks in cups or glasses per day. Coffee (56 %), black 
tea (22 %), sugar-containing soft drinks including “energy drinks” (7 %), sugar-free soft drinks (7 %) 
and chocolate (7 %) accounted for > 98 % of caffeine intake, although predominant sources of 
caffeine varied across quartiles of caffeine intake (chocolate in the first, black tea in the second and 
third and coffee in the fourth quartile). Self-reported pre-pregnancy median intake of caffeine from 
coffee, black tea and soft drinks was 126 mg per day (IQR 40 to 254 mg per day) for all 59 123 
women, including 7 406 (12.5 %) women who did not consume any caffeine at all. At gestational 
week 17, the number of non-consumers almost doubled (14 012 women: 24 %) and the median 
caffeine intake had decreased to 44 mg per day (IQR 13 to 104 mg per day). At gestational week 30, 
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the median caffeine intake had increased again to 62 mg per day (IQR 21 to 130 mg per day) and 
9 792 (16.5 %) women remained non-consumers. 
When caffeine intake and intake of caffeinated beverages were analysed as continuous variables, and 
after adjusting for confounding variables, total caffeine and coffee caffeine were significantly 
associated with increased gestational length. Conversely, total caffeine and soft drink caffeine were 
significantly associated with decreased gestational length in non-coffee drinkers, whereas no 
association was found with black tea or chocolate caffeine. Total caffeine and caffeine intake from the 
individual sources were significantly associated with lower birth weight. An additional 100 mg total 
caffeine per day was associated with a 21- to 28-g birth weight decrease, depending on the growth 
curve. There were 1 451 cases of spontaneous pre-term delivery (240 early spontaneous pre-term 
deliveries, between weeks 22 and 33 + 6 days, and 1 211 late spontaneous pre-term deliveries, 
between weeks 34 and 36 + 6 days). There was no significant association between total or coffee 
caffeine intake and the odds for overall, early or late spontaneous pre-term delivery, whereas black tea 
caffeine was associated with increased risk of early spontaneous pre-term delivery (OR 1.61, 95 % 
CI = 1.10–2.35, p = 0.01). Total and coffee caffeine intakes were significantly associated with higher 
odds for SGA in all three SGA models, and with soft drink and black tea caffeine in two SGA models. 
All these associations remained when only non-smokers were considered (n = 54 136) in the analyses. 
The analyses were also conducted with caffeine intake as a categorical variable (six categories) to test 
threshold effects (0 to 14.6, reference; 14.6 to 32.1; 32.1 to 57.3; 57.3 to 96.0; 96.0 to 163.8; 
> 163.8 mg per day). The ORs for SGA consistently increased in the three models of SGA from the 
third of the six categories upwards compared with the reference category. Categorising caffeine intake 
based on current Nordic (up to 200 mg per day) and World Health Organization recommendations (up 
to 300 mg per day), women with a daily caffeine intake of 51 to 200 mg per day (43.5 %), of 200 to 
300 mg (7.7 %) and of > 300 mg (3.3 %) had significantly higher odds for SGA (1.09 to 1.18, 1.27 to 
1.62 and 1.62 to 1.66, respectively, depending on the SGA definition) than the lowest (0 to 50 mg per 
day) reference category. The Panel notes that this study shows a dose-dependent positive association 
between caffeine intake during pregnancy and adverse birth weight-related outcomes. The risk 
becomes statistically significant at caffeine doses > 50 mg per day but increases notably at > 200 mg 
per day. The Panel also notes that the relationship between caffeine intake and outcomes related to the 
length of gestation is inconsistent. 
The third study (Bakker et al., 2010) was conducted in 7 346 pregnant women participating in a 
population-based prospective cohort study from early pregnancy onwards in the Netherlands (2001–
2005). Fetal growth characteristics were assessed by ultrasound in the first, second and third 
trimesters. SGA at birth was defined as a gestational age-adjusted birth weight below the fifth 
percentile in the study cohort (< −1.81 SD score for boys and −1.73 SD score for girls). Caffeine 
intake from coffee and tea in the first (gestational age < 18.0 weeks), second (gestational age 18.0–
24.9 weeks) and third (gestational age ≥ 25.0 weeks) trimesters of pregnancy was assessed by postal 
questionnaires. Intakes of caffeinated and decaffeinated coffee and tea were converted to caffeine 
units, each unit of caffeine intake reflecting caffeine exposure based on one cup (90 mg caffeine) of 
caffeinated coffee. Total caffeine intake was subsequently categorised as < 2, 2–3.9, 4–5.9 and ≥ 6 
units per day for statistical analysis. No clear dose–response associations were found for caffeine 
intakes during pregnancy and fetal growth. Mothers who consumed ≥ 6 caffeine units per day had a 
smaller first-trimester fetal crown–rump length, smaller third-trimester femur length and impaired fetal 
weight and length growth than those who consumed no caffeine. Caffeine intake was positively 
associated with the risks of delivering an SGA child. Compared with mothers who consumed < 2 units 
caffeine per day, the adjusted ORs were 1.38 (95 % CI = 1.08–1.76), 1.50 (95 % CI = 0.96–2.36) and 
1.87 (95 % CI = 0.84–4.15) for mothers consuming 2–3.9, 4–5.9 and ≥ 6 units caffeine per day, 
respectively (p trend < 0.01). The Panel notes that this study did not assess caffeine intake during 
pregnancy from all dietary sources. The Panel also notes that the reference category includes women 
with caffeine intakes up to 180 mg per day from tea and coffee, and that this categorisation does not 
allow the low end of the caffeine consumption curve to be explored in relation to the outcomes 
investigated. 
Safety of caffeine 
 
EFSA Journal 2015;13(5):4102 67 
One recent study (McMahon et al., 2014) assessed the allelic variation in two genetic loci which have 
been associated with habitual caffeine consumption, one in the CYP1A1 and CYP1A2 gene region 
(rs2472297) and one near the AHR gene (rs6968865), and its contribution to the inter-individual 
variability in habitual caffeine intake in a sample of pregnant women who participated in the Avon 
Longitudinal Study of Parents and Children (ALSPAC). Genetic information and data on self-reported 
coffee, tea and cola consumption (including consumption of decaffeinated drinks) at multiple time 
points (8, 18 and 32 weeks’ gestation and 2, 47, 85, 97 and 145 months after delivery) were available 
from between 4 460 and 7 520 women. Caffeine intake generally increased across time points. Cola 
contributed to about 4–11 % of caffeine intake. Both genotypes were individually associated with total 
caffeine consumption and with the consumption of caffeinated drinks (coffee and tea) at all time 
points, but not with the consumption of decaffeinated drinks. However, the proportion of phenotypic 
variance (i.e. observed variability in caffeine intake) explained by these two genotypes was small: 
CYP1A1 accounted for 0.15–0.88 %, AHR accounted for 0.04–0.048 % and the two combined 
accounted for about 0.16–1.28 %. Whether or not the allelic variation in these two genetic loci 
influences the risk of adverse birth weight-related outcomes associated with caffeine consumption 
during pregnancy has not been investigated prospectively (e.g. using Mendelian randomisation). 
4.5.3.3. Case–control and cross-sectional studies 
The available case–control and cross-sectional studies on the relationship between caffeine 
consumption and pregnancy-related outcomes published up to 2008 have been thoroughly reviewed in 
previous assessments (COT, 2008). Overall, the results from these studies support a positive 
association between caffeine intake and the risk of adverse birth weight-related outcomes, whereas the 
relationship between caffeine consumption during pregnancy and other pregnancy outcomes (e.g. in 
relation to length of gestation or fetal death) was less consistent (COT, 2008), as observed in the 
prospective cohort studies described above. 
Some of these studies have investigated whether or not the association between caffeine intake and 
adverse pregnancy outcomes could be modulated by differences in the activity of enzymes involved in 
the metabolism of caffeine, such as xanthine oxidase or N-acetyltransferase, or by genetic 
polymorphisms of the CYP1A2, CYP1B1 and CYP2E1 genes (Fenster et al., 1998; Signorello et al., 
2001; Karypidis et al., 2006; Infante-Rivard, 2007). However, the results from these studies are not 
consistent, and whether genetic polymorphisms and/or phenotypic differences in the activity of 
enzymes involved in caffeine metabolism modify the relationship between caffeine intakes and 
adverse pregnancy-related outcomes has not been investigated in prospective studies. 
4.5.3.4. Conclusions on pregnancy outcomes 
The Panel notes that two prospective cohort studies (CARE Study Group, 2008; Sengpiel et al., 2013) 
show a dose-dependent positive association between caffeine intake during pregnancy from all dietary 
sources and the risk of adverse birth weight-related outcomes (i.e. FGR, SGA). The Panel also notes 
that the relationship between caffeine intakes and adverse birth weight-related outcomes is observed at 
all levels of intake, with no threshold below which the relationship is not observed. However, the 
Panel considers that the risk becomes clinically relevant at daily doses of about 200 mg of caffeine 
from all sources. In addition, the Panel also notes that pregnant women tend to reduce (pre-pregnancy) 
consumption of caffeine, and that decreasing caffeine intake from about 300 mg per day to about 
100 mg per day in the third trimester of pregnancy does not decrease the risk, as observed in one 
human intervention study (Bech et al., 2007). Major sources of caffeine in the studies reviewed were 
coffee and tea, followed by soft drinks (including cola drinks) and chocolate. “Energy drinks” 
contributed 2 % (alone) (CARE Study Group, 2008) and 7 % (in combination with sugar-containing 
soft drinks) (Sengpiel et al., 2013) to caffeine intake in the two studies reporting on this source. 
Genetic polymorphisms for genes involved in caffeine metabolism have been shown to explain only a 
small proportion of the inter-individual variability in caffeine intake during and after pregnancy 
(McMahon et al., 2014), and there is no evidence that such polymorphisms influence the risk of 
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adverse birth weight-related outcomes significantly, although prospective studies investigating this 
topic are lacking. 
5. Dose–response assessment and derivation of intake levels of no concern 
Consistent with the Panel’s interpretation of the terms of reference (Section 1), this section addresses 
the derivation of caffeine intake levels of no concern for: 
i. habitual caffeine consumption (i.e. a daily intake of caffeine from all sources which, if 
consumed ad libitum and throughout the day for long periods of time, does not give rise to 
concerns about harmful effects to health for the normal healthy population, divided into 
various life-stage groups as appropriate, but excluding sub-populations with extreme and 
distinct vulnerabilities due to genetic predisposition or other considerations); 
ii. single doses of caffeine consumed prior to physical activity; 
iii. caffeine (single doses and habitual consumption) consumed in combination with other 
common constituents of “energy drinks” (i.e. taurine, D-glucurono-γ-lactone) and/or with 
alcohol, or in combination with p-synephrine. 
5.1. Adults 
5.1.1.  Single doses of caffeine 
To provide advice on caffeine consumption (dose and timing) prior to physical activity that does not 
give rise to safety concerns, the Panel considers that clinically relevant changes in MBF are the 
appropriate health outcome on which to base such advice. 
Single doses of caffeine up to 200 mg, corresponding to about 3 mg/kg bw for a 70-kg adult, or the 
same amount consumed within a short period of time, are unlikely to induce clinically relevant 
changes in MBF in the general healthy adult population, either at rest or when consumed less than two 
hours prior to intense physical exercise, under normal environmental conditions. The Panel notes that 
this may not be the case when caffeine is consumed prior to physical exercise under unusual 
environmental conditions (e.g. very high altitude). The Panel also notes that no studies are available in 
pregnant women or middle-aged/elderly subjects undertaking intense physical exercise. As only single 
doses of caffeine of 200 mg have been tested in relation to this outcome, a dose–response relationship 
cannot be derived on the basis of the data available. 
Single doses of caffeine up to 200 mg are also unlikely to induce clinically relevant changes in blood 
pressure, hydration status or body temperature. This is the case both at rest or when consumed less 
than two hours prior to intense physical exercise under normal environmental conditions. This applies 
to non-habitual caffeine consumers, to caffeine-deprived subjects and to habitual caffeine consumers. 
Single doses of caffeine up to 200 mg (about 3 mg/kg bw for a 70-kg adult) are unlikely to reduce the 
perceived exertion/effort during exercise. Higher doses could lead to prolonged physical exercise that 
might compromise the cardiovascular and/or musculoskeletal systems. 
Single doses of caffeine up to 200 mg (about 3 mg/kg bw for a 70-kg adult) are also unlikely to mask 
the subjective perception of alcohol intoxication when alcohol is consumed at doses up to about 
0.65 g/kg bw. 
The human intervention studies on which these conclusions are based (Section 4.4) were primarily 
conducted with caffeine supplements for most of the outcomes assessed (i.e. changes in MBF, 
hydration status, body temperature, perceived exertion/effort during exercise, sleep). Changes in BP 
were assessed using caffeine supplements, coffee, tea and “energy drinks” as sources of caffeine, 
whereas the subjective perception of alcohol intoxication was tested using caffeine either from 
supplements or from “energy drinks”. 
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The Panel notes that 100 mg (about 1.4 mg/kg bw for a 70-kg adult) of caffeine may increase sleep 
latency and reduce sleep duration in some adult individuals, particularly when consumed close to 
bedtime. 
5.1.2. Single doses of caffeine in combination with other common constituents of “energy 
drinks”, alcohol and p-synephrine 
Other common constituents of “energy drinks” at concentrations commonly present in such beverages 
(typically about 300–320, 4 000 and 2 400 mg/L of caffeine, taurine and D-glucurono-γ-lactone, 
respectively) would not affect the safety of single doses of caffeine up to 200 mg. Up to these levels of 
intake, other common constituents of “energy drinks” are not expected to adversely interact with 
caffeine on its effects on the CVS, the CNS or hydration status. 
Alcohol consumption at doses up to about 0.65 g/kg bw, leading to a BAC of about 0.08 %, would not 
affect the safety of single doses of caffeine up to 200 mg from any dietary source, including “energy 
drinks”. Up to these levels of intake, caffeine is unlikely to mask the subjective perception of alcohol 
intoxication. 
The Panel also considers that the question of whether or not p-synephrine modifies the acute 
cardiovascular effects of single doses of caffeine has not been adequately investigated in humans, 
particularly if consumed shortly before intense physical exercise, and therefore no conclusions could 
be drawn. 
5.1.3. Repeated doses of caffeine within a day 
The Panel notes the absence of data for repeated caffeine doses in relation to the majority of health 
outcomes discussed for single doses of caffeine. However, the Panel considers that repeated doses of 
caffeine which do not give rise to safety concerns for non-pregnant adults in the general population 
should take into account the half-life of caffeine (mean four hours, range two to eight hours) so as not 
to exceed the maximum plasma concentrations achieved with a single 200 mg dose. 
5.1.4. Habitual caffeine consumption 
Caffeine intakes from all sources up to 400 mg per day (corresponding to about 5.7 mg/kg bw for a 
70-kg adult) consumed throughout the day do not give rise to safety concerns for healthy adults in the 
general population, except for pregnant women (see Section 5.2). No health concerns in relation to 
acute toxicity, bone status, cardiovascular health, cancer risk or male fertility have been raised by 
other bodies in previous assessments for this level of habitual caffeine consumption and no new data 
have become available on these or other clinical outcomes which could justify modifying these 
conclusions. 
5.1.5. Habitual caffeine consumption in combination with other common constituents of 
“energy drinks”, alcohol and p-synephrine 
The Panel notes that, in the prospective cohort studies considered in relation to CVD risk, the 
consumption of “energy drinks” was zero (i.e. studies which collected intake data before “energy 
drinks” appeared on the market) or unknown. However, based on the data available regarding the 
acute effects of caffeine in combination with other common constituents of “energy drinks” on the 
CVS, the Panel considers that such constituents at the doses commonly present in “energy drinks” 
(typically about 300–320, 4 000 and 2 400 mg/L of caffeine, taurine and D-glucurono-γ-lactone, 
respectively) would not affect the safety of habitual caffeine consumption up to 400 mg per day. In 
addition, the Panel considers that moderate habitual alcohol consumption would not affect the safety 
of habitual caffeine consumption up to 400 mg per day. 
The Panel considers that the question of whether or not p-synephrine modifies the long-term effects of 
caffeine on the cardiovascular system has not been adequately investigated in humans, and therefore 
no conclusions could be drawn. 
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5.2. Pregnant women 
5.2.1. Single doses of caffeine 
There are no studies on the health effects of single doses of caffeine consumed by pregnant women 
prior to intense physical exercise. Taking into account the different kinetics of caffeine in this 
population subgroup, the Panel considers that single doses of caffeine which are of no safety concern 
for non-pregnant adults may not apply to pregnant women performing physical exercise. 
5.2.2. Habitual caffeine consumption 
Caffeine intakes from all sources up to 200 mg per day consumed throughout the day by pregnant 
women in the general population do not give rise to safety concerns for the fetus. This conclusion is 
based on two prospective cohort studies (CARE Study Group, 2008; Sengpiel et al., 2013) showing a 
dose-dependent positive association between caffeine intakes during pregnancy and the risk of adverse 
birth weight-related outcomes (i.e. FGR, SGA). The association between caffeine intakes and other 
adverse pregnancy-related outcomes is less consistent. 
The Panel notes that prospective cohort studies cannot provide evidence for a causal association 
between caffeine and adverse birth weight-related outcomes. However, given the consistency of the 
association, the dose–response relationship observed in these studies and the plausibility of the 
proposed mode of action by which caffeine could affect fetal development, the Panel assumes that the 
relationship is causal in the context of this safety assessment. In these studies, the contribution of 
“energy drinks” to total caffeine intake was low (about 2 % when considered alone, about 7 % in 
combination with sugar-containing soft drinks). 
5.3. Lactating women 
5.3.1. Single doses of caffeine 
Single doses of caffeine up to 200 mg consumed by lactating women in the general population do not 
give rise to safety concerns for the breastfed infant. Daily caffeine intakes by the breastfed infant 
would not exceed 0.3 mg/kg bw (Hildebrandt and Gundert-Remy, 1983), which is 10-fold below the 
lowest dose of 3 mg/kg bw tested in a dose finding study (Steer et al., 2003). For this dose, only 1 out 
of 42 pre-term infants showed tachycardia and jittering, and only tachycardia (with no jittering) was 
observed in 8 out of 45 infants at doses 100-fold higher (30 mg/kg bw). 
5.3.2. Repeated doses of caffeine within a day and habitual caffeine consumption 
Repeated doses of caffeine consumed by lactating women in the general population which do not give 
rise to safety concerns for the breastfed infant should take into account the half-life of caffeine (mean 
four hours, range two to eight hours) in women and the longer half-life in infants (i.e. 50–103 hours in 
neonates with no CYP1A2 activity, about 14 hours at three to four months of age). In this context, the 
Panel considers that doses of 200 mg per day from all sources consumed throughout the day by 
lactating women do not give rise to safety concerns for the breastfed infant. 
5.4. Children and adolescents (1 to < 18 years) 
The Panel notes that the information available for this population subgroup on the relationship 
between caffeine intakes and health outcomes is insufficient to derive a safe level of caffeine intake. 
5.4.1. Single doses of caffeine 
The Panel considers that single doses of caffeine of no concern derived for adults (3 mg/kg bw per 
day) may also apply to children, considering that caffeine clearance in children and adolescents is at 
least that of adults, and that the limited studies available on the acute effects of caffeine on anxiety and 
behaviour in children and adolescents support this level of no concern. 
Safety of caffeine 
 
EFSA Journal 2015;13(5):4102 71 
The Panel notes that, like for adults, caffeine doses of about 1.4 mg/kg bw may increase sleep latency 
and reduce sleep duration in some children and adolescents, particularly when consumed close to 
bedtime. 
5.4.2. Habitual caffeine consumption 
As mentioned above, caffeine clearance in children and adolescents is at least that of adults. Therefore, 
the same levels of no concern derived for adults (i.e. 5.7 mg/kg bw for a 70-kg adult) may also apply 
to children, unless there are data showing a higher sensitivity to the effects of caffeine of this age 
group (i.e. difference in pharmacodynamics). As only limited studies are available on the longer-term 
effects of caffeine on anxiety and behaviour in children and adolescents, there is substantial 
uncertainty regarding longer-term effects of habitual caffeine consumption in this age group. The 
Panel, therefore, considers a level of no safety concern for habitual caffeine consumption by children 
and adolescents of 3 mg/kg bw per day (i.e. the level of no safety concern derived for single doses of 
caffeine for adults) as appropriate. The Panel notes that this approach is rather conservative in relation 
to the effects of caffeine on the CVS, but the limited studies available regarding the longer-term 
effects of caffeine on anxiety and behaviour in children and adolescents support this caffeine intake 
level of no safety concern. 
6. Characterisation of the risk 
Daily caffeine intake from foods and beverages obtained from the EFSA Comprehensive Database 
was used to characterise the risk of habitual caffeine consumption. The Panel notes that the surveys 
considered did not report on the consumption of caffeine from food supplements, and that there are no 
data on the frequency and quantity of consumption of caffeine from this source in Europe in different 
subgroups of the population. 
6.1. Adults 
6.1.1. Single doses of caffeine 
There are no data available to characterise the risk of single doses of caffeine consumed by adults in 
relation to physical exercise. The EFSA energy drink report, however, provides information to 
estimate caffeine intakes from “energy drinks” in “single sessions”, defined as periods of time of a 
couple of hours, and in connection with physical exercise. 
Considering the most common concentration of caffeine in “energy drinks” (320 mg/L) and the most 
common format (250 mL/can), it can be estimated that about 19 % of adult “energy drink consumers” 
and about 6 % of the total adult population may exceed caffeine intakes of 200 mg from “energy 
drinks” in a “single session” (Table 4), and that 14 % of adult “energy drink consumers” and 4 % of 
the total adult population may do so in relation to physical exercise (Table 5). 
On the one hand, the Panel notes that this information is not available for other sources of caffeine, or 
for caffeine from all sources, including food supplements, and thus the percentage of adults exceeding 
200 mg caffeine in a single sports session may be underestimated. On the other hand, caffeine intakes 
of no concern up to 200 mg refer to single doses of caffeine, whereas “a single sports session” may be 
extended for longer periods of time (e.g. a couple of hours or more), and the percentage of subjects 
exceeding 200 mg caffeine from “energy drinks” consumed as single doses in relation to physical 
exercise may have been overestimated. 
6.1.2. Habitual caffeine consumption 
For 7 out of 13 Member States, estimates of the 95
th
 percentile of daily caffeine intake from foods and 
beverages exceeded 400 mg. In these countries, the estimated proportion of the adult population 
exceeding daily intakes of 400 mg ranged from about 6 % to almost one-third (32.9 %) (Appendix B). 
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The Panel notes that coffee was the main source of dietary caffeine in the seven countries for which 
the 95
th
 percentile of daily caffeine intake exceeded 400 mg, and that the use of a mean value for the 
caffeine content in coffee on a volume basis may not accurately reflect caffeine intakes in all 
countries. More accurate estimates of caffeine intakes within a given country could be obtained by 
using national caffeine occurrence data, if available. 
6.2. Pregnant women 
6.2.1. Single doses of caffeine 
There are no data to characterise the risk of single doses of caffeine consumed by pregnant women. 
6.2.2. Habitual caffeine consumption 
The mean and the 95
th
 percentile of the daily caffeine intakes from foods and beverages in the only 
survey available were 109 mg and 206 mg per day, respectively. About 6.5 % of the women in that 
survey (n = 1 002) had daily caffeine intakes > 200 mg per day. The Panel notes the limited caffeine 
intake data available for this population subgroup (Appendix B). 
6.3. Lactating women 
6.3.1. Single doses of caffeine 
There are no data to characterise the risk of single doses of caffeine consumed by lactating women. 
6.3.2. Habitual caffeine consumption 
The mean and the 95
th
 percentile of the daily caffeine intakes from food and beverages in the only 
survey available were 31 mg and 97 mg per day, respectively, which are well below 200 mg. No 
women in that small survey (n = 65) consumed more than 400 mg of caffeine per day. The Panel notes 
the limited intake data available for this population subgroup (Appendix B). 
6.4. Adolescents (10 to < 18 years) 
6.4.1. Single doses of caffeine 
Like for adults, there are no data available to characterise the risk of single doses of caffeine from all 
sources consumed by adolescents in relation to physical exercise. In the absence of such data, 
estimates of the proportion of single days in which caffeine intake exceeds 3 mg/kg bw among all 
survey days using the EFSA Comprehensive Database may serve as a conservative approximation. 
For 6 out of 16 Member States, the estimated 95
th
 percentile of caffeine intake from foods and 
beverages on a single day exceeded 3 mg/kg bw. The proportion of days on which daily intakes of 
caffeine from food and beverages exceeds 3 mg/kg bw in these countries ranges from about 7% to 
about 12 % (Appendix D). 
6.4.2. Habitual caffeine consumption 
For 5 out of 13 Member States, the 95
th
 percentile of caffeine intake from food and beverages 
exceeded 3 mg/kg bw per day. In these countries, the estimated proportion of the adolescent 
population exceeding caffeine intakes of 3 mg/kg bw per day from food and beverages ranged from 5 
to 10 % (Appendix B). The mean age of the adolescents studied in the surveys of these five countries 
ranged from 13 to 16 years. 
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6.5. Children (3 to < 10 years) 
6.5.1. Single doses of caffeine 
There are no data available to characterise the risk of single doses of caffeine consumed by children. 
Like for adolescents, estimates of the proportion of single days in which caffeine intake exceeds 
3 mg/kg bw among all survey days using the EFSA Comprehensive Database may serve as a 
conservative approximation. 
For 9 out of 16 Member States, the estimated 95
th
 percentile of caffeine intake from food and 
beverages on a single day exceeded 3 mg/kg bw. The proportion of days on which daily intakes of 
caffeine from food and beverages exceeds 3 mg/kg bw in these countries ranges from about 6 % to 
about 15 % (Appendix D). 
6.5.2. Habitual caffeine consumption 
For 6 out of 14 Member States the estimates of the 95
th
 percentile of daily caffeine intake from all 
sources exceeds 3 mg/kg bw. The estimated proportion of children with intakes exceeding 3 mg/kg bw 
per day of caffeine from foods and beverages in these countries ranged from 6 % to about 13 % 
(Appendix B). 
The Panel notes that chocolate beverages were important contributors to total caffeine intakes in this 
age group in most countries, and that the use of a conservative caffeine value for this food category 
may have led to an overestimation of caffeine intakes in children. 
6.6. Toddlers (12 to < 36 months) 
6.6.1. Single doses of caffeine 
There are no data available to characterise the risk of single doses of caffeine consumed by toddlers. In 
the absence of such data, estimates of the proportion of single days with caffeine intakes exceeding 
3 mg/kg bw among all survey days using the EFSA Comprehensive Database may serve as a 
conservative approximation. 
For 3 out of 10 Member States, the estimated 95
th
 percentile of caffeine intake from all sources on a 
single day exceeded 3 mg/kg bw. The proportion of days in which daily intakes of caffeine from all 
sources exceeds 3 mg/kg bw ranges from 7 % to 37 % (Appendix D). 
6.6.2. Habitual caffeine consumption 
For only one out of nine Member States did the 95
th
 percentile of caffeine intake from all sources 
exceed 3 mg/kg bw per day. About 6 % of the toddlers had a daily consumption > 3 mg/kg bw in that 
country (Appendix B). 
The Panel notes that chocolate beverages were important contributors to total caffeine intakes in this 
age group in most countries, and that the use of a conservative caffeine value for this food category 
may have led to an overestimation of caffeine intakes in toddlers. 
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CONCLUSIONS 
On the basis of the data available, the NDA Panel reached the following conclusions on caffeine 
intakes which do not give rise to safety concerns for specific groups of the general population. In line 
with the interpretation of the terms of reference, these conclusions do not apply to subgroups of the 
population selected on the basis of a disease condition or to sub-populations with extreme and distinct 
vulnerabilities due to genetic predisposition or other conditions which may require individual advice. 
Adults 
Single doses of caffeine 
Single doses of caffeine up to 200 mg (about 3 mg/kg bw for a 70-kg adult) from all sources do not 
give rise to safety concerns for the general healthy adult population. The same amount of caffeine does 
not give rise to safety concerns when consumed less than two hours prior to intense physical exercise 
under normal environmental conditions. No studies are available in pregnant women or middle-
aged/elderly subjects undertaking intense physical exercise. Single doses of 100 mg (about 1.4 mg/kg 
bw for a 70-kg adult) of caffeine may increase sleep latency and reduce sleep duration in some adult 
individuals, particularly when consumed close to bedtime. 
Other common constituents of “energy drinks” at concentrations commonly present in such beverages 
(typically about 300–320, 4 000 and 2 400 mg/L of caffeine, taurine and D-glucurono-γ-lactone, 
respectively) would not affect the safety of single doses of caffeine up to 200 mg. Up to these levels of 
intake, other common constituents of “energy drinks” are not expected to adversely interact with 
caffeine on its effects on the CVS, the CNS or hydration status. Alcohol consumption at doses up to 
about 0.65 g/kg bw, leading to a BAC of about 0.08 %, would not affect the safety of single doses of 
caffeine up to 200 mg from any dietary source, including “energy drinks”. Up to these levels of intake, 
caffeine is unlikely to mask the subjective perception of alcohol intoxication. 
The human intervention studies on which these conclusions are based (see Section 4.4) were primarily 
conducted with caffeine supplements for most of the outcomes assessed (i.e. changes in MBF, 
hydration status, body temperature, perceived exertion/effort during exercise, sleep). Changes in BP 
were assessed using caffeine supplements, coffee, tea and “energy drinks” as sources of caffeine, 
whereas the subjective perception of alcohol intoxication was tested using caffeine either from 
supplements or from “energy drinks”. 
The question of whether or not p-synephrine modifies the acute cardiovascular effects of single doses 
of caffeine has not been adequately investigated in humans, particularly if consumed shortly before 
intense physical exercise, and therefore no conclusions could be drawn. 
About 6 % of the adult population may exceed 200 mg of caffeine in a single session of “energy 
drink” consumption, and about 4 % do so in connection with physical exercise. This information is not 
available for other sources of caffeine. 
Habitual caffeine consumption 
Caffeine intakes from all sources up to 400 mg per day (about 5.7 mg/kg bw per day for a 70-kg adult) 
consumed throughout the day do not give rise to safety concerns for healthy adults in the general 
population, except pregnant women (see below). No health concerns in relation to acute toxicity, bone 
status, cardiovascular health, cancer risk or male fertility have been raised by other bodies in previous 
assessments for this level of habitual caffeine consumption and no new data have become available on 
these or other clinical outcomes which could justify modifying these conclusions. 
Other common constituents of “energy drinks” at the doses commonly present in such beverages 
and/or moderate habitual alcohol consumption would not affect the safety of habitual caffeine 
consumption up to 400 mg per day. 
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The question of whether or not p-synephrine modifies the acute cardiovascular effects of single doses 
of caffeine or the long-term effects of caffeine on the cardiovascular system has not been adequately 
investigated in humans and therefore no conclusions could be drawn. 
In 7 out of 13 countries, the 95
th
 percentile of daily caffeine intake from foods and beverages exceeded 
400 mg. In these countries, the estimated proportion of the adult population exceeding daily intakes of 
400 mg ranged from 6 % to almost one-third, and coffee was the main source of caffeine. More 
accurate estimates of caffeine intakes within a given country could be obtained by using national 
caffeine occurrence data, if available. 
Pregnant women 
Single doses of caffeine 
There are no studies on the health effects of single doses of caffeine consumed by pregnant women 
prior to intense physical exercise. With regard to the different kinetics of caffeine in this population 
subgroup, single doses of caffeine which are of no safety concern for non-pregnant adults may not 
apply to pregnant women performing physical exercise. 
Habitual caffeine consumption 
Caffeine intakes from all sources up to 200 mg per day consumed throughout the day by pregnant 
women in the general population do not give rise to safety concerns for the fetus. This conclusion is 
based on prospective cohort studies showing a dose-dependent positive association between caffeine 
intakes during pregnancy and the risk of adverse birth weight-related outcomes (i.e. FGR, SGA) in the 
offspring. In these studies, the contribution of “energy drinks” to total caffeine intake was low (about 
2 %). 
Data to characterise the risk of habitual caffeine consumption in this population subgroup are scarce. 
Lactating women 
Single doses of caffeine and habitual caffeine consumption 
Single doses of caffeine up to 200 mg and habitual caffeine consumption at doses of 200 mg per day 
consumed by lactating women in the general population do not give rise to safety concerns for the 
breastfed infant. At these doses of caffeine, daily caffeine intakes by the breastfed infant would not 
exceed 0.3 mg/kg bw, which is 10-fold below the lowest dose of 3 mg/kg bw tested in a dose finding 
study and at which no adverse effects were observed in the majority of infants. 
There are no data to characterise the risk of single doses of caffeine consumed by lactating women, 
and data on habitual caffeine consumption in this population subgroup are scarce. 
Children and adolescents 
The information available for this population subgroup on the relationship between caffeine intakes 
and health outcomes is insufficient to derive a safe level of caffeine intake. 
Single doses of caffeine 
Single doses of caffeine of no concern derived for adults (3 mg/kg bw per day for a 70-kg adult) may 
also apply to children, considering that caffeine clearance in children and adolescents is at least that of 
adults, and that the limited studies available on the acute effects of caffeine on anxiety and behaviour 
in children and adolescents support this level of no concern. Like for adults, caffeine doses of about 
1.4 mg/kg bw may increase sleep latency and reduce sleep duration in some children and adolescents, 
particularly when consumed close to bedtime. 
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There are no data available to characterise the risk of single doses of caffeine from all sources 
consumed by children and adolescents. Estimates of the proportion of single days in which caffeine 
intake exceeds 3 mg/kg bw among all survey days using the EFSA Comprehensive Database were 
used as a conservative approximation. 
The estimated 95
th
 percentile of caffeine intake from foods and beverages on a single day exceeded 
3 mg/kg bw in 6 out of 16 countries for adolescents (10 to < 18 years), in 9 out of 16 countries for 
children (3 to < 10 years) and in 3 out of 10 countries for toddlers (12 to < 36 months). The proportion 
of survey days in which the level was exceeded ranged from 7.2 to 11.8 % in adolescents, from about 
6 to 15 % in children and from 7 to 37 % in toddlers in the aforementioned countries. Chocolate 
beverages were important contributors to total caffeine intakes in children and toddlers in most 
countries, and the use of a conservative caffeine value for this food category may have led to an 
overestimation of caffeine intakes in these age groups. 
Habitual caffeine consumption 
As caffeine clearance in children and adolescents is at least that of adults, the same levels of no safety 
concern derived for adults (i.e. 5.7 mg/kg bw) may also apply to children, unless there are data 
showing a higher sensitivity to the effects of caffeine in this age group (i.e. difference in 
pharmacodynamics). As only limited studies are available on the longer-term effects of caffeine on 
anxiety and behaviour in children and adolescents, there is substantial uncertainty regarding longer-
term effects of habitual caffeine consumption in this age group. A level of no safety concern of 
3 mg/kg bw per day (i.e. the level of no concern derived for single doses of caffeine for adults) is 
proposed for habitual caffeine consumption by children and adolescents. This approach is rather 
conservative in relation to the effects of caffeine on the CVS, but the limited studies available 
regarding the longer-term effects of caffeine on anxiety and behaviour in children and adolescents 
support the proposed caffeine intake level of no safety concern. 
The estimated 95
th
 percentile of daily caffeine intake from foods and beverages exceeded 3 mg/kg bw 
in 5 out of 13 countries for adolescents, in 6 out of 14 countries for children (3 to < 10 years) and in 1 
out of 9 countries for toddlers (12 to < 36 months). The proportion of subjects exceeding that level of 
intake in the above-mentioned countries was about 5 to 10 % for adolescents, 6 to 13 % for children 
and about 6 % for toddlers. Chocolate beverages were important contributors to total caffeine intakes 
in children and toddlers in most countries, and the use of a conservative caffeine value for this food 
category may have led to an overestimation of caffeine intakes in these age groups. 
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APPENDICES 
Appendix A.  Dietary surveys used for the assessment of caffeine intakes 
Country Survey name/acronym Survey period No of days 
per subject 
No of subjects/No of days 
Toddlers Other 
children 
Adolescents 
(mean age) 
Adults Elderly Very elderly 
Belgium Regional Flanders 
(a)
 2002–2002 3 36/108 625/1 875 – – – – 
Belgium Diet National 2004 
(a)
 2004 2 – – 576/1 187 
(16 years) 
1 292/2 648 511/1 045 704/1 408 
Bulgaria NSFIN 
(a)
 2004 1   –/162 –/691 –/151 –/200 
Bulgaria NUTRICHILD 
(a)
 2007 2 428/856 433/867 – – – – 
Cyprus Childhealth 
(a)
 2003 3 – – 303/909 
(13 years) 
– – – 
Czech 
Republic 
SISP04 
(a)
  2003–2004 2 – 389/778 298/596 
(13 years) 
1 666/3 332 – – 
Denmark DANSDA 2005–08 
(b)
 2005–2008 7 – 298/2 085 377/2 622 
(13 years) 
1 739/12 127 274/1 916 12/84 
Denmark IAT 2006–07 
(b)
 2006–2007 7 917/6 388 – – – – – 
Estonia NDS 1997 
(a)
 1997 1   – –/1866 – – 
Finland DIPP 2001–2009 
(b)
 2001–2009 3 500/1 500 750/2 250 – – – – 
Finland NWSSP07–08 
(b)
 2007–2008 4 – – 306/1 186 
(13 years) 
– – – 
Finland FINDIET2012 
(b)
 2012 2 – – – 1 295/2 590 413/826 – 
France INCA2 
(a)
 2007 7 – 482/3 315 973/6 728 
(14 years) 
2 276/15 727 264/1 824 84/571 
Germany VELS 
(b)
 2001–2002 6 348/1 947 293/1 610 – – – – 
Germany EsKiMo 
(b)
 2006 3 – 835/2 498 393/1 179 
(11 years) 
– – – 
Germany National Nutrition Survey II 
(a)
 2007 2 – – 1 011/2 022 
(16 years) 
10 419/20 838 2 006/4 012 490/980 
Greece Regional Crete 
(a)
 2004–2005 3 – 838/2 508 – – – – 
Greece DIET LACTATION GR 
(b)
 2005–2007 3 – – – 65/350 – – 
Hungary National Repr Surv 
(a)
 2003 3 – – – 1 074/3 222 206/618 80/240 
Ireland NANS 2012 
(b)
 2008–2010 4 – – – 1 274/5 096 149/596 77/308 
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Country Survey name/acronym Survey period No of days 
per subject 
No of subjects/No of days 
Toddlers Other 
children 
Adolescents 
(mean age) 
Adults Elderly Very elderly 
Italy INRAN SCAI 2005–2006 
(a)
 2005–2006 3 36/108 193/579 247/741 
(14 years) 
2 313/6 939 290/870 228/684 
Latvia EFSA TEST 
(a)
 2008 2  187/377 453/979 
(14 years) 
1 271/2 655 – – 
Latvia FC PREGNANTWOMEN 2011 
(b)
 2011 2 – – – 1 002/2 005 – – 
Netherlands VCP kids 
(a)
 2006–2007 3 322/644 957/1 914 – – – – 
Netherlands VCPBasis AVL2007–2010 
(b)
 2007–2010 2 – 447/894 1 142/2 284 
(14 years) 
2 057/4 114 173/346  
Netherlands VCP-Elderly 
(b)
 2010–2012 2 – – – – 289/578 450/900 
Poland IZZ FAO 2000 
(a)
 2000 1 –/79 –/409 –/666 
(14 years) 
–/2 527 –/329 –/124 
Romania Dieta Pilot Children 
(b)
 2012 1 – –/205 –/567 
(14 years) 
– – – 
Romania Dieta Pilot Adults 
(b)
 2012 7 – – – 1 254/8 770 83/581 45/315 
Slovakia SK MON 2008 
(a)
 2008 1 – – – 2 761 – – 
Slovenia CRP 2008 
(a)
 2007–2008 1 – – – 407 – – 
Spain enKid 
(a)
 1998–2000 2 17/34 156/312 209/418 
(12 years) 
– – – 
Spain AESAN 
(a)
 1999–2001 3 – – – 410/828 – – 
Spain NUT INK05 
(a)
 2004–2005 2 – 399/798 651/1 302 
(14 years) 
– – – 
Spain AESAN FIAB 
(a)
 2009 3 – – 86/226 
(17 years) 
981/2 748 – – 
Sweden NFA 
(a)
 2003 4 – 1473/5 875 1 018/4 047 
(12 years) 
– – – 
Sweden Riksmaten 2010 
(b)
 2010–2011 4 – – – 1 430/5 680 295/1 167 72/288 
United 
Kingdom 
NDNS Rolling Programme Years 
1–3 (b) 
2008–2011 4 185/737 651/2 595 666/2 653 
(14 years) 
1 266/5 040 166/662 139/552 
United 
Kingdom 
DNSIYC 2011 
(b)
 2011 4 1 314/5 217 – – – – – 
(a): Dietary surveys included in the 2010 release of the EFSA Comprehensive European Food Consumption Database (FoodEx classification). 
(b): Dietary surveys added to the EFSA Comprehensive European Food Consumption Database for the 2014 release (FoodEx2 classification). 
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Appendix B.  Daily caffeine intake by country survey and age class 
Age class Country Survey No of 
subjects 
Caffeine intake % of subjects with a mean daily intake of 
mg per day mg/kg bw per day 
Mean P95 (a) Mean P95 (a) > 3 mg/kg bw > 400 mg  
(> 5.7 mg/kg bw) 
Toddlers 
(12 to < 36 
months) 
10 surveys 
Belgium Regional Flanders 36 14.8 – 1.1 – 8.3 n.a. (b) 
Bulgaria NUTRICHILD 428 3.0 16.6 0.3 1.4 0.5 n.a. 
Denmark IAT 2006–2007 917 3.4 11.2 0.3 0.9 0.4 n.a. 
Finland DIPP 2001–2009 500 0.3 0.8 0.0 0.1 0.0 n.a. 
Germany VELS 348 5.9 27.3 0.5 2.2 3.2 n.a. 
Italy INRAN SCAI 2005–2006 36 3.6 – 0.3 – 2.8 n.a. 
Netherlands VCP kids 322 9.1 45.4 0.7 3.5 5.9 n.a. 
Spain enKid 17 30.3 – 2.1 – 17.6 n.a. 
United Kingdom NDNS Rolling Programme Years 1–3 185 4.9 30.6 0.4 2.2 2.2 n.a. 
DNSIYC 2011 1 314 2.0 7.8 0.2 0.7 1.8 n.a. 
Other children 
(3 to < 10 years) 
17 surveys 
Belgium Regional Flanders 625 10.4 37.8 0.6 2.3 2.9 n.a. 
Bulgaria NUTRICHILD 433 3.5 19.8 0.2 1.2 1.4 n.a. 
Czech Republic SISP04 389 47.1 93.5 2.0 4.0 12.9 n.a. 
Denmark DANSDA 2005–2008 298 15.6 41.7 0.6 1.5 0.3 n.a. 
Finland DIPP 2001–2009 750 20.7 87.1 1.1 4.4 11.1 n.a. 
France INCA2 482 21.0 60.6 1.0 2.8 4.6 n.a. 
Germany EsKiMo 835 17.2 54.8 0.6 2.1 1.9 n.a. 
VELS 293 13.5 47.4 0.8 2.6 3.4 n.a. 
Greece Regional Crete 838 8.9 34.2 0.4 1.6 1.4 n.a. 
Italy INRAN SCAI 2005–2006 193 25.8 77.9 1.1 4.3 5.7 n.a. 
Latvia EFSA TEST 187 45.1 102.6 1.5 4.0 9.6 n.a. 
Netherlands VCP kids 957 14.8 57.6 0.7 2.8 4.6 n.a. 
VCPBasis AVL2007–2010 447 25.8 96.4 0.9 3.6 6.0 n.a. 
Spain enKid 156 35.8 94.5 1.4 4.6 11.5 n.a. 
NUT INK05 399 29.0 77.0 1.1 3.0 4.5 n.a.
 (b)
 
Sweden NFA 1473 9.9 37.3 0.4 1.4 0.6 n.a. 
United Kingdom NDNS Rolling Programme Years 1–3 651 9.9 46.9 0.4 1.8 1.4 n.a. 
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Age class Country Survey No of 
subjects 
Caffeine intake % of subjects with a mean daily intake of 
mg per day mg/kg bw per day 
Mean P95 (a) Mean P95 (a) > 3 mg/kg bw > 400 mg  
(> 5.7 mg/kg bw) 
Adolescents 
(10 to < 18 
years) 
16 surveys 
Belgium Diet National 2004 576 68.3 190.8 1.1 3.0 5.2 0.7 (1.2) 
Cyprus Childhealth 303 38.2 133.5 0.7 2.4 3.0 0.0 (0.0) 
Czech Republic SISP04 298 50.1 119.8 1.1 2.4 4.0 0.3 (0.3) 
Denmark DANSDA 2005–2008 377 30.8 92.8 0.6 1.6 1.3 0.3 (0.3) 
Finland NWSSP07–08 306 52.1 172.9 1.0 3.4 6.9 0.0 (1.0) 
France INCA2 973 30.5 95.4 0.6 1.9 1.7 0.0 (0.2) 
Germany National Nutrition Survey II 1011 59.4 208.1 1.0 3.5 6.6 0.6 (1.1) 
EsKiMo 393 22.0 68.9 0.6 1.8 1.5 0.0 (0.3) 
Italy INRAN SCAI 2005–2006 247 43.5 136.7 0.8 2.3 2.8 0.0 (0.0) 
Latvia EFSA TEST 453 67.8 152.7 1.4 3.1 5.3 0.2 (0.9) 
Netherlands VCP Basis AVL2007–2010 1 142 69.5 211.6 1.3 4.1 10.0 0.5 (1.6) 
Spain AESAN FIAB 86 40.3 114.3 0.7 2.3 2.3 0.0 (1.2) 
enKid 209 38.2 105.0 0.8 2.4 2.9 0.0 (1.0) 
NUT INK05 651 47.8 109.2 0.9 2.2 2.0 0.3 (0.3) 
Sweden NFA 1 018 17.6 60.5 0.4 1.5 0.5 0.0 (0.1) 
United Kingdom NDNS Rolling Programme Years 1–3 666 37.0 126.4 0.7 2.2 2.4 0.0 (0.2) 
Adults 
(18 to < 65 
years) 
16 surveys 
Belgium Diet National 2004 1 292 191.9 543.3 2.7 7.6 n.a. 10.4 (9.1) 
Czech Republic SISP04 1 666 124.8 269.7 1.7 3.8 n.a. 1.2 (0.7) 
Denmark DANSDA 2005–2008 1 739 319.4 742.4 4.3 10.0 n.a. 32.9 (29.1) 
Finland FINDIET2012 1 295 236.0 538.5 3.1 6.9 n.a. 13.4 (10.6) 
France INCA2 2 276 154.5 414.0 2.3 6.4 n.a. 5.8 (6.7) 
Germany National Nutrition Survey II 10 419 238.0 538.7 3.2 7.3 n.a. 14.6 (11.8) 
Greece Diet Lactation Gr 65 31.3 97.4 0.5 1.6 n.a. 0.0 
(c)
 
Hungary National Repr Surv 1 074 103.0 268.1 1.5 3.8 n.a. 1.4 (1.7) 
Ireland NANS 2012 1 274 149.0 346.2 2.0 4.7 n.a. 3.0 (2.7) 
Italy INRAN SCAI 2005–2006 2 313 139.3 323.1 2.1 4.8 n.a. 2.1 (2.8) 
Latvia EFSA TEST 1 271 149.4 310.4 2.0 4.4 n.a. 1.6 (1.3) 
Pregnant Women 2011 1 002 108.6 205.7 1.6 3.0 n.a. 6.5 
(c)
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Age class Country Survey No of 
subjects 
Caffeine intake % of subjects with a mean daily intake of 
mg per day mg/kg bw per day 
Mean P95 (a) Mean P95 (a) > 3 mg/kg bw > 400 mg  
(> 5.7 mg/kg bw) 
Netherlands VCP Basis AVL2007–2010 2 057 258.5 589.2 3.3 7.7 n.a. 17.6 (13.3) 
Romania Dieta Pilot Adults 1 254 36.5 108.6 0.5 1.5 n.a. 0.1 (0.1) 
Spain AESAN 410 51.6 157.2 0.7 2.2 n.a. 0.2 (0.2) 
Spain AESAN FIAB 981 66.8 156.0 1.0 2.6 n.a. 1.5 (1.7) 
Sweden Riksmaten 2010 1 430 205.3 482.2 2.8 6.7 n.a. 9.0 (8.0) 
United Kingdom NDNS Rolling Programme Years 1–3 1 266 138.2 318.4 1.8 4.4 n.a. 2.4 (2.4) 
Elderly 
(65 to < 75 
years) 
13 surveys 
Belgium Diet National 2004 511 216.3 472.8 3.0 6.5 n.a. 9.6 (8.2) 
Denmark DANSDA 2005–2008 274 362.1 715.7 4.8 10.4 n.a. 34.7 (29.9) 
Finland FINDIET2012 413 214.2 416.1 2.8 5.9 n.a. 6.3 (5.6) 
France INCA2 264 130.1 309.1 1.9 4.4 n.a. 2.3 (2.3) 
Germany National Nutrition Survey II 2 006 241.4 486.4 3.2 6.3 n.a. 10.4 (7.7) 
Hungary National Repr Surv 206 75.2 178.7 1.0 2.3 n.a. 1.0 (0.0) 
Ireland NANS 2012 149 167.3 348.5 2.3 5.1 n.a. 2.0 (3.4) 
Italy INRAN SCAI 2005–2006 290 122.7 321.7 1.7 4.6 n.a. 2.1 (2.4) 
Netherlands VCPBasis AVL2007–2010 173 280.4 548.2 3.7 7.6 n.a. 17.3 (15.0) 
Netherlands VCP-Elderly 289 265.7 470.4 3.4 6.0 n.a. 12.5 (6.9) 
Romania Dieta Pilot Adults 83 22.6 96.3 0.3 1.5 n.a. 0.0 (0.0) 
Sweden Riksmaten 2010 295 222.2 445.0 3.0 6.4 n.a. 7.1 (6.1) 
United Kingdom NDNS Rolling Programme Years 1–3 166 164.9 377.0 2.1 5.3 n.a. 4.2 (3.0) 
Very elderly 
(≥ 75 years) 
11 surveys 
Belgium Diet National 2004 704 197.5 422.8 2.9 6.1 n.a. 6.8 (7.2) 
Denmark DANSDA 2005–08 12 416.8 – 6.0 – n.a. 41.7 (58.3) 
France INCA2 84 108.2 271.5 1.5 3.8 n.a. 2.4 (2.4) 
Germany National Nutrition Survey II 490 208.2 397.9 2.8 5.2 n.a. 4.9 (3.5) 
Hungary National Repr Surv 80 68.6 174.0 1.0 2.3 n.a. 1.3 (1.3) 
Ireland NANS 2012 77 160.2 291.9 2.4 5.9 n.a. 2.6 (5.2) 
Italy INRAN SCAI 2005–2006 228 101.4 262.6 1.5 4.2 n.a. 1.8 (1.3) 
Netherlands VCP-Elderly 450 239.2 454.5 3.2 5.9 n.a. 9.8 (6.2) 
Romania Dieta Pilot Adults 45 21.8 – 0.3 – n.a. 0.0 (0.0) 
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Age class Country Survey No of 
subjects 
Caffeine intake % of subjects with a mean daily intake of 
mg per day mg/kg bw per day 
Mean P95 (a) Mean P95 (a) > 3 mg/kg bw > 400 mg  
(> 5.7 mg/kg bw) 
Sweden Riksmaten 2010 72 194.3 446.8 2.7 6.1 n.a. 8.3 (6.9) 
United Kingdom NDNS Rolling Programme Years 1–3 139 151.9 303.5 2.2 4.7 n.a. 0.7 (0.7) 
(a): The 95th percentile estimates based on dietary surveys/age classes with fewer than 60 subjects may not be statistically robust (EFSA, 2011b) and consequently were not considered (“–”). 
(b): n.a. = not applicable. 
(c): % exceeding 200 mg/kg bw per day. 
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Appendix C.  95th percentile of caffeine intake from all sources for “all days” and for 
“consumption days”  
Age class Food groups 95
th
 percentile caffeine intake (a) 
(all days) 
95
th
 percentile caffeine intake (a) 
(consumption days) 
mg per day mg per day mg per day mg per day 
Min. (b) Max. (b) Min. (b) Max. (b) Min. (b) Max. (b) Min. (b) Max.( b) 
Toddlers 
(12 to < 36 
months) 
11 surveys 
Total intakes (c) 0.0 82.5 0.0 7.1 
(d) (d) (d) (d) 
Chocolate 0.4 25.2 0.0 1.8 8.4 60.5 0.6 5.3 
Coffee 0.0 5.6 0.0 0.4 – – – – 
Cola beverages 0.0 48.6 0.0 3.2 – – – – 
“Energy drinks” – – – – – – – – 
Tea 0.0 82.5 0.0 7.1 27.6 110.0 2.6 9.6 
Other 
children 
(3 to < 10 
years) 
19 surveys 
Total intakes  0.0 130.1 0.0 5.7 
(d) (d) (d) (d) 
Chocolate 7.7 126.0 0.4 5.4 9.5 136.1 0.6 7.7 
Coffee 0.0 71.2 0.0 2.2 44.5 385.6 2.4 15.1 
Cola beverages 0.0 37.3 0.0 1.8 35.6 75.6 1.7 3.2 
“Energy drinks” – – – – – – – – 
Tea 0.0 123.8 0.0 5.3 66.0 132.0 2.5 5.4 
Adolescents 
(10 to < 18 
years) 
19 surveys 
Total intakes  0.0 239.8 0.0 4.3 
(d) (d) (d) (d) 
Chocolate 8.4 169.1 0.1 3.3 33.6 253.6 0.7 5.4 
Coffee 0.0 133.5 0.0 2.7 138.0 445.0 2.4 7.1 
Cola beverages 0.0 108.0 0.0 1.8 64.8 142.6 1.5 2.4 
“Energy drinks” – – – – 240.0 329.6 4.4 5.2 
Tea 0.0 148.5 0.0 3.2 69.3 308.0 1.8 5.0 
Adults 
(18 to < 65 
years) 
24 surveys 
Total intakes  0.0 809.3 0.0 10.8 
(d) (d) (d) (d) 
Chocolate 1.7 50.4 0.0 0.9 33.6 151.2 0.5 2.3 
Coffee 66.6 801.0 1.0 10.5 106.8 890.0 1.5 11.4 
Cola beverages 0.0 89.6 0.0 1.3 54.0 216.0 0.9 2.3 
“Energy drinks” – – – – 320.0 330.2 4.2 5.3 
Tea 0.0 264.0 0.0 3.6 41.3 308.0 0.9 4.4 
Elderly 
(65 to < 75 
years) 
15 surveys 
Total intakes  0.0 784.3 0.0 10.7 
(d) (d) (d) (d) 
Chocolate 0.0 30.2 0.0 0.4 23.6 121.0 0.3 1.6 
Coffee 89.0 756.5 1.2 10.3 111.3 801.0 1.7 10.6 
Cola beverages 0.0 26.1 0.0 0.3 54.4 108.0 0.7 1.5 
“Energy drinks” – – – – – – – – 
Tea 0.0 316.8 0.0 4.2 99.0 338.8 1.2 4.3 
Very elderly 
(≥ 75 years) 
13 surveys 
Total intakes  0.0 801.0 0.0 13.1 
(d) (d) (d) (d) 
Chocolate 1.1 35.5 0.0 0.6 37.8 504.0 0.5 8.1 
Coffee 66.8 801.0 0.9 10.5 144.6 801.0 2.1 10.5 
Cola beverages 0.0 16.2 0.0 0.2 81.0 81.0 1.1 1.1 
“Energy drinks” – – – – – – – – 
Tea 0.0 288.2 0.0 4.1 66.0 312.4 1.1 4.2 
(a): The 95th percentile estimates based on dietary surveys/age classes with fewer than 60 days of data may not be 
statistically robust (EFSA, 2011b) and consequently were not considered (“–”) in this table. 
(b): Minimum and maximum 95th percentile across the correspondent statistic calculated for each age class and dietary 
survey. 
(c): Please note that “total intakes” are not derived by summing the minimum and maximum values for the different food 
categories, but reflect the minimum and maximum total caffeine intakes from all sources for all days in that survey.  
(d): Minimum and maximum total caffeine intakes on consumption days cannot be calculated because the value would 
depend on the food group which is used to define a consumption day.  
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Appendix D.  Caffeine intake on a single day by country survey and age class 
Age class Country Survey No of days 95
th
 percentile caffeine intake (a) % of days with an intake of 
mg per day mg/kg bw  
per day 
> 3 mg/kg bw > 400 mg  
(> 5.7 mg/kg bw) 
Toddlers 
(12 to < 36 months) 
11 surveys 
Belgium Regional Flanders 108 53.1 4.3 10.2 n.a. 
(b)
 
Bulgaria NUTRICHILD 856 22.1 1.9 1.4 n.a. 
Denmark IAT 2006–07 6 388 17.1 1.4 1.0 n.a. 
Finland DIPP 2001–2009 1 500 0.5 0.1 0.1 n.a. 
Germany VELS 1 947 27.7 2.2 3.0 n.a. 
Italy INRAN SCAI 2005–06 108 24.8 2.0 3.7 n.a. 
Netherlands VCP kids 644 47.1 3.6 7.3 n.a. 
Poland IZZ FAO 2000 79 82.5 7.1 36.7 n.a. 
Spain enKid 34 – – 23.5 n.a. 
United Kingdom NDNS Rolling Programme Years 1–3 737 33.7 2.6 3.7 n.a. 
DNSIYC 2011 5 217 5.5 0.6 1.6 n.a. 
Other children 
(3 to < 10 years) 
19 surveys 
Belgium Regional Flanders 1 875 48.6 2.8 4.1 n.a. 
Bulgaria NUTRICHILD 867 21.6 1.3 2.4 n.a. 
Czech Republic SISP04 778 99.0 4.6 15.4 n.a. 
Denmark DANSDA 2005–08 2 085 58.5 2.2 2.3 n.a. 
Finland DIPP 2001 2009 2 250 114.1 5.7 12.3 n.a. 
France INCA2 3 315 75.6 3.3 6.7 n.a. 
Germany EsKiMo 2 498 69.8 2.6 4.0 n.a. 
VELS 1 610 51.7 3.0 5.0 n.a. 
Greece Regional Crete 2 508 37.8 1.7 1.4 n.a. 
Italy INRAN SCAI 2005–06 579 99.0 4.3 8.1 n.a. 
Latvia EFSA TEST 377 118.8 4.3 11.4 n.a. 
Netherlands VCP kids 1 914 63.3 3.2 6.2 n.a. 
VCP Basis AVL2007–2010 894 104.9 3.7 7.6 n.a. 
Poland IZZ FAO 2000 409 130.1 5.7 35.9 n.a. 
Romania Dieta Pilot Children 205 126.0 3.8 6.8 n.a. 
Spain enKid 312 105.0 4.4 14.1 n.a. 
NUT INK05 798 87.4 3.2 6.0 n.a. 
Sweden NFA 5 875 54.0 2.0 1.8 n.a. 
United Kingdom NDNS Rolling Programme Years 1–3 2 595 51.8 2.2 2.0 n.a. 
Adolescents 
(10 to < 18 years) 
19 surveys 
Belgium Diet National 2004 1 187 216.0 3.5 7.2 0.0 
Bulgaria NSFIN 162 93.1 1.8 3.1 0.0 
Cyprus Childhealth 909 141.9 3.0 5.1 0.0 
Czech Republic SISP04 596 131.5 2.9 4.2 0.0 
Safety of caffeine 
 
EFSA Journal 2015;13(5):4102 104 
Age class Country Survey No of days 95
th
 percentile caffeine intake (a) % of days with an intake of 
mg per day mg/kg bw  
per day 
> 3 mg/kg bw > 400 mg  
(> 5.7 mg/kg bw) 
Denmark DANSDA 2005–08 2 622 116.8 2.3 2.6 0.0 
Finland NWSSP07–08 1 186 219.2 4.1 11.0 0.0 
France INCA2 6 728 115.3 2.3 2.8 0.0 
Germany National Nutrition Survey II 2 022 239.8 3.8 7.7 0.0 
EsKiMo 1 179 89.4 2.4 3.1 0.0 
Italy INRAN SCAI 2005–06 741 156.3 2.7 4.3 0.0 
Latvia EFSA TEST 949 177.7 3.5 8.0 0.0 
Netherlands VCP Basis AVL2007–2010 2 284 235.6 4.3 11.8 0.0 
Poland IZZ FAO 2000 666 170.8 3.9 11.0 0.0 
Romania Dieta Pilot Children 567 89.0 1.8 1.9 0.0 
Spain AESAN FIAB 226 122.8 2.3 2.2 0.0 
enKid 418 126.0 2.6 3.1 0.0 
NUT INK05 1 302 123.0 2.3 2.2 0.0 
Sweden NFA 4 047 77.9 2.0 1.7 0.0 
United Kingdom NDNS Rolling Programme Years 1–3 2 653 155.0 2.5 4.0 0.0 
Adults 
(18 to < 65 years) 
24 surveys 
Austria ASNS 2 123 356.0 5.4 n.a. 3.4 (4.1) 
Belgium Diet National 2004 2 648 538.7 7.7 n.a. 11.0 (10.1) 
Bulgaria NSFIN 691 155.1 2.4 n.a. 0.3 (0.3) 
Czech Republic SISP04 3 332 298.0 4.2 n.a. 1.9 (1.9) 
Denmark DANSDA 2005–08 12 127 809.3 10.8 n.a. 31.8 (29.6) 
Estonia NDS 1997 1 866 311.5 4.6 n.a. 1.9 (2.7) 
Finland FINDIET2012 2 590 538.5 7.0 n.a. 14.1 (11.9) 
France INCA2 15 727 445.0 6.7 n.a. 6.6 (7.8) 
Germany National Nutrition Survey II 20 838 561.7 7.7 n.a. 16.9 (13.4) 
Greece Diet Lactation GR 350 114.9 1.8 n.a. 0.0 
Hungary National Repr Surv 3 222 270.1 4.2 n.a. 1.3 (1.9) 
Ireland NANS 2012 5 096 378.4 5.1 n.a. 4.5 (3.7) 
Italy INRAN SCAI 2005–06 6 939 325.7 5.1 n.a. 3.2 (3.6) 
Latvia EFSA TEST 2 655 338.2 4.8 n.a. 2.3 (2.2) 
FC Pregnant Women 2011 2 005 221.8 3.3 n.a. 0.0 
(c) 
Netherlands VCP Basis AVL2007– 2010 4 114 622.5 8.1 n.a. 19.0 (14.7) 
Poland IZZ FAO 2000 2 527 347.3 5.5 n.a. 2.4 (4.0) 
Romania Dieta Pilot Adults 8 770 122.4 1.8 n.a. 0.2 (0.2) 
Slovakia SK MON 2008 2 761 305.0 4.4 n.a. 1.8 (1.6) 
Slovenia CRP 2008 407 211.9 3.2 n.a. 1.0 (1.2) 
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Age class Country Survey No of days 95
th
 percentile caffeine intake (a) % of days with an intake of 
mg per day mg/kg bw  
per day 
> 3 mg/kg bw > 400 mg  
(> 5.7 mg/kg bw) 
Spain AESAN 828 155.7 2.3 n.a. 0.4 (0.5) 
AESAN FIAB 2 748 178.1 2.8 n.a. 1.5 (1.5) 
Sweden Riksmaten 2010 5 680 535.1 7.2 n.a. 11.2 (9.6) 
United Kingdom NDNS Rolling Programme Years 1–3 5 040 353.2 4.9 n.a. 3.5 (3.1) 
Elderly 
(65 to < 75 years) 
15 surveys 
Belgium Diet National 2004 1 045 511.8 6.9 n.a. 11.0 (10) 
Bulgaria NSFIN 151 89.0 1.2 n.a. 0.0 (0.0) 
Denmark DANSDA 2005–08 1916 784.3 10.7 n.a. 35.0 (31.8) 
Finland FINDIET2012 826 440.6 5.9 n.a. 6.9 (5.7) 
France INCA2 1 824 335.5 4.7 n.a. 2.4 (2.6) 
Germany National Nutrition Survey II 4 012 507.3 6.6 n.a. 12.8 (9.3) 
Hungary National Repr Surv 618 201.1 2.7 n.a. 1.5 (0.5) 
Ireland NANS 2012 596 385.2 5.5 n.a. 3.9 (4.5) 
Italy INRAN SCAI 2005–06 870 338.3 4.6 n.a. 3.1 (2.4) 
Netherlands VCP Basis AVL2007–2010 346 557.6 7.6 n.a. 18.8 (17.3) 
VCP-Elderly 578 481.3 6.2 n.a. 13.3 (8.7) 
Poland IZZ FAO 2000 329 301.3 4.3 n.a. 0.9 (0.9) 
Romania Dieta Pilot Adults 581 111.3 1.6 n.a. 0.0 (0.0) 
Sweden Riksmaten 2010 1 167 479.9 6.4 n.a. 9.4 (7.5) 
United Kingdom NDNS Rolling Programme Years 1–3 662 396.7 5.4 n.a. 5.0 (3.9) 
Very elderly 
(≥ 75 years) 
13 surveys 
Belgium Diet National 2004 1 448 445.0 6.6 n.a. 8.1 (8.1) 
Bulgaria NSFIN 200 66.8 0.9 n.a. 0.0 (0.0) 
Denmark DANSDA 2005–08 84 801.0 13.1 n.a. 45.2 (46.2) 
France INCA2 571 319.2 4.4 n.a. 2.6 (2.8) 
Germany National Nutrition Survey II 980 422.8 5.7 n.a. 7.8 (4.9) 
Hungary National Repr Surv 240 191.3 2.9 n.a. 1.3 (0.8) 
Ireland NANS 2012 308 313.9 5.7 n.a. 2.9 (5.2) 
Italy INRAN SCAI 2005–06 684 274.8 4.3 n.a. 1.9 (2.2) 
Netherlands VCP-Elderly 900 472.6 6.3 n.a. 11.0 (7.9) 
Poland IZZ FAO 2000 124 250.3 3.8 n.a. 0.0 (0.8) 
Romania Dieta Pilot Adults 315 102.7 1.5 n.a. 0.0 (0.0) 
Sweden Riksmaten 2010 288 465.5 6.4 n.a. 7.6 (5.6) 
United Kingdom NDNS Rolling Programme  552 338.2 4.7 n.a. 1.8 (2.0) 
(a): The 95th percentile estimates based on dietary surveys/age classes with fewer than 60 days of data may not be statistically robust (EFSA, 2011b) and consequently were not considered (–). 
(b): n.a. = not applicable for the population group. 
(c): % exceeding 200 mg/kg bw per day. 
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Appendix E.  Food sources contributing to daily caffeine intake 
Age class Country Survey Food sources contributing to daily caffeine intake 
(%) 
Coffee Tea Chocolate Cola 
beverages 
Energy 
Drinks 
(b)
 
Toddlers 
(12 to < 36 
months) 
Belgium Regional Flanders 
(a)
 12.7 0.0 29.6 57.7 0.0 
Bulgaria NUTRICHILD 
(a)
 0.0 49.2 49.9 0.9 0.0 
Denmark IAT 2006–07 0.9 32.3 66.9 0.0 0.0 
Finland DIPP 2001–2009 6.2 0.0 89.9 3.9 0.0 
Germany VELS 0.3 13.0 84.5 2.3 0.0 
Italy INRAN SCAI 2005–06 (a) 0.0 53.6 37.6 8.8 0.0 
Netherlands VCP kids 
(a)
 2.6 73.2 20.3 3.9 0.0 
Spain enKid 
(a)
 0.0 0.0 100.0 0.0 0.0 
United 
Kingdom 
DNSIYC 2011 0.3 35.8 63.0 0.6 0.3 
NDNS Rolling 
Programme Years 1–3 
0.1 76.4 17.5 6.0 0.0 
Median  0 34 56 3 0 
Range  (0–13) (0–73) (20–100) (0–58) (0) 
Other 
children 
(3 to < 10 
years) 
Belgium Regional Flanders 
(a)
 19.8 7.5 20.4 52.1 0.2 
Bulgaria NUTRICHILD 
(a)
 0.0 6.9 77.6 15.5 0.0 
Czech 
Republic 
SISP04 
(a)
 5.4 67.6 27.0 0.0 0.0 
Denmark DANSDA 2005–08 2.7 14.9 42.2 40.2 0.0 
Finland DIPP 2001–2009 3.2 0.7 89.3 6.8 0.0 
France INCA2 
(a)
 6.6 7.8 68.5 17.1 0.0 
Germany EsKiMo 2.1 32.2 55.6 9.6 0.6 
VELS 0.2 12.3 85.3 2.2 0.0 
Greece Regional Crete  
(a)
 1.8 3.7 85.1 9.3 0.0 
Italy INRAN SCAI 2005–06 (a) 39.9 19.1 32.8 8.1 0.0 
Latvia EFSA TEST 
(a)
 15.0 64.2 18.8 2.0 0.0 
Netherlands VCPBasis AVL2007–
2010 
2.5 55.7 21.3 19.2 1.3 
VCP kids 
(a)
 2.4 64.9 18.3 14.4 0.0 
Spain NUT INK05 
(a)
 1.8 0.2 90.9 7.1 0.0 
enKid 
(a)
 2.1 0.0 97.9 0.0 0.0 
Sweden NFA 
(a)
 2.3 12.6 39.0 45.4 0.7 
United 
Kingdom 
NDNS Rolling 
Programme Years1–3 
2.3 46.9 21.1 27.0 2.7 
Median  2 13 42 10 0 
Range  (0–40) (0–68) (18–98) (0–52) (0–3) 
 Adolescents 
(10 to < 18 
years) 
Belgium Diet National 2004 
(a)
 24.2 16.9 14.8 38.8 5.3 
Cyprus Childhealth 
(a)
 53.2 9.2 37.6 0.0 0.0 
Czech 
Republic 
SISP04 
(a)
 14.4 65.3 20.3 0.0 0.0 
Denmark DANSDA 2005–08 17.6 25.1 24.4 32.9 0.0 
Finland NWSSP07–08 19.7 2.1 61.3 13.3 3.6 
France INCA2 
(a)
 22.8 15.6 39.4 22.2 0.0 
Germany EsKiMo 2.6 34.0 42.7 19.7 0.9 
National Nutrition Survey 
II 
(a)
 
33.3 33.1 16.3 17.3 0.0 
Italy INRAN SCAI 2005–06 (a) 42.1 22.6 20.2 14.4 0.7 
Latvia EFSA TEST 
(a)
 32.4 53.4 11.5 2.3 0.3 
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Age class Country Survey Food sources contributing to daily caffeine intake 
(%) 
Coffee Tea Chocolate Cola 
beverages 
Energy 
Drinks 
(b)
 
Netherlands VCPBasis AVL2007–
2010 
13.9 42.8 12.3 22.9 8.1 
Spain AESAN FIAB 
(a)
 41.1 1.0 41.9 15.9 0.0 
NUT INK05 
(a)
 17.4 1.5 64.5 16.5 0.0 
enKid 
(a)
 8.2 0.0 91.8 0.0 0.0 
Sweden NFA 
(a)
 2.7 20.7 33.0 42.1 1.6 
United 
Kingdom 
NDNS Rolling 
Programme Years 1–3 
10.2 39.2 7.5 32.7 10.5 
Median  19 22 29 17 0 
Range  (3–53) (1–65) (8–92) (0–42) (0–13) 
Adults 
(18 to ≤ 65 
years) 
Belgium Diet National 2004 
(a)
 81.3 5.8 2.9 9.4 0.7 
Czech 
Republic 
SISP04 
(a)
 71.5 25.9 2.6 0.0 0.0 
Denmark DANSDA 2005–08 87.9 8.1 2.0 2.0 0.0 
Finland FINDIET2012 93.8 2.5 2.0 1.0 0.6 
France INCA2 
(a)
 80.5 13.3 3.2 3.0 0.0 
Germany National Nutrition Survey 
II 
(a)
 
84.1 10.9 1.8 3.1 0.0 
Hungary National Repr Surv 
(a)
 57.0 29.8 8.5 4.7 0.0 
Ireland NANS 2012 32.5 59.4 1.3 3.9 3.0 
Italy INRAN SCAI 2005–06 (a) 91.4 5.0 2.0 1.5 0.1 
Latvia EFSA TEST 
(a)
 75.0 22.1 2.2 0.6 0.1 
Netherlands VCPBasis AVL2007–
2010 
70.1 20.7 1.7 6.1 1.3 
Romania Dieta Pilot Adults 82.6 2.1 12.0 3.0 0.3 
Spain AESAN 
(a)
 40.5 20.7 16.5 18.1 4.2 
AESAN FIAB 
(a)
 76.2 0.7 14.1 8.7 0.3 
Sweden Riksmaten 2010 85.0 11.3 0.9 2.5 0.3 
United 
Kingdom 
NDNS Rolling 
Programme Years 1–3 
34.2 56.5 1.4 6.7 1.2 
Median  78 12 2 3 0 
Range  (33–94) (1–59) (1–17) (0–18) (0–4) 
Greece Diet Lactation Gr 69 4.2 20 7.0 0.0 
Latvia FC Pregnant Women 2011 42 52 5.9 0.4 0.0 
Elderly 
(65 to < 75 
years) 
Belgium Diet National 2004 
(a)
 92.9 4.2 1.6 1.1 0.2 
Denmark DANSDA 2005–08 91.3 7.0 1.4 0.3 0.0 
Finland FINDIET2012 97.2 1.7 1.0 0.1 0.0 
France INCA2 
(a)
 78.9 19.1 1.5 0.5 0.0 
Germany National Nutrition Survey 
II 
(a)
 
86.5 12.1 0.8 0.5 0.0 
Hungary National Repr Surv 
(a)
 58.5 35.2 5.3 1.0 0.0 
Ireland NANS 2012 23.5 74.1 1.6 0.8 0.0 
Italy INRAN SCAI 2005–06 (a) 92.3 6.6 0.8 0.2 0.0 
Netherlands VCP-Elderly 73.1 25.1 1.1 0.7 0.0 
VCPBasis AVL2007–
2010 
79.5 18.6 0.6 1.2 0.0 
Romania Dieta Pilot Adults 83.6 6.3 10.0 0.0 0.0 
Sweden Riksmaten 2010 88.9 10.1 0.6 0.4 0.0 
United 
Kingdom 
NDNS Rolling 
Programme Years 1–3 
32.6 64.9 1.3 0.8 0.4 
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Age class Country Survey Food sources contributing to daily caffeine intake 
(%) 
Coffee Tea Chocolate Cola 
beverages 
Energy 
Drinks 
(b)
 
Median  84 12 1 1 0 
Range  (24–97) (2–74) (0–10) (0–1) (0) 
 Very 
elderly 
(≥  75 years) 
Belgium Diet National 2004 
(a)
 93.1 4.9 1.1 0.9 0.0 
Denmark DANSDA 2005–08 91.8 5.9 2.2 0.1 0.0 
France INCA2 
(a)
 81.3 11.0 7.4 0.4 0.0 
Germany National Nutrition Survey 
II 
(a)
 
84.8 13.8 1.2 0.1 0.0 
Hungary National Repr Surv 
(a)
  41.9 50.6 7.3 0.3 0.0 
Ireland NANS 2012 20.3 78.5 1.2 0.0 0.0 
Italy INRAN SCAI 2005–06 (a) 88.3 9.0 1.5 0.2 1.0 
Netherlands VCP-Elderly 66.4 31.6 1.5 0.5 0.1 
Romania Dieta Pilot Adults 77.0 3.9 17.9 1.2 0.0 
Sweden Riksmaten 2010 89.0 10.2 0.8 0.0 0.0 
United 
Kingdom 
NDNS Rolling 
Programme Years 1–3 
27.9 68.1 3.3 0.5 0.2 
Median  81 11 2 0 0 
Range  (28–93) (4–79) (1–18) (0–1) (0–1) 
(a):  Dietary surveys included in the 2010 release of the EFSA Comprehensive European Food Consumption Database 
(FoodEx classification). 
(b):  For dietary surveys included in the 2010 release of the EFSA Comprehensive European Food Consumption Database 
(FoodEx classification), products coded as “carbohydrate-rich energy food products for sports people” or 
“carbohydrate–electrolyte solutions for sports people” at the third level of FoodEx, within the first-level category of 
“Products for special nutritional use”, were used to calculate caffeine consumption from “energy drinks” and their 
contribution to total caffeine intake. 
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Appendix F.  Human intervention studies on the vascular effects of a single dose and of repeated doses of caffeine consumed within a day 
Study Design Subjects, 
habitual daily 
consumption 
Run-in 
period 
(a)
 
n (I/C) 
(b)
 
Intervention Caffeine 
(mg) 
Control Outcomes 
Arterial 
stiffness 
Endothelial 
function 
BP Other 
Single doses of caffeine 
Vlachopoulos 
et al. (2003)  
rdb-X Healthy, 
> 100 mg 
caffeine 
12 h 20 Caffeine  250 Placebo PWV, AI – Radial, aortic 
and pulse BP 
– 
Hartley et al. 
(2004): 
Women 
rdb-P Healthy, 50–
700 mg caffeine 
14 h 42 
(21/21) 
Caffeine 3.3 mg/kg 
bw 
Placebo Peripheral 
resistance, 
arterial 
compliance 
– Brachial BP, 
MABP, pulse 
pressure 
Stroke 
volume, 
cardiac 
output Hartley et al. 
(2004): Men 
rdb-P 35 
(16/19) 
Swampillai et 
al. (2006) 
nr-P Healthy, 
> 100 mg 
caffeine 
12 h 27 
(17/10) 
Caffeine  100 Water FCW, 
FEW, WR, 
WS 
– Brachial BP – 
Umemura et 
al. (2006)  
rdb-P Healthy, non-
habitual caffeine 
consumers 
24 h 20 
(10/10) 
Caffeine  300 Placebo – FBF  Brachial BP – 
Astorino et al. 
(2007) 
rdb-X Resistance 
trained, 0–
600 mg caffeine 
per day  
48 h 22 Caffeine  6 mg/kg 
bw 
Placebo – – Brachial BP, 
MABP, RPP 
– 
Arciero and 
Ormsbee 
(2009): pre-
menopausal  
rdb-X Healthy, 
< 400 mg 
caffeine 
48 h 10 Caffeine 5 mg/kg 
FFM 
208–270 
Placebo 
(lactose) 
– – Brachial BP – 
Arciero and 
Ormsbee 
(2009): post-
menopausal  
10 
Farag et al. 
(2010) 
rdb-X Healthy, 3–4 
cups coffee  
6 d 
(c)
 165 Caffeine 250 Placebo – – Brachial BP – 
Mahmud and 
Feely (2001)  
rdb-X Healthy, NR 12 h 7 Coffee 150 DC PWV, AI – Brachial BP – 
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Study Design Subjects, 
habitual daily 
consumption 
Run-in 
period 
(a)
 
n (I/C) 
(b)
 
Intervention Caffeine 
(mg) 
Control Outcomes 
Arterial 
stiffness 
Endothelial 
function 
BP Other 
Papamichael et 
al. (2005)  
rsb-X Healthy, 1–2 
cups coffee  
12–24 h 17 Coffee 80 DC – FMD 
(brachial 
artery) 
Brachial BP – 
Buscemi et al. 
(2010)  
rdb-X Healthy,  2 cups 
coffee  
24 h 20 Coffee 130 Decaffeinated 
coffee 
– FMD 
(brachial 
artery) 
Brachial BP – 
Buscemi et al. 
(2011)  
rdb-X Healthy,  2 cups 
coffee  
24 h 40 Coffee 130 Decaffeinated 
coffee 
– – Brachial BP QT, 
QTc 
Hodgson et al. 
(1999)  
rsb-X Healthy, NR  24 h 20 Caffeine 
Black tea 
Green tea 
180 Water – – Brachial BP - 
Vlachopoulos 
et al. (2006) 
black tea 
rsb-X Healthy, NR 12 h 16 Black tea 
Caffeine  
175 
175 
Water PWV, WR 
(AI, AP) 
– Radial and 
aortic BP, pulse 
pressure 
– 
Vlachopoulos 
et al. (2006) 
green tea 
rsb-X Healthy, NR 12 h 13 Green tea 
Caffeine  
125 
125 
Water PWV, WR 
(AI, AP) 
– Radial and 
aortic BP, pulse 
pressure 
– 
Repeated doses of caffeine consumed within a day 
Lane et al. 
(2002)  
rdb-X Healthy, 
2–7 cups coffee 
12 h 47 Caffeine 250 + 250 
4 h apart 
Placebo – – Day ambulatory 
BP 
– 
Farag et al. 
(2005a, b) 
rdb-X Healthy, 
50–700 mg 
caffeine 
5 d 
(d)
 85 Caffeine 250  3, 
4 h apart 
Placebo 
(lactose) 
– – Brachial BP – 
AI = augmentation index; AP = augmented pressure; BP = blood pressure; DC = decaffeinated coffee; FCW = forward compression wave; FEW = forward expansion wave; FFM =  fat-free 
mass; HR = heart rate; MABP = mean arterial blood pressure; nr-P = non-randomised, parallel; NR = not reported; PWV = pulse wave velocity; QT = QT interval; QTc = corrected QT 
interval; rdb-X = randomised, double-blind, cross-over; rdb-P = randomised, double-blind, parallel; rsb-X = randomised, single-blind, cross-over; RPP = rate–pressure product; WR = wave 
reflections; WS = wave speed. 
(a): Refers to the time of abstinence from caffeine before testing, unless otherwise noted. 
(b): Number of participants (intervention/control). Only one number is given for cross-over designs, in which subjects act as their own controls. 
(c): Subjects consumed 80 mg of caffeine three times per day for six days before testing. 
(d): Subjects consumed 0, 300 or 600 mg of caffeine (in three divided daily doses) per day for five days before testing. 
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Appendix G.  Randomised, placebo-controlled human intervention studies on the effect of single doses of synephrine on blood pressure 
Study Design
 (a)
 Run-in 
period
 (b)
 
Duration n Synephrine (mg) Caffeine (mg)  SBP (mmHg)  DBP (mmHg) 
Penzak et al. (2001) rol-X 8 h
 (c)
 13 h 12 13.5 – NS NS 
Min et al. (2005) rdb-X 12 h 8 h 18 27 – NS NS 
Haller et al. (2005a)  rdb-X 24 h 6 h 10 46.9 – NS NS 
Haller et al. (2005a)  rdb-X 24 h 6 h 10 5.5 + 5.7
 (d)
 239.2 +9.6  6.2* +9.1  7.8* 
Bui et al. (2006)  rdb-X 10 h 6 h 15 54 – +7.3  4.6* +2.6  3.8* 
Sale et al. (2006)  rdb-X 48 h 7 h 10 12 150 NS NS 
Haller et al. (2008)  rdb-X 24 h 2 h 10 21 304 NS +8.7  3.8* 
Seifert et al. (2011)  rdb-X 24 h
 (e)
 24 h 23 13 176 NS NS 
Stohs et al. (2011)  rdb-P 8–10 h 2 h 10 (f) 50 – NS NS 
NR= not reported; NS = non-significant; rdb-X = randomised, double-blind, cross-over; rdb-P = randomised, double-blind, parallel; rol-X = randomised, open-label, cross-over. 
(a): All studies had a double-blind cross-over design and used placebo capsules as control, except the study by Penzak et al. (2001), which was an open-label study and used orange juice as 
intervention and water as placebo, and that of Soths et al. (2011), which was a double-blind parallel study. 
(b): Refers to the time of abstinence from caffeine before testing, unless otherwise noted 
(c): Subjects consumed 13.5 mg of synephrine eight hours before testing. 
(d): Doses refer to synephrine + octopamine. 
(e): Subjects consumed three capsules (one capsule per meal) containing 13 mg synephrine and 176 mg caffeine (39 mg synephrine and 528 mg caffeine) the day before testing. 
(f): Refers to the number of subjects per arm. 
*Statistically significant. 
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Appendix H.  Human intervention studies on the longer-term ( 7 days) effects of caffeine or coffee on blood pressure 
 Design Sex n (I/C) 
(a)
 I, C Coffee (cups 
per day) 
Coffee 
(ml per day) 
Caffeine  
(mg per day) 
Duration
  (b) 
(weeks) 
Studies with caffeine 
Arciero et al. (1998)
 (c)
 rdb-X M 10 Caffeine, placebo – – 295 4 
Bak and Grobbee (1991) 
(a)
 rdb-P M/F 62 (32/30) Caffeine + D, placebo – – 375 7 
James (1994)
 (c)
 rdb-X M/F 36 Caffeine, placebo – – 336–410 (d) 1 
Robertson et al. (1984)
 (a)
 rdb-P M/F 17 (9/8) Caffeine, placebo – – 750 12 
Watson et al. (2000)
 (c)
 rdb-X M/F 34 Caffeine, placebo – – 400 12 
Studies with coffee 
Agudelo et al. (2008)
 (e)
 rol-P M/F 116 (29/29/ 
29/30) 
F, N 2, 4, 6 300, 600, 900
 (f)
 180, 360, 540
 (g)
 6 
Ammon et al. (1983)
 (h)
 rdb-X M 8 In, D 8 1200
 (f)
 720
 (g)
 4 
Bak and Grobbee (1990)
 (c) (e) (h)
 rol-P M/F 111 (77/34) B, F or N 4–6 700 469 9 
Burr et al. (1989)
 (c) (e) (h)
 rol-X M/F 54 In or D, N  5 1235 741 4 
van Dusseldorp et al. (1989)
 (c) (h)
 rdb-X M/F 45 F, D 5 750
 (f)
 435
 (g)
 6 
van Dusseldorp et al. (1991) 
(c) (e) (h)
 rol-P M/F 64 (43/21) B (+F), N 6 900 (774–798) 11 
Eggertsen et al. (1993)
 (c) (h)
 rdb-X M/F 23 In, D 3–4 525 (f) 263 (g) 2 
Funatsu et al. (2005)
 (e)
 rol-X M 42 F, N 3.4 510
 (f)
 306
 (g)
 4 
Hofer and Battig (1994)
 (c)
 rol-P M/F 120 (80,/40) In, D – 998 335 1 
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 Design Sex n (I/C) 
(a)
 I, C Coffee (cups 
per day) 
Coffee 
(ml per day) 
Caffeine  
(mg per day) 
Duration
  (b) 
(weeks) 
MacDonald et al. (1991)
 (c) (e) (h)
 rol-X M/F 50 In or D, N > 3 450
 (f)
 225 2 
Rakic et al. (1999)
 (c) (e)
 rol-P M/F 27 (14/13) In, N 5 750
 (f)
 300 2 
Rosmarin et al. (1990)
 (c) (e) (h)
 rol-X M 21 F, N 3.6 540
 (f)
 270
 (g)
 8 
Strandhagen and Thelle (2003)
 (e)
 rol-X 
(i)
 M/F 121 F, N 4 600
 (f)
 360
 (g)
 4 
Superko et al. (1991)
 c) (e)
 rol-P M 181 (123/58) F or D, N 4.5 1 067 615 8 
Superko et al. (1994)
 (c) (h)
 rol-P M 150 (100/50) F or D, N 4.5 1 067 615 8 
B = boiled coffee; C = control; D = decaffeinated coffee; F = females; I = intervention; In = instant coffee; M = males; N = no coffee; rdb-P = randomised, double-blind, parallel; rdb-X = 
randomised, double-blind, cross-over; rol-P= randomised, open-label, parallel; rol-X = randomised, open-label, cross-over 
(a): Number of participants (intervention/control). Only one number is given for cross-over designs, in which subjects act as their own controls. 
(b): Duration of the intervention. 
(c): Included in Noordzij et al. (2005). 
(d): Estimated from caffeine dose given in mg per day (about 5.25 mg/kg bw) assuming a mean body weight of 78 kg for males and of 64 kg for females. 
(e): Included in Steffen et al. (2012). 
(f): Estimated assuming that one cup of coffee corresponds to 150 ml. 
(g): Estimated assuming that one cup of coffee corresponds to 90 mg of caffeine. 
(h): Included in Jee et al. (1999). 
(i): Study not randomised. All subjects received no coffee/coffee in the same sequence. 
Safety of caffeine 
 
EFSA Journal 2015;13(5):4102 114 
Appendix I.  Meta-analyses of prospective cohort studies on the relationship between habitual caffeine consumption and cardiovascular disease 
risk 
 Meta-analyses 
Ding et 
al. 
(2014) 
Cheng 
et al. 
(2014) 
Caldeira 
et al. 
(2013) 
(a)
 
Motofsky 
et al. 
(2012) 
Kim et 
al. 
(2012) 
Larsson 
and 
Orsini 
(2011) 
Steffen et 
al. (2012) 
Zang et 
al. 
(2011) 
Wu et 
al. 
(2009) 
Sofi et 
al. 
(2007) 
Outcomes CVD, 
CHD, 
stroke 
AF AF 
 
HF Stroke Stroke HT HT CHD CHD 
Individual studies C Sex Outcomes  
 Wilhelmsen et al. (1977)* SE M nf-MI X – – – – – – – X – 
Murray et al. (1981)  US M f-IHD – – – – – – – – X – 
Jacobsen et al. (1986)  NO M/F CHD – – – – – – – – X – 
LaCroix et al. (1986) US M/F CHD – – – – – – – – – X 
LeGrady et al. (1987) 
Chicago Western Electric 
Company Study 
US M f-CHD 
f-Stroke 
X – – – – – – – X – 
Yano et al. (1987) US M f-CHD 
nf-MI 
– – – – – – – – X – 
Martin et al. (1988) 
Hypertension Detection 
and Follow-up Program  
US M/F f-CHD 
f-Stroke 
 
X – – – – – – – X – 
Wilson et al. (1989) US M/F CVD – – – – – – – – X – 
Grobbee et al. (1990) 
Health Professionals 
Follow-up Study 
US M CVD 
CHD 
MI 
Stroke 
X – – – – X – – – – 
Klatsky et al. (1990)** US M/F nf-CHD 
nf-MI  
X – – – – – – – X X 
Tverdal et al. (1990) NO M/F f-CHD X – – – – – – – – – 
Rosengren and 
Wilhelmsen (1991) 
Primary Prevention Study 
SE M nf-MI 
f-CHD 
X – – – – – – – X – 
Lindsted et al. (1992)  US M f-CVD 
f-IHD 
X – – – – – – – X X 
Klatsky et al. (1993) US M/F f-CHD – – – – – – – – – X 
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 Meta-analyses 
Ding et 
al. 
(2014) 
Cheng 
et al. 
(2014) 
Caldeira 
et al. 
(2013) 
(a)
 
Motofsky 
et al. 
(2012) 
Kim et 
al. 
(2012) 
Larsson 
and 
Orsini 
(2011) 
Steffen et 
al. (2012) 
Zang et 
al. 
(2011) 
Wu et 
al. 
(2009) 
Sofi et 
al. 
(2007) 
Outcomes CVD, 
CHD, 
stroke 
AF AF 
 
HF Stroke Stroke HT HT CHD CHD 
Individual studies C Sex Outcomes  
Klag et al. (1994) US M CHD, MI X – – – – – – – X X 
Gyntelberg et al. (1995) 
Copenhagen Male Study  
DK M nf-IHD X – – – – – – – X X 
Stensvold and Tverdal 
(1995) 
NO M/F nf-MI – – – – – – – – X – 
Hart and Smith (1997)  UK M f-CHD X – – – – – – – X X 
Hakim et al. (1998) 
Honolulu Heart Program 
US M Stroke 
subtypes 
X – – – – – – – – – 
Woodward and Tunstall-
Pedoe (1999), Scottish 
Heart Health Study 
UK M/F CHD X – – – – – – – X – 
Kleemola et al. (2000) FI M/F f-CHD 
nf-MI 
X – – – – – – – X – 
Wilhelmsen et al. (2001a, 
b), Multifactor Primary 
Prevention Study 
SE M HF, AF – X X X – – – – – – 
Klag et al. (2002), Johns 
Hopkins Precursors Study 
US M HT – – – – – – X X – – 
Jazbec et al. (2003) HR M/F f-CVD X – – – – – – – – – 
Happonen et al. (2004) 
Kuopio Ischaemic Heart 
Disease Risk Factor Study 
FI M f-CHD 
nf-MI 
X – – – – – – – X – 
Frost and Vestergaard 
(2005), Danish Diet, 
Cancer, and Health Study 
DK M/F AF – X X – – – – – – – 
Winkelmayer et al. (2005) 
Nurses’ Health Study I, II 
US F HT – – – – – – X X – – 
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 Meta-analyses 
Ding et 
al. 
(2014) 
Cheng 
et al. 
(2014) 
Caldeira 
et al. 
(2013) 
(a)
 
Motofsky 
et al. 
(2012) 
Kim et 
al. 
(2012) 
Larsson 
and 
Orsini 
(2011) 
Steffen et 
al. (2012) 
Zang et 
al. 
(2011) 
Wu et 
al. 
(2009) 
Sofi et 
al. 
(2007) 
Outcomes CVD, 
CHD, 
stroke 
AF AF 
 
HF Stroke Stroke HT HT CHD CHD 
Individual studies C Sex Outcomes  
Bidel et al. (2006) FI M/F f-CVD 
f-CHD 
f-Stroke 
X – – – – X – – – – 
Andersen et al. (2006) 
Iowa Women’s Health 
Study 
US F f-CVD X – – – – – – – X X 
Lopez-Garcia et al. (2006) 
Health Professionals 
Follow-up Study 
Nurses’ Health Study 
US M/F CHD 
f-CHD 
nf-MI 
X – – – – – – – X X 
Greenberg et al. (2007) 
NHANES I-NHEFS 
US M/F f-CVD 
f-CHD 
f-Stroke 
X – – – – – – – – – 
 Hu et al. (2007)  FI M/F HT – – – – – – X X – – 
Palatini et al. (2007) 
HARVEST study 
IT M/F HT – – – – – – X X – – 
 Rosner et al. (2007) 
Swedish Mammography 
Cohort 
SE F MI – – – – – – – – X – 
Silletta et al. (2007) 
GISSI-Prevention Trial 
IT M/F CV death 
nf-MI 
nf-stroke 
X – – – X X – – – – 
Uiterwaal et al. (2007) 
Doetinchem Cohort Study 
DK M/F HT – – – – – – X X – – 
Greenberg et al. (2008) 
Framingham Heart Study  
US M/F CVD, CHD 
Stroke 
X – – – X – – – – – 
Happonen et al. (2008)  FI M/F f-CVD X – – – – – – – – – 
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 Meta-analyses 
Ding et 
al. 
(2014) 
Cheng 
et al. 
(2014) 
Caldeira 
et al. 
(2013) 
(a)
 
Motofsky 
et al. 
(2012) 
Kim et 
al. 
(2012) 
Larsson 
and 
Orsini 
(2011) 
Steffen et 
al. (2012) 
Zang et 
al. 
(2011) 
Wu et 
al. 
(2009) 
Sofi et 
al. 
(2007) 
Outcomes CVD, 
CHD, 
stroke 
AF AF 
 
HF Stroke Stroke HT HT CHD CHD 
Individual studies C Sex Outcomes  
Larsson et al. (2008) 
Alpha-Tocopherol, Beta-
Carotene Cancer 
Prevention Study 
FI M  Stroke X – – – X X – – – – 
 Ahmed et al. (2009) 
Cohort of Swedish Men 
SE M HF X – – X –  – – – – 
Lopez-Garcia et al. (2009) 
Nurses’ Health Study  
US F Stroke X – – – X X – – – – 
Mukamal et al. (2009) 
Stockholm Heart 
Epidemiology Program 
SE M/F HF, AF 
Stroke 
f-MI 
X X X X X X – – – – 
Zhang et al. (2009, a, b)  US M/F CVD, CHD 
f-CHD 
nf-MI 
Stroke 
 – – – X – – – – – 
Conen et al. (2010) 
Women’s Health Study 
US F AF  X X – – – – – – – 
de Koning Gans et al. 
(2010), EPIC-NL 
NL M/F CHD 
Stroke 
X – – – X X – – – – 
Leurs et al. (2010)*** 
The Netherlands Cohort 
Study 
NL M/F f-CHD 
f-Stroke 
X – – – – X – – – – 
Shen et al. (2011) 
Framingham Heart Study  
US M/F AF – X X – – – – – – – 
Sugiyama et al. (2010) JP M/F f-CVD, 
f-CHD 
f-Stroke 
X – – – – X – – – – 
Klatsky et al. (2011)  US M/F AF, other 
arrhythmias 
– X X – – – – – – – 
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 Meta-analyses 
Ding et 
al. 
(2014) 
Cheng 
et al. 
(2014) 
Caldeira 
et al. 
(2013) 
(a)
 
Motofsky 
et al. 
(2012) 
Kim et 
al. 
(2012) 
Larsson 
and 
Orsini 
(2011) 
Steffen et 
al. (2012) 
Zang et 
al. 
(2011) 
Wu et 
al. 
(2009) 
Sofi et 
al. 
(2007) 
Outcomes CVD, 
CHD, 
stroke 
AF AF 
 
HF Stroke Stroke HT HT CHD CHD 
Individual studies C Sex Outcomes  
Larsson et al. (2011), 
Levitan et al. (2011) 
Swedish Mammography 
Cohort 
SE F HF 
Stroke 
X – – X X X – – – – 
Mineharu et al. (2011) JP M/F f-CHD 
f-Stroke 
X – – – – X – – – – 
Wang et al. (2011) 
FINRISK study 
FI M/F HF – – – X – – – – – – 
Freedman et al. (2012),  
National Institutes of 
Health–AARP Diet and 
Health Study 
US M/F CHD 
Stroke 
X – – – – – – – – – 
Floegel et al. (2012) 
EPIC-Germany 
DE M/F CVD, MI 
Stroke 
X – – – – – – – – – 
Rautiainen et al. (2012), 
Swedish Mammography 
Cohort 
SE F MI X – – – – – – – – – 
Kokubo et al. (2013)  JP M/F CVD, CHD 
Stroke  
X – – – – – – – – – 
AF = atrial fibrillation; CHD = coronary heart disease; CVD = cardiovascular disease; CSD = Caffeinated soft drinks; EPIC = European Prospective Investigation into Cancer and Nutrition; f-
 = fatal; F = females; GISSI = Gruppo Italiano per lo Studio della Sopravvivenza nell’Infarto miocardico; HF = heart failure; HT = hypertension; M = males; MI = myocardial infarction; nf-
 = non-fatal; NHANES I- NHEFS = National Health and Nutrition Examination Survey Epidemiologic Follow-Up Study; SHEEP = Stockholm Heart Epidemiology Program. 
*Prospective cohort and case–control study; **nested case–control study; ***prospective case–control study. 
(a): Also includes a case–control study (Mattioli et al., 2005). 
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ABBREVIATIONS 
ADHD attention deficit hyperactivity disorder 
AF atrial fibrillation 
AHR aryl-hydrocarbon receptor 
ANS EFSA Panel on Food Additives and Nutrient Sources Added to Food 
ANSES French Agency for Food, Environmental and Occupational Health and Safety 
BAC blood alcohol concentration 
BfR Federal Institute for Risk Assessment 
BP blood pressure 
bw body weight 
CABG coronary artery bypass grafting 
CAD coronary artery disease 
CHD coronary heart disease 
CI confidence interval 
COT UK Committee on Toxicity of Chemicals in Food, Consumer Products and the 
Environment 
CVD cardiovascular disease 
CNS central nervous system 
CVS cardiovascular system 
CYP cytochrome 
DBP diastolic blood pressure 
FDA US Food and Drug Administration 
FFQ food frequency questionnaire 
FGR fetal growth retardation 
FMD flow-mediated dilation 
FSANZ Food Standards Australia and New Zealand 
HR heart rate 
IQR interquartile range 
LOAEL lowest observed adverse effect level 
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MABP mean arterial blood pressure 
MBF myocardial blood flow 
MFR myocardial blood flow reserve 
MI myocardial infarction 
MPI myocardial perfusion imaging 
MS Member State 
NOAEL no observed adverse effect level 
NOEL no observed effect level 
NNT Nordic Working Group on Food Toxicology and Risk Evaluation 
OR odds ratio 
PET positron emission tomography 
PTCA percutaneous transluminal coronary angioplasty 
PWV pulse-wave velocity 
RASFF Rapid Alert System for Food and Feed 
RCT randomised controlled trial 
RPE ratings of perceived exertion 
RR relative risk 
SBP systolic blood pressure 
SCD sudden cardiac death 
SCF Scientific Committee on Food 
SGA small for gestational age 
SHC Belgium’s Superior Health Council 
SNP single nucleotide polymorphism 
SPECT single-photon emission computed tomography 
UL upper tolerable level of intake 
